

BIOTECH IN BAVARIA

TRANSFORMATION IN PROGRESS

REPORT
2018/19

managed by



including more than 300 company
profiles and contact details



Future X Healthcare


The digital (r)evolution –
a new era for patients

14 November 2019 | Munich
www.fhx2019.com

Future X Healthcare
From Science to Patients

Bio^M – central point of contact for pharma and biotechnology in Munich and Bavaria

- consulting for founders-to-be, start-ups & SMEs
- grant & seed financing support
- pre-seed incubation & m⁴ award
- matchmaking, networking & partnering
- events, conferences & training
- representing Bavarian biotechnology world-wide
- investment opportunities
- central online platform: job exchange, company database and much more





Bavarian Ministry of
Economic Affairs,
Regional Development
and Energy



invest
in
bavaria

Never stop exploring.

Be part of the digital future.

Right this way for R&D

Bavaria is the leading biotech and pharma location in Germany. With a high number of international pharma companies and new rising biotech stars, Bavaria offers the right environment and infrastructure for your company – especially when it comes to R&D.

In Bavaria you'll find the right ingredients: a wealth of potential partners and customers throughout the entire industry value chain and highly qualified personnel. Bavaria is the home of digital future and your perfect business location.

Discover the benefits of expanding your business to Bavaria. We do everything to get your business started: From arranging contacts with relevant players to identifying the perfect location for your company.

Our service is confidential and free of charge. Get in touch with us!

→ www.invest-in-bavaria.com

CONTENT

Greeting	5
Hubert Aiwanger, Bavarian State Minister of Economic Affairs, Regional Development and Energy	
<hr/>	
Preface - Biotechnology in Transformation	7
Prof. Horst Domdey – Spokesman Bavarian Biotechnology Cluster	
<hr/>	
Company Development	8
Stable and growing	
<hr/>	
FCF Life Science Monitor 2018 Advertorial	18
Dr. Mathias Schott and Sebastian Sommer	
<hr/>	
Scientific Landscape	20
Outstanding Research in Bavaria	
<hr/>	
DigiMed Bayern	26
Digitization Lighthouse Project in Bavaria	
<hr/>	
Bio^M for BioEntrepreneurs	29
Guiding you from Idea to Success	
<hr/>	
International Affairs	30
Bavaria going global	
<hr/>	
Innovation Centers in Bavaria	32
Regional Networks in Life Sciences	
<hr/>	
20 Years of BioPark Regensburg Advertorial	35
Dr. Thomas Diefenthal – CEO of BioPark Regensburg GmbH	
<hr/>	
Bio^M - Your Gateway to the Bavarian Biotech Community	36
<hr/>	
Company Profiles	37

About this Study:

For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. Since conventional pharmaceutical companies are also increasingly using such methods, it is often difficult to differentiate between biotech and pharma.

The biotechnology companies were classified according to the location of the headquarter as 'international' or 'native Bavarian'. The classification into OECD and non-OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem.

Part of the data were collected in cooperation with Bio-Deutschland e.V. It was possible to achieve a response rate to the survey of more than 50%. Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2018.

There are about 300 company profiles listed in the appendix of this brochure (pp. 37). Not every company listed is also considered in this survey, for example some companies with very specific services, or selected medical engineering companies. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the database of Bio^M. Also more than 500 Bavarian companies in medical engineering are not included in this survey.


Published in April, 2019



BIOLOGISCHE MECHANISMEN ENTSCHLÜSSELN UND PATIENTEN HELFEN

Wir bei Amgen wollen mit den Möglichkeiten der Biotechnologie innovative Therapien und Lösungen für Patienten mit schweren Erkrankungen schaffen. Um neue Therapieansätze zu finden, nehmen wir die komplexen molekularen Mechanismen einer Erkrankung ins Visier. Unser Ziel ist es, nicht nur zur Linderung einer Erkrankung beizutragen, sondern auch die Lebensqualität von Patienten zu verbessern.

Weitere Informationen über Amgen finden Sie unter:
www.amgen.de



GREETING

Bavarian State Minister of Economic Affairs

Discussions of the opportunities and risks have been a constant companion to biotechnology since it first emerged in the 1990s – also in Bavaria. The debates concerning the value of medical progress alone are a good example. On the one hand, people are understandably very open to new possibilities when they themselves are affected by illness. Making immediate use of innovative technology that promises a cure should then be possible. On the other hand, the social discourse with respect to preimplantation diagnostics, for example, clearly indicates the high level of ethical responsibility that is associated with new procedures. In such a case, people expect the various interests to be deliberated thoroughly.

The task and the challenge from a political perspective is to find the right balance in this complex scenario. Firstly, a framework must be established in which to facilitate progress technologically. Secondly, the ethical demands of society must be met politically. In this regard, the Bavarian State Government is pursuing a very clear, long-term goal: to further integrate biotechnology into the Bavarian landscape. We therefore support innovation spaces where disruptive innovations can grow and flourish. We invite stakeholders from business, science and society alike to become involved in this process so that the



HUBERT AIWANGER

Bavarian State Minister of Economic Affairs,
Regional Development and Energy

various interests can be reconciled in the best way possible through dialogue. Innovation and responsibility are not mutually exclusive in the Free State of Bavaria.

More than 20 years ago, the Bavarian State Government set up this innovation space for biotechnology. The unmistakable achievements demonstrate that it was the right approach. In drug development, there are many solutions in Bavaria that have made the leap from laboratory to real life. With respect to industrial biotechnology, the Free State is also home to globally renowned centers where, almost daily, new opportunities are created thanks to experimental development. The dynamic nature of the industry in Bavaria is very special, particularly when compared on an international scale. The interplay of medium-sized enterprises and large corporations is especially impressive. The large biotech companies have only achieved so much due to the impressive efforts of the Bavarian SMEs in enabling technologies.

The Bavarian biotech industry has an excellent standing and, as a location, Bavaria is attractive to companies from around the globe. I wish everyone in the Bavarian biotech sector continued success with their ventures into the 'real world' and will be glad to continue supporting them in the future.

Hubert Aiwanger

Hubert Aiwanger



VISION AHEAD?

We help you to achieve your vision by linking the value of intellectual property to company performance.

As one of the largest tech transfer offices in Europe, we protect and commercialize innovations from 33 research institutes.

BIOTECH IN BAVARIA

Biotechnology in Transformation

Dear Reader,

Although biotechnological procedures such as brewing beer or making wine, cheese and bread have existed for thousands of years, the term biotechnology does not seem to have been used until 1919, when the director of the Cattle Utilization Cooperative of Hungarian landowners Karoly Ereky published his book „Biotechnologie der Fleisch-, Fett- und Milcherzeugung im landwirtschaftlichen Grossbetriebe“ in Berlin. Hence, 2019 is the year in which we can celebrate the 100th anniversary of the term **biotechnology**.

Today, modern biotechnology provides a strong impetus for the economy, the research landscape and, above all, the health care sector. In Germany, we have produced a respectable number of very successful biotech companies, such as Qiagen, Evotec, MorphoSys, Miltenyi and many others who have become global leaders in their field.

This also holds true for Bavaria: one of the four companies mentioned above is based in the greater Munich area. In 2018, MorphoSys became one of the few companies to have a dual listing on the Frankfurt stock exchange and, more recently, the US Nasdaq. Having raised more than USD 200 million with their IPO in New York, the company can continue with its clinical development in late-phase trials.

Besides the many drug developing biotech companies located in Bavaria, we can also be proud of the many companies that supply the tools for pursuing research –



PROF.
HORST DOMDEY

CEO of Bio^M; Spokesman Bavarian
Biotechnology Cluster


or ‘Tools for Life Sciences’, as we call this special interest group (see p. 16). Many of these companies operate globally, and some are even leaders in their field. To achieve this, they have had to adapt rapidly to the expectations of their customers and must continue to do so, e.g., by integrating artificial intelligence and implementing machine learning in the instruments they are developing and bringing to the market.

Last but not least, we are witnessing how the shift from experimentally based inventions and innovations to the creation of new diagnostic concepts and treatments based on the use of big data

is – albeit slowly – taking off. With the help of DigiMed Bayern, a EUR 22.5 million program funded by the State of Bavaria, we have taken the lead in Germany in this field. The data of thousands of patients suffering from atherosclerosis will be collected, analyzed and interpreted, thus enabling physicians to select the most reliable diagnostic tool and best treatment. Though DigiMed Bayern is still an academic project it is clear that this academic ‘experimental setting’ will eventually evolve into an economically driven industry (see p. 26).

I am in no doubt: At this 100-year mark, the **transformation** in and with biotechnology has only just begun. With the biotech companies and the scientific landscape of which we can boast in Bavaria and all the partners in the Bavarian Biotechnology Cluster, I am confident that we can add value not only to our economy but also to our society, while coming closer to our vision: Bavaria – the place for the medicine of the future.

Sincerely yours,



Prof. Horst Domdey

COMPANY DEVELOPMENT

Stable and growing

In 2018, Bavarian biotechnology companies had varying degrees of success in attracting external funding. While listed companies achieved a total of approx. EUR 240 million, representing roughly 27% of the total capital invested in Germany's biotech enterprises, privately financed ventures procured 'only' approx. EUR 20 million. This sum was shared between several companies and by numbers alone, Bavaria is ahead of the other federal states; however, in percentage terms the huge investment of EUR 225 million in BioNTech (Mainz) tipped the balance to such an extent that only a single-figure result remained. This was surely influenced by the lingering effects of very prolific private investment activities in 2016 and 2017.

Given that external funding is important only to a certain group of companies (developers of therapeutics, in particular) and that most other Bavarian companies have already been successful in placing products on the market, it is still the case that during the reporting period – as in previous years – the Bavarian Biotechnology Cluster and the individual regional sites can claim to be very stable economically based on current knowledge.



DR. MARION JUNG

CEO
ChromoTek

ChromoTek has just celebrated ten years as a pioneer with unparalleled experience in developing nanobodies with designed affinities, valencies and specificities. Camelid nanobodies are the most powerful antibody building blocks for applications in research, imaging and therapy. We are proud that

ChromoTek's innovative single domain antibody products enable groundbreaking discoveries worldwide. In addition, we wish to congratulate our peers in biotherapeutic development: Ablynx/Sanofi received approval for the first nanobody drug as treatment for a rare blood disorder.

Number of Companies

In 2018, a total of 410 companies were operating in the biotechnology and pharmaceutical industry in Bavaria. The Bavarian sector is particularly strong in the area of small and innovative drug developers. We are counting 237 biotech companies, 75 pharmaceutical companies, 68 contract research organizations, and 30 suppliers. The 237 biotech companies include 185 Bavarian biotech companies (with headquarters in Bavaria) and 52 international biotech companies (with their subsidiary of a foreign parent company). Among the 'native Bavarian Biotech' the majority is small and medium-sized and only some 15 of them have more than 100 employees. The largest of all is **Roche** (6,200 employees in Penzberg researching and producing biopharmaceuticals).

As for the 75 pharmaceutical companies, this category includes both subsidiaries of international companies such as **BMS, Daiichi Sankyo, GSK** or **MSD**, and stand-alone companies like **Bencard, Dr. Pfleger, Denk Pharma**, and many others. Not all of them are active in biopharmaceuticals.



The 68 contract research organizations make an important contribution to the biomedical environment through their expertise in (pre)clinical studies. These organizations are service providers for both local and international drug developers and make Munich a leading center for clinical trials and drug development. Finally, 30 suppliers complete the picture of our ecosystem by delivering material such as lab or microscopy consumables.

Bavarian biotech SMEs are the main target group of BioM's networking activities and funding initiatives. These companies are focused on the development of new therapeutics and diagnostics, a field in which about 60 companies are active. The area is further strengthened by 38 providers of technology platforms, mainly assisting drug development. Likewise, the area of biotech devices and reagents is highly developed and features 27 companies providing specialized laboratory equipment, assay systems, and measuring instruments for research, among other things. In addition, biotech SMEs are active in the fields of industrial biotechnology, agriculture and food as well as bioinformatics and others.

The Bavarian Biopharma Sector – Number of Companies



410
Companies



Newly founded Companies

As in the previous year, start-up activities in Bavaria can be described as very positive. A preliminary overview reveals that ten new biotechnology companies have been founded in Bavaria. Conversely, we are aware of five companies that have been closed, sold or left the region. In the pharmaceutical/biotech sector, on the other hand, three international players have settled in Bavaria. Another four (international) acquisitions have given the region an additional boost: the acquired companies now have access to additional resources as part of larger global enterprises, as shown in the case of Exosome Diagnostics (see Financing, p.12). Overall, the number of Biotech companies has again risen slightly according to preliminary figures (+ three).

Three of the ten start-ups are spin-offs of scientific research institutions. Four start-ups were launched as spin-offs with experienced management teams from other companies and are testament to the maturity of the location, where a good project idea is sure to find an established, well-versed management team. The Bio^M network is tremendously helpful in this regard. These new companies are not only actively involved in the development of therapeutic and diagnostic applications but also deliver services for research and laboratories and bioinformatics/data management.

In the up-and-coming field of digital medicine, Bavaria has witnessed the emergence of around 50 start-ups in the space of just a few years. For this reason, and with special funding from the Bavarian Ministry of Economic Affairs, numerous business incubators have been established throughout Bavaria. We can therefore expect this positive momentum to continue.

NEW COMPANIES (FOUNDED & RELOCATED)

COMPANY	CATEGORY	LOCATION
Adivo	Therapeutics	Munich
Analife	Data Science	Würzburg
DX-Labtrack	Devices	Munich
EpiQMAx	Diagnostics	Munich
Gotham therapeutics	Therapeutics	Munich/USA
Invitrocue	Diagnostics	Munich
Ipsen	Therapeutics	Munich
ISAR Bioscience GmbH	Preclinical Services	Munich
LDC Biologics	Therapeutics	Munich
NCD Company	Services	Munich
Octamer	Diagnostics	Munich
PhenYTE UG	Nutrition	Regensburg
Telexos	Diagnostics	Munich



DR. DANIEL VITT

CEO
Immunic AG

2018 was a groundbreaking year for Immunic. Having received IND approval from the US FDA for a clinical phase II trial with our most advanced product candidate, IMU-838, in ulcerative colitis in January, the first patient was already enrolled by April. Another milestone was the global option and license agreement

signed with Tokyo-based Daiichi Sankyo in November. This granted us exclusive, worldwide rights to IMU-856, a promising drug development program using an undisclosed new target and mode of action for the treatment of inflammatory bowel diseases (IBD). Towards the end of the year, we started preparing for the reverse takeover with US-based Vital Therapies, with which we will achieve Nasdaq listing after closing in Q2/2019 – a transformative milestone that will shape the coming months and years.

Since their scope is often much broader, the digital health companies are not categorized specifically as belonging to the biotechnology/pharmaceutical sector; hence, they have so far been addressed only briefly in this report. The Bio^M network and advisory service have supported most of the start-ups across the entire health sector.

Employment

With 14,800 employees (+2%) in 237 biotech companies, Bavaria shows stable growth in 2018 – again as in previous years. In respect to the ‘native Bavarian Biotech’, they show an even stronger increase in employment with + 5,6% to around 4,700 staff in those 185 SMEs – which is slightly above the growth in Germany on a nationwide survey (where a plus of 4% is stated for all Biotech companies in Germany in total). The number of employees has been growing for years, making the sector an interesting employer with highly qualified jobs. This growth is a clear indicator of global competitiveness, which is

The Bavarian Biopharma Sector – Employment

Employees in Biopharma
Companies





33,800

Employees in Life Sciences
Research



10,000





**PROF. TORSTEN
HAFERLACH**

CEO
MLL München Leukämielabor GmbH

The current trend in medical science is very clearly towards artificial intelligence. MLL München Leukämielabor is making full use of these new technologies. Having sequenced 5000 genomes, we are using AI to analyse the acquired data and, with the knowledge gained, enhance diagnostics and discover new pathways. We are convinced that AI will become an important

part of routine diagnostic procedures in the next five years, meaning that cases of leukaemia will be easier to identify, and personalized forms of treatment can be deployed with greater efficacy.

impressively underlined by the Bavarian predominantly small and medium-sized companies. Together with around 29,000 employees in pharmaceutical companies, CROs, service providers, as well as production and supplier companies, the Bavarian Biotech and Pharmaceutical industry employs around 34,000 people.

In addition, about 10,000 scientists work at university and non-university research institutions of the life sciences in Bavaria. No other location in Germany offers a comparable density of highly qualified and talented people in biomedicine and other application areas of biotechnology. Further information is given in the section Scientific Landscape, starting page 20.

Drug pipeline

The technology platforms owned by the Bavarian biotech companies are constantly delivering new therapeutic solutions. These drugs are currently being used in more than 230 R&D, preclinical and clinical projects. Although 57% of the projects are run through partnerships with pharmaceutical corporations, the Biotech companies' proprietary portfolios account for the rest.

Cancer remains the leading medical indication with 98 active projects followed by autoimmune disorders, which

are the focus of almost 27 ongoing projects. The therapeutic portfolio that has been made available for these two indications includes not only standard and established approaches such as antibodies, vaccines, small molecules, engineered proteins and antisense oligonucleotides but also more innovative methodologies. A special mention goes to two of the most advanced and modern technologies currently used in the field of precision oncology, namely cell therapeutics (produced by **Medigene**, **apceth**, **Multimmune** and **T-CURX**) and radionuclides. The latter are targeted first-in-class radioconjugates, developed by **ITM Isotopen Technologien**, that have both therapeutic and diagnostic properties (Theranostics).

Diseases of the central nervous system, cardiovascular and infectious diseases are also an essential part of the drug pipeline. The leader in the field of infectious diseases is **Bavarian Nordic**, a manufacturer of several vaccines.

To date, a total of nine drugs produced by Bavarian Biotech companies have been launched onto the market.

Financing


Stockmarket

MorphoSys raised more than USD 200 million with its phenomenal initial public offering (IPO) on the Nasdaq. The Munich-based company thus achieved the largest IPO to date by a German biotech company in the USA and one of the largest share placements ever in the German biotech industry. MorphoSys will use this fresh capital to further expand its clinical research activities and prepare for the prospective market launch of its first proprietary product candidate in 2020. With a double listing both in Frankfurt (as before) and now on the US Nasdaq, MorphoSys is one of the few companies to venture into such a transatlantic stock market split.


Immunic Therapies also successfully joined the Nasdaq. Its fusion with Nasdaq-listed Vital Therapies paved the way for the Martinsried-based company's smooth accession to the US stock market. On completion of the transaction, an investor consortium intends to additionally invest approx. EUR 26 million in the company. The capital will be used to drive forward the development of Immunic's drug candidates.

Medigene also attracted an impressive sum and has expanded its strategic alliance with US-based **bluebird bio** in the development of immune therapies, doubling its number of projects from two to four. The two com-

Drug Pipeline of Bavarian Biotech SMEs – Number of Projects by Phase and Indication



Indications



* not included are around 80 different antibody programs by Morphosys in pre-clinic



PROF. DOLORES SCHENDEL

CEO
Medigene

Last year marked the start of our first clinical TCR trial with MDG1011 at three Bavarian university hospitals. It is the first T-cell immune therapy we have developed ourselves for the treatment of three types of blood cancer. Clinical experts and scientists have been recruited to join our projects, leading to a 23% increase in the workforce in 2018. We now have

118 employees! The attractive location and position of Martinsried, as Munich's biotech hub, are of course very helpful to us in our search for new talent. Furthermore, Medigene was able to raise more than EUR 32 million in a successful round of financing.

panies are jointly researching and developing T-cell receptor-modified T-cell (TCR-T) immune therapies for cancer. The agreement entails an upfront payment of USD eight million and payments of up to USD 250 million per T-cell receptor project. Medigene AG also raised EUR 32 million on the stock market through an oversubscribed private placement. The revenue from this transaction will be used to expand the company's proprietary program of TCR-based T-cell immune therapies.

Collaborations, Deals and Funding

Regensburg-based **numares** and **Mayo Clinic Laboratories** in the US announced that they would be collaborating on the development of clinical diagnostic tests. Their aim is to identify relevant biomarkers and investigate their relationships with one another more closely. This will involve processing and analyzing a huge amount of data, which numares will manage with the aid of artificial intelligence (AI) and machine learning.

SIRION Biotech entered into a mega deal with US-based **Denali** and has opened a US subsidiary in Boston. SIRION has been a dependable partner for products and services in the cell and gene therapy

industry for over ten years. The exact figures are not known, but the Munich-based company will be reimbursed by the US Nasdaq-listed Denali Therapeutics Inc. for its development expenses along with receiving substantial advance payments in cash.

The **PreOmics** start-up, a spin-off of the Max Planck Institute of Biochemistry in Martinsried and winner of the 2013 **m⁴ Award**, evolved into a company in 2016 with the support of intensive coaching and expertise from the Bio^M ecosystem. It raised EUR 3.3 million in its first major financing round with High-Tech Gründerfonds, Think.Health Ventures and Business Angels.

The newly founded biotech company, **adivo** (see Newly founded Companies), likewise benefited from various consultations and training sessions offered by Bio^M. With a view to developing therapeutic antibodies for dogs against cancer and chronic inflammatory diseases, the Munich-based company successfully raised seed funding from three investors (HighTech-Gründerfonds, Occident, Morphosys AG).

Acquisitions

M&A activities are further testament to the appeal of Bavaria as a location and the maturity of its companies. With offices in Munich-Großhadern and Ottobrunn near Munich, **apceth Biopharma** is a pioneer in the production of cell and gene therapies – expertise worth EUR 75 million to **Hitachi Chemical**. The acquisition and continued operation of the apceth sites means that Munich will benefit overall from the presence of this significant global player.

Exosome Diagnostics was acquired by the **Bio-Techne Corporation** for the sum of USD 250 million. An additional USD 325 million could be forthcoming for defined milestones. Based on its proprietary platform for analyzing exosomes from biofluids, Exosome Diagnostics offers non-invasive tests and liquid biopsy techniques with which to identify cancer and other diseases. The company is headquartered in the USA and in 2012 set up its European HQ at the IZB Innovation and Start-Up Center for Biotechnology in Martinsried.

MAB Discovery has achieved tremendous success with its therapeutic antibody development technology. Consequently, the operational antibody generation unit of the Neuried-based biotech enterprise was acquired by

BioNTech in Mainz – the culmination of five years of successful collaboration between the two companies. MAB Discovery has retained ownership and all rights to its proprietary preclinical development pipeline and its existing service agreements with third-party suppliers, including those from its partnership with **Cullinan Oncology** since the beginning of 2018.

VC Settlements

Following the successful first closing of the new, now third Kurma Biofunds (Kurma Biofunds III) in December 2018, **Kurma Partners** also opened an office in Munich. The European venture capitalist with French roots sees great potential in Bavarian biotechnology.

Similarly, the Swiss **OCCIDENT** group is establishing a foothold in Munich, having been impressed by the city's top universities and world-leading technology companies, as well as established network of esteemed investors.

Awards/company highlights

Every year, **BayStartUP** opens its Munich business plan competition, comprising three phases, to the best start-ups from Munich and southern Bavaria. The 2018 winner was **Kumovis** from Munich, a team developing 3D printers designed specifically to meet medical technology requirements that can be used, for example, to produce cranial or spinal implants.

Two of the national **GO-Bio award** winners also hail from Munich and will benefit from millions of euros in funding from the Federal Ministry of Education and Research (BMBF). With their **Nano-Capture** project, the team led by Petar Marinković is working to improve the efficacy of cancer treatments. Active substances will therefore specifically target the tumor tissue, thereby working more efficiently and causing as few side effects as possible. Improving cancer therapy is also the goal of Johannes B. Woehrstein and his team at **DEOXY Technologies**. To identify particularly aggressive tumor cells, the team intends to establish its own platform technology for single-cell analysis based on specially generated fluorescent nanoparticles. Consequently, it should be possible to classify tumor cell types and thus select a personalized treatment strategy.

The 2018 Leibniz start-up prize went to Berlin and Munich. **Tubulis Technologies** is a joint project between the Berlin Leibniz Research Institute for Molecular Pharmacology



DR. GARWIN PICHLER

CEO
PreOmics

Our highlights in 2018 include closing a financing round at approx. €3.3 million, the development and successful market launch of our new iST-NHS and iST-HT kits, standardizing and simplifying technologies designed for multiplexing and automated workflows, and appointing distribution partners in Japan and Australia.

This extraordinary and very successful year was only possible thanks to our outstanding team. We look forward to expanding the team and continued success in 2019.

(FMP) and **Ludwig-Maximilian Universität München** (LMU). Their aim is to create an alternative to conventional chemotherapies using targeted active substances.

The Munich start-up **Inveox** won the Munich Start-up Award 2018 and the Golden Pretzel in the **Bits & Pretzels** start-up challenge. The company made a persuasive pitch at the start-up festival when presenting its solution for safe and efficient handling of biopsy specimens. Shortly before, the up-and-coming start-up convinced its existing investors to pledge an additional five million euros – funding that will be used to bring its core product to market.

Participation in the **Roche** Digital Health Accelerator program and Plug and Play in Munich in 2017 will certainly have helped Inveox raise further funding. Meanwhile, **Startup Creasphere**, the digital health accelerator recently established in Werk1 at Munich East station has become a hub for innovation with a reputation extending beyond Munich and Germany's borders. **Sanofi** is the latest company to join the platform. The goal of Startup Creasphere is to create the ultimate hub for innovations and disruptive start-ups in the European digital health sector. Startup Creasphere is supported by Plug and Play, a global innovation ecosystem and venture capital fund from Silicon Valley that specializes in early-to-growth stage technology start-ups.



CHRISTIAN THIRION

CEO
SIRION Biotech

SIRION doubled its business in 2018 and strengthened its position as the world's leading commercial and independent partner for viral vector and delivery technologies for gene and cell therapy. An application for marketing authorization has been filed for the first cell product manufactured with

SIRION's LentiBoost™ technology. SIRION also entered into a major partnership with Denali Therapeutics, San Francisco, with a view to developing novel AAV vectors for the treatment of CNS diseases. In 2019, SIRION expects to obtain approval for its first gene therapy product manufactured with LentiBoost™.

Nanotemper Technologies once again picked up an award: As innovator of the year, the Munich-based team came first in its class in the TOP 100 Award for the second time in succession – a first in the competition's 25-year history.

At the 70th Conference of the American Association of Clinical Chemistry (AACC), the **Disruptive Technology Award** went to **GNA Biosolutions** from Martinsried, having presented data on their proprietary pulse controlled amplification (PCA) technology. With ultra-fast molecular diagnostic testing of patient specimens, GNA Biosolutions not only impressed both the jury and expert audience, but also won the audience choice award for best technology. GNA Biosolutions has also entered into a research partnership with **Boehringer Ingelheim** focused on the development of a rapid test for African swine fever (ASF). They aim to bring the global spread of this deadly disease under control with the aid of a portable diagnostic system.

Bavarian companies are also venturing into the global market independently: **Nanion**, a leading supplier of instruments for the discovery and screening of ion channels, opened an office in a high-tech start-up center in the strategic location of **Silicon Valley**.

Bavaria is home not only to start-ups, but also to numerous long-established and successful companies. **Cfm Oskar Tropitzsch** celebrated its **230-year anniversary** with the opening of its new facility in Marktredwitz. As the first industrial production site founded in Germany, the company today supports the chemical, pharmaceutical and biotech industries in sourcing and producing rare raw materials.

Networks

To strengthen the position of biotech companies in Bavaria, networking across different sectors and disciplines is essential.

With 185 SMEs, 30 suppliers, 70 CROs and 75 pharmaceutical companies, a multitude of topics and interdisciplinary technological approaches, the Bavarian biotech cluster has all it takes to endorse targeted networking groups.

On this premise, Bio^M has already founded two consortia, namely **ImmPact Bavaria** and the **Diagnostic Network**, which focus on immunotherapy and diagnostics-related activities, respectively. These two projects were inspiration for the foundation of a third, newer network embodying another category of SMEs that develop and produce innovative, implementable tools for the life sciences sector. Currently, nearly 30 SMEs in the region are actively involved in the **Tools for Life Sciences** network.

The common goals of all these consortia are to (1) enhance collaboration between companies, (2) increase their visibility and competitiveness on the international stage and (3) host theme-oriented networking meetings where needs, trends, problems and open questions can be regularly discussed.

As cluster management organization, Bio^M constantly collects feedback from its partners to elaborate customized strategies that can satisfy their respective requirements, while utilizing its broad network to bring the right players together and enlarge these communities of experts.

Bayern Kapital

Venture Capital für Bayern



NEU:
Wachstumsfonds
Bayern



Ihr Hightech-Unternehmen sucht Eigenkapital?

Bayern Kapital bietet:

- Eigenkapital für Seedphase, F&E, Markteinführung und Wachstum
- Co-Investments mit Partnern
- Langjährige Finanzierungserfahrung
- Zugang zu einem starken Netzwerk

WWW.BAYERNKAPITAL.DE

Bayern Kapital GmbH | Ländgasse 135 a | 84028 Landshut

Telefon 0871 92325-0 | info@bayernkapital.de

IMPROVING
LIVES
WITH
NEXT
GENERATION
CELL
THERAPIES

- More than 10 years experience in GMP-manufacturing of cell and gene therapies
- Pioneer in genetically modified cell products
- We excel in quality and safety

 **apceth**
BIOPHARMA




We are hiring!
contact@apceth.com
www.apceth.com

SOME DISILLUSIONMENT – BUT ALSO A LITTLE BIT OF HOPE

Dr. Mathias Schott and Sebastian Sommer,
FCF Fox Corporate Finance GmbH

To start off with the good news, Bavaria has proven its position within the German Biotech scene last year. The Free State accounted for an astonishing 40 percent of the German deals, which ranged from EUR 25m to EUR 222m in the last three years (see graph 1). The by far biggest transaction, however, was the 2018 BioNTech deal with a volume of EUR 222m. With such a



remarkable sum, the German BioNTech placed the 2nd biggest transaction within the European Life Science industry of the last three years. What is more, Bavaria still dominates with the “conventional VC rounds” with an invested volume of EUR 113m and AuM of EUR 4,550m, not taking into account the governmental KfW Förderbank - the biggest Life Science investor in Germany.

Nevertheless, a look at the German market is still associated with a drop of

bitterness. While the number of VC deals in Europe increased, they have decreased in Germany. Practically, Germany only accounted for 7% of the European volume (see graph 2).


In a market that is dominated by the United Kingdom, France being a distant second, Germany only made it to the 3rd rank based on volume and 4th rank based on number of deals. One can look at it with cautious optimism: Less deals but higher volumes, underlining the principle “quality over quantity”, which is not necessarily wrong, especially in a sector as sophisticated as biotechnology. Still, one might ask whether Germany is selling themselves short.

Many transactions take place in the United Kingdom, these are however also the most important. During the last three years, 60 percent of the top 10 deals originated on the island. As previously mentioned, BioNTech is the only German company that could break through the phalanx of British top deals. This underlines a significant point.

One might argue that the British dominance is no surprise, as over the past five years 85 percent of the UK’s funding has been reinvested into its own country, which is why the largest deals come from the UK. But this idea lags: Germany in comparison invested only 70 percent in domestic companies during this period - the home bias is apparently not as distinctive as across the English Channel. In fact, for the first time, German investors invested more in foreign companies than in their own country in 2018. The question arises as to whether foreign biotech companies simply perform better or are smarter in attracting capital.


Putting it another way: German biotech companies are more dependent on foreign investors. Most of the funds come from Switzerland, followed by, not surprisingly, Great Britain. Another reason why no German investors are among the top 10 investors in Europe in the last three years, thus making German biotechs increasingly dependent on foreign investors, is probably the backlog demand Germany has for investor hubs: German cities were not among the locations of the largest investor hubs of the past five years. Again, the UK and France are much better represented.

Nevertheless, it is doubtful that Germany’s lag in life science is due to the performance of the biotechs



Graph 2: European and German Life Science Transactions (L5Y)

Graph 3: German Therapeutics Transactions by Indication (2018)



Graph 4: German Therapeutics Transactions by Development Stage (2018)



themselves for the following reasons: The importance of Germany’s contribution to the international biotechnology sector is apparent when looking at the indications that receive funding. Excluding the BioNTech mega deal, the majority of the funds target oncology (see graph 3). Additionally, three investments were made into companies specialising in cardiovascular diseases, thus supporting research and development in the fight against the world’s leading cause of death. The development stage of the companies is a major factor in Germany, where investments are preferred from phase II onwards (three transactions in phase II, one in phase III and one in market maturity) (see graph 4).

However, Germany is not inactive in the fight against capital shortages. In 2018, five VC funds with a total volume of EUR 1,500m were set up in Germany, which include LSP and Forbion due to their large involvement in the German life science industry. With TVM Capital, to get back to the point made at the beginning of this article, one fund comes from Munich and another one, namely Occident Capital from Switzerland, successfully settled in Munich. This, last but not least, emphasises again the important role Bavaria plays in biotechnology on both the technical and financial side, not only for Germany but also for Europe.

Source: Pitchbook and GlobalData as of 8th March, 2019; FCF Equity Research

Financing Specialist for Innovative Life Science Companies

Over EUR 2bn Life Science transaction volume¹

Over 10 Professionals

Over 80 completed Life Science transactions¹

Access to > 1000 international investors

Life Science Advisory Board

4 regularly published Life Science reports

Over 100 years in aggregated Life Science experience

Leading EIB advisor in Europe


FCF
THE FINANCING SPECIALIST

¹ comprising Professionals and Advisory Board

SCIENTIFIC LANDSCAPE

Outstanding Research in Bavaria

The research landscape in Bavaria offers fertile ground for innovation and progress. It is a world-class location that is home not only to research-based biotech and pharmaceutical companies but also to superb universities and colleges, and non-university research institutes in the life sciences sector. A large number of successful spin-offs have been cultivated by these institutions.



PROF. HERIBERT SCHUNKERT

Director of the Cardiology Department and Medical Director of the German Heart Centre Munich

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next ten years?

With genome sequencing and innovative high-throughput methods, the last ten years have led to a completely new understanding

of how atherosclerosis develops. We have therefore realized, among other things, that some therapeutic approaches were completely missing the mark while others were discovered instead. As a result, I generally expect individualized and more effective prophylaxis and treatment to emerge for this widespread disease.

How is digitization changing your research?

The achievements of recent years have only been possible through digitization. But what lies ahead is even more exciting. The aim will be to establish links between different data sources: imaging and laboratory data, and genomic and proteomic information should help us to identify patterns that indicate the risks and chances on a personalized level.

Universities

Munich's two universities, namely Ludwig-Maximilians-Universität München (LMU) and the Technical University of Munich (TUM), occupy the top two spots in Germany according to the World University Rankings 2019 (Times Higher Education). Internationally, these universities also rank among the best in the world. Six scientists at TUM are among the world's most influential in medicine and in natural and life sciences.* One researcher cited most frequently in his field, for example, is **Prof. Heribert Schunkert** of the Faculty of Cardiology at the German Heart Center Munich (see box left and DigiMed Bayern, p. 26); another is **Prof. Matthias Mann** of the Max Planck Institute of Biochemistry.

In March 2018, **Prof. Christian Haass**, Professor at Ludwig-Maximilians-Universität München, together with three other neuroscientists, won the world's most prestigious brain research prize for their research. The **Brain Prize 2018**, worth EUR one million, was awarded in recognition of the scientists' pioneering study of Alzheimer's disease.

Alongside **Prof. Thomas Misgeld** (TUM), **Prof. Haass** is also coordinator of the excellence cluster, **SyNergy – the Munich Cluster for Systems Neurology**. In this top-level research project, selected and sponsored by the national Excellence Commission, scientists are analyzing the pathogenesis of neurological disorders such as multiple sclerosis and Alzheimer's.

At the Dr. von Haunersches Kinderspital (LMU Munich), the European consortium **TRACE** has been successfully launched: the project aims to develop a curative immune therapy for life-threatening viral infections in patients whose immune systems are compromised following stem cell transplant. For this purpose, the **first phase III clinical trial involving adoptive T-cell transfer** is now underway. The consortium is supported by the European Commission as part of the Horizon2020 program.

Research into immune therapy is also advancing in northern Bavaria: the first clinical trial in Germany into an alternative approach to treating certain types of leukemia and lymphoma has been initiated. The new T-cell receptor therapy by **Medigene** in Munich is designed to support the immune system in the fight against cancer. In the first national clinical trial by Medigene, doctors and scientists

* Highly Cited Researchers: <https://hcr.clarivate.com/>

at the **university hospitals of Regensburg (UKR), Erlangen and Würzburg**, led by UKR, are investigating whether T-cells derived from leukemia or lymphoma patients can be modified in such a way that they can destroy cancer cells.

To consolidate the existing knowledge of both translational cancer research and treatment, the cancer units at the medical centers of the Ludwig-Maximilians-Universität München (LMU) and Klinikum rechts der Isar (TUM) have merged with the Tumor Center Munich to become **CCC Munich**. In 2018, CCC Munich was again named as one of the 13 leading oncology centers in Germany. Thanks to EUR three million of funding over the next four years, CCC Munich aims to offer even more patients the opportunity to take part in clinical trials so that they can benefit directly from scientific progress.

The first company-financed study in Europe to use the **CRISPR/Cas9** gene-editing system in human cells was launched by **CRISPR Therapeutics and Vertex Pharmaceuticals**, also at the University Hospital Regensburg. The treatment targets beta thalassemia, a chronic genetic blood disease that can cause life-threatening anemia and other severe complications.

In the field of AIDS research, **Prof. Ivan Huc**, a chemist at Ludwig-Maximilians-Universität München, has potentially uncovered an entirely new therapeutic strategy. He has succeeded in mimicking the features of a DNA double helix so closely that proteins interact with the mimic. These artificial DNA mimics, called **foldamers**, can inhibit various viral enzymes, including HIV integrase. The HIV virus inserts its genome into the host cell with the aid of the integrase. The scientist has even demonstrated that the HIV integrase binds to the foldamer more strongly than to the original DNA. In the journal *Nature Chemistry*, Huc has published his work on the artificial molecules that can be formed using a kind of origami technique in accordance with their natural counterparts.

Helmholtz Association

As the largest research-based association in Germany, comprising 19 research centers focusing on natural science and biomedical engineering, the Helmholtz Association aims to make a significant contribution to solving society's major challenges. As the German Research Center for

Environmental Health (HMGU), the **Helmholtz Zentrum Munich** investigates the pathogenic mechanisms behind common diseases such as diabetes mellitus, cancer, allergies and chronic lung diseases. To develop new concepts for prevention, diagnosis and treatment, the HMGU is studying the correlations between environmental factors, lifestyle and individual genetic disposition.



**PROF. CLAUDIA
TRAILD-HOFFMANN**

Director of the Faculty for Environmental
Medicine at the TU Munich

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next ten years?

Environmental medicine is the study of human and environmental interactions using the latest

laboratory technology. This helps us to understand these interactions at the molecular level. Neurodermatitis and allergies are one particular focus. We will identify which environmental factors influence our health, and how. In doing so we hope that new, individualized concepts for treatment and prevention can be developed.

How is digitization changing your research?

Digitization permits multifactorial data sets to be examined. To do so, we need processing power and intelligent software – something that can be achieved with bioinformatics. Digitization facilitates "assimilation of the environment". Fully automated measuring equipment will permit precise measurement of environmental factors in the air, such as pollen or pollutants. More accurate, real-time research will be the result.

Led by the Helmholtz Zentrum München, the Technical University of Munich and the University of Edinburgh, an international team of researchers has elucidated the maturation of **cancer-causing microRNAs** (oncomiRs) in gene regulation. The molecules, which consist of short RNA sequences, can prevent the synthesis of certain proteins and thus protect against uncontrolled growth. The findings could also be transferable to other microRNAs and lead to the development of new therapeutic options. The scientists have published their work in the prestigious journal, *Nature Chemistry*.

Researchers from the Helmholtz Zentrum München and the German Center for Diabetes Research have published new data in *Nature Communications*. They have identified a **genetic network** that could play an important role in the emergence of metabolic diseases such as **diabetes**.

In addition, two new studies, **POInT** and **Freder1k**, focus on the prevention of **type 1 diabetes**. For the first time, scientists and doctors are administering prophylactic treatment to healthy infants with an increased risk of type 1 diabetes in an attempt to prevent the condition from developing.

Top researchers are essential to the successful study and treatment of diabetes. As of 2019, the Helmholtz Association is also supporting the **International Helmholtz Research School for Diabetes**: the goal is to train a new generation of scientists specialized in the widespread condition of diabetes. In the next six years, the Helmholtz Association will contribute a total of EUR 1.8 million to the project, in addition to EUR 4.7 million provided by existing partners, TU Munich and the University of Alberta.

With the newly created **Helmholtz Pioneer Campus**, the Helmholtz Association hopes to attract top researchers who have already achieved success in their respective fields. The interdisciplinary HPC is under the scientific guidance of **Prof. Vasilis Ntziachristos** (TUM and HMGU) and **Prof. Matthias Tschöp**, who since July 2018 has been the new scientific director and spokesperson for the executive board of the Helmholtz Zentrum München. The Helmholtz Pioneer Campus is an intelligent fusion of biomedical sciences, engineering and digitization in research. Young scientists from renowned universities and research institutes worldwide will spend five to seven

years studying diseases such as diabetes and obesity, as well as related disciplines such as stem cell research, neurobiology and immunobiology, and cancer research. Furthermore, through patents and spin-offs, this research should be directly transferable to medical applications.

To guide the way from research to practical application, the Helmholtz Association provides entrepreneurs from the world of science with various means of support. It has proudly spawned 176 spin-offs since 2005, with roughly half of these having been supported by the **Helmholtz Enterprise** funding program.

Theraselect is one of the sponsored projects. The scientists in the team led by **Dr. Achim Buck** of Helmholtz Zentrum München aim to improve the treatments available to cancer patients by developing new diagnostic and pharmacological tests. Using specially developed mass spectrometry imaging methods, doctors could in future make personalized therapeutic decisions and set new standards in cancer diagnosis.

The Helmholtz Association is also supporting the **Eximmium** spin-off with funding of approx. EUR 230,000. **Prof. Reinhard Zeidler** and **Dr. Kathrin Gärtner** are working with a novel platform technology to develop innovative antibodies. The first antibody, which targets malignant brain tumors (glioblastoma multiforme), is due to be studied in patients as part of a phase I trial. Other antibodies with diagnostic or therapeutic potential are already in the pipeline.

To understand why some people are affected by cancer, diabetes, or cardiovascular disease, but others are not, biospecimens from 200,000 healthy subjects are being studied over a long period of time as part of the **German National Cohort** (GNC; German abbreviation: **NAKO**), which began in 2014. One third of the 30 million biospecimens are kept at the respective study centers, and about two thirds at the newly opened central biospecimen repository at Helmholtz Zentrum München. The **Biorepository** in Neuherberg, which was built at a cost of approx. EUR 17 million and is equipped with all the latest technology, should serve as a biomedical archive for future generations and pave the way for personalized medicine.

Max Planck Society

The Max Planck Society has been conducting basic research in natural and life sciences and humanities since 1948. The institution has already yielded 18 Nobel Prize winners. In Bavaria, the Max Planck Society not only has its administrative headquarters in Munich but has three institutes for biology and medicine in Martinsried and Munich, as well as a research team in Würzburg.

At the **MPI for Neurobiology** in Martinsried, scientists are investigating the basic functions and the development of the brain and nervous system right through to pathogenic mechanisms. The research teams are studying how the brain reacts to environmental changes and how memory works (**Prof. Tobias Bonhoeffer**), how behavioral patterns are triggered by stimulus conduction (**Prof. Herwig Baier**), how molecular and cellular levels interact and how this can also be visualized with cutting-edge imaging technology (**Prof. Winfried Denk**). Other research teams, together with neuroscience researchers at universities and non-university institutions, have formed an extremely strong community for basic research, extending as far as therapeutic application in patients. At the **MPI of Biochemistry**, cutting-edge research is conducted in the field of biomedicine using the latest biomolecular techniques. It is therefore making a substantial contribution towards research into disease etiology and, furthermore, to the development of new therapeutic concepts. Along with Nobel laureate **Prof. Robert Huber**, Max Planck directors **Prof. Franz-Ulrich Hartl** and **Prof. Wolfgang Baumeister** are leading the way in structural research. **Prof. Brenda Schulman** is studying important molecular switches in cells that control various cellular functions. Ubiquitin is a small molecule that can trigger significant changes in activity. The findings in this area are of particular relevance because dysregulation of the ubiquitin system is associated with cancer, neurodegenerative disorders, and infections. Prof. Schulman has received the Gottfried Wilhelm Leibniz Prize, worth EUR 2.5 million, for her significant work.

Research into psychological disorders is also becoming increasingly relevant. The **Max Planck Institute of Psychiatry** in Munich focuses on the combination of basic research, clinical research and patient care. Its scientists aim to develop new diagnostic methods as well as innovative concepts for prevention and treatment based on their research results.



PROF. PETRA SCHWILLE

Director, Cellular and Molecular Biophysics, Max Planck Institute of Biochemistry

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next ten years?

The minimal (or artificial) cell, which is my research focus, is still a basic science at present. In the next ten years, I anticipate an experimental

breakthrough in one area, namely: where exactly does the transition from inanimate to animate matter lie, which for decades was bogged down somewhat in various theories. Perhaps we will indeed observe how a chemical system organizes itself to become a living cell in the laboratory.

How is digitization changing your research?

Data and data processing and, in turn, digitization, have always played a very important role in the study of life sciences. As in almost all data-intensive environments, biomedicine will break new ground in interpreting large volumes of data in the years to come with the aid of machine learning and artificial intelligence.

Fraunhofer-Gesellschaft

The Fraunhofer-Gesellschaft is the largest organization for applied research in Europe. The aim of its research activities, which are conducted at 72 institutes and research establishments throughout Germany, is the deployment of new technologies. The research organization has its headquarters in Munich.

When it comes to putting research into everyday practice, the marketing of intellectual property, among others, plays a major role. **Fraunhofer Technologie Transfer Fonds GmbH**,



**PROF. PHILIPP
BECKHOVE**

Director RCI Regensburg Centre for
Interventional Immunology

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next ten years?

The growing understanding of the extensive role played by immune cells in keeping the body healthy –

not only with respect to fighting pathogens, but also to maintaining tissue function. Identifying and understanding the diverse communication lines between immune cells and tumor cells is particularly exciting, as this will dictate how successfully we can treat cancer in the future.

How is digitization changing your research?

Digitization is the prerequisite for collecting highly complex data sets that will help us to describe the interactions of countless cells in the immune system with each other and with the other cells in the body. We need these data sets – which often contain comprehensive genetic information about thousands of single cells – if we are to determine and explain fundamental cellular communication mechanisms. Consequently, real progress in the field of immuno-oncology is almost inconceivable without digitization.

a company established specially for this purpose, will have an exclusive opportunity to identify and finance spin-offs and licensing models from the Fraunhofer institutes during the early stages of innovation. Working with the European Investment Fund (EIF), and with a total volume of EUR 60 million, the Fraunhofer-Gesellschaft aims to close the gaps in funding during the early commercialization phase and thus improve the conditions for a larger number of high-tech start-ups across Germany and Europe. In terms of personalized tumor therapy, the **Fraunhofer**

Institute for Toxicology and Experimental Medicine (ITEM) in Regensburg is pursuing outstanding research with the goal of developing individualized treatment for patients. ITEM has therefore signed a strategic collaborative agreement with **Assay.Works**, its neighbor at BioPark Regensburg. Through this partnership, the Fraunhofer ITEM will have access to the complete state-of-the-art HTS infrastructure available at Assay.Works. Under the guidance of **Prof. Christoph Klein**, it can utilize high-throughput technologies to expand patient-derived tumor cells and high-throughput screening methods to identify therapeutic compounds and drug targets.

Individualized medicine has now been accomplished with Kymriah® (tisagenlecleucel), the first CAR-T cell therapy approved by the US Food and Drug Administration (FDA) for patients with acute lymphoblastic leukemia (ALL) or diffuse large-cell B-cell lymphoma (DLBCL). Novartis has entered into an agreement with the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, where tisagenlecleucel will be produced. The IZI serves as a central production and development site for the cell therapy for use in clinical studies and compassionate-use programs in patients across Europe. In terms of quality assurance, all individualized tisagenlecleucel cell therapies for patients in Europe are checked and released by Quality Management at **Novartis in Nuremberg**.

Innovation is therefore actually reaching patients. The latest agreement on an innovative reimbursement model between **Novartis Pharma** and **GWQ ServicePlus** (organization for efficiency and quality in medical insurance) signifies the interest of both parties in sustainable financing for the German health system. Accordingly, GWQ will be refunded a portion of the drug costs for Kymriah® by Novartis if the treatment outcome, defined as survival, is not achieved within a defined period. Hence, patients should also have faster access to innovative treatments. Other organizations in Bavaria are also working on the translation, i.e., the targeted transfer of preclinical research results into medical applications and treatments to the benefit of patients.

Scientists from different disciplines are working together at the **Center for Translational Cancer Research (TranslaTUM)** of Klinikum rechts der Isar hospital, for example, to discover new cancer treatments. Regular exchange and proximity to the hospital should help accelerate translation into clinical practice. Patient-driven research and close collaboration with clinicians are the goals also pursued by the **Translational**

Research Center in Erlangen. Interdisciplinary projects permit new findings from one indication to be applied in the treatment of other diseases.

The **University of Würzburg** now offers “Translational Medicine” and “Translational Neuroscience” as Master courses. Content such as experimental procedures, epidemiology and healthcare research will permit students to accelerate the transfer of new findings from basic research into clinical practice.

Biomaterial is an indispensable resource for translational research. Eleven biobanks make up the **German Biobank Alliance**, funded by the German Federal Ministry of Education and Research (BMBF). Bavaria is represented by the **Joint Biobank Munich**, the **Interdisciplinary Bank of Biomaterials and Data Würzburg**, and the faculty of **Medical Informatics at the University of Erlangen-Nuremberg**. The aim of this alliance is to facilitate the national and pan-European exchange of biosamples and data through harmonization and quality control.

Working beyond organizational Borders

Translation is one of the major challenges in healthcare research. Here, in particular, collaboration between different organizations is crucial. To drive the translation of promising, innovative research projects forward, the Fraunhofer-Gesellschaft, the Helmholtz Association, and the German umbrella association for university medical research, Deutsche Hochschulmedizin, have made EUR 12 million available for a joint **Proof of Concept** project. A jury of high-ranking experts from science, economics and regulatory authorities has shortlisted the most promising research projects for funding. The list also features Bavarian projects, including the team led by **Dr. Michael Hudecek** from the **University of Würzburg**. He is no stranger to the prize, having already won the EUR 2.5 million m⁴ Award in 2015. Once again, he is among the nominees.

The foundation of a new graduate school, the **Munich School for Data Science**, is an example of how well such transorganizational projects work, having been established as a joint venture between the Helmholtz Zentrum München, the Max Planck Institute of Plasma Physics (IPP), the German Aerospace Center (DLR), the Technical University of Munich (TUM) and Ludwig-



PROF. MATTHIAS
MACK

University Hospital Regensburg, Internal
Medicine II - Nephrology

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next ten years?

What's exciting is that the possibilities and resources for patient-driven research are improving, meaning that the know-how

gained from basic science and animal models can be put into practice and tested in clinical trials. New methods for detailed analysis of large patient populations, biobanking and bioinformatics are also making useful contributions. As far as autoimmune diseases are concerned, I expect to see much better responses to treatment due to more precise patient stratification, supported by diagnostic and therapeutic biomarkers.

How is digitization changing your research?

The amount of data generated per experiment is growing substantially thanks to new methods of analysis (e.g. single-cell analyses). The analysis and meaningful interpretation of the data are greatly influenced by bioinformatics and digitization and will shed new light on pathological processes.

Maximilians-Universität München (LMU) Munich. A total of EUR 12 million will be poured into the project over the course of six years. In addition, the **Leibniz Supercomputing Center (LRZ)** and the **Max Planck Computing & Data Facility (MPCDF)** are two major computing centers in the Munich area involved in the project.

Digitization and big data both play a significant role in almost all aspects of biomedical research. Hence, with its lighthouse project **DigiMed Bayem**, Bio^M hopes to turn the opportunities offered by this development into a specific indication (see next page).

DIGIMED BAYERN

Digitization Lighthouse Project in Bavaria



To promote the implementation of P4-medicine (predictive, preventive, personalized, participatory), the DigiMed Bayern project was launched at the end of 2018 with over EUR 20 million in funding from the **Bavarian State Ministry of Health and Care** as part of the regional BAYERN DIGITAL II program. Bio^M is responsible for management and project coordination of DigiMed Bayern. The scientific management of the project is led by the German Heart Centre Munich (DHM).

Why?

One of the most promising developments in medicine is the integration and analysis of clinical, real world and research data, the latter largely generated by molecular characterizations (omics technologies). The aim is to implement P4 medicine in the clinical routine for improved, holistic and efficient health care.

What?

This five-year lighthouse project focuses on developing (building blocks of) P4 medicine, centered on atherosclerosis, the deadliest disease in industrial civilizations, as a case example. DigiMed Bayern combines comprehensive clinical and epidemiological data from patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched through state-of-the-art multi-dimensional molecular

characterization (genomics, transcriptomics, proteomics and metabolomics) of associated sample material. For integrative analysis of the resulting "big data", an ethically and legally compliant, highly secure and sustainable digital infrastructure is required. This shall be fundamentally designed and implemented with a view to privacy-aware sharing of sensitive medical data.

The greater vision is to then generate real-life improvements in disease risk prediction, targeted prevention, health care management, diagnostics and therapy. In addition, DigiMed Bayern will endeavor to leave a footprint, concepts and infrastructure for other institutions and disease areas. Statements were obtained from the ethics committee and the state data protection officer early on and will be considered throughout the ongoing, detailed design and execution phases of the project. In conclusion, we believe that multi-scale system medicine and modern digital solutions will open up new avenues and help shape the medicine of the future.

Who?

The project's scientific leader, **Prof. Heribert Schunkert**, is Director of the Department of Cardiovascular Diseases and Deputy Medical Director of the German Heart Center Munich. Executive leadership and project coordination are the responsibility of **Prof. Horst Domdey**, Managing Director of Bio^M, the Bavarian coordinating body for innovations in medical biotechnology. In addition, DigiMed Bayern is supported by world-leading consortium partners from Bavaria: clinics specializing in heart disease and stroke, a patient organization, and research institutes in the field of omics technologies and molecular biology, epidemiology, human genetics, medical law and ethics.



Kick off meeting of the partners of DigiMed Bayern on October 1, 2018.



VOSSIUS & PARTNER

Special ideas require special protection.

For over 50 years, VOSSIUS & PARTNER has been providing high-end consultancy for innovative companies in all fields of patent, trademark, design and copyright law. VOSSIUS & PARTNER works in your interest: competently, reliably, precisely and creatively.

Legal areas. Patents, trademarks and brands, design rights, copyrights, know-how protection, domains, competition law, anticounterfeiting, software and IT, data protection, law on employees' inventions, licensing, food law, distribution agreements, franchise agreements, R & D agreements, media law, right of publicity, antitrust aspects in licensing, supplementary protection certificates, pharmaceutical law.

Technical areas. Mechanical & electrical engineering, IT, physics, chemistry, biotechnology, pharmacology, life sciences.

Services. IP prosecution, IP litigation, IP searches, freedom to operate, contracts, annuities, arbitration, mediation, IP portfolio management, due diligence, strategic IP consulting, IP landscaping, IP valuation services.

It is not without reason that VOSSIUS & PARTNER is among Europe's most renowned law firms in the field of intellectual property.

BioEntrepreneurship Summit 2019

create the future of medicine

Munich, October 15 - 16, 2019

- Be part of the bioentrepreneurial ecosystem !
- Don't miss key trends shaping the industry and the future of medicine !
- Meet exciting pre-seed and start-up showcases !
- Learn from peers, experienced entrepreneurs and industry leaders !
- Be inspired by key notes and captivating panel discussions !
- Participate in workshops, clinics and other interactive formats !
- Enjoy the m⁴ award ceremony !



The BioEntrepreneurship Summit brings together all relevant stakeholders of the bioentrepreneurial and health tech ecosystem.



Bayerisches Staatsministerium für
Wirtschaft, Landesentwicklung und Energie

www.bioentrepreneurshipsummit.org

Platinum sponsor



Sponsors



Gold sponsor



Venues

TranslaTUM + Munich Residence

Bio^M FOR BIOENTREPRENEURS

Guiding you from Idea to Success

Bio^M supports Bavarian biotech companies at every stage of setting up their business. Therefore, Bio^M has developed a unique support program tailor-made for aspiring start-ups and entrepreneurs in the life sciences sector.

Start-ups and young entrepreneurs in medical biotechnology receive extensive and individual coaching from Bio^M. Teams receive guidance in the development of a sustainable business model, setting up a plausible business plan, and identifying the appropriate financing and funding opportunities. In addition to many years of experience, Bio^M has a comprehensive network of industry representatives, investors and other relevant stakeholders. By involving the active cluster community, Bio^M supports founders from lab to market:

Around 60 experienced biotech and pharmaceutical experts in the **Mentor Circle** support aspiring start-ups and young entrepreneurs on a voluntary basis.

Founders meet three to four times a year in the informal setting of the **BioEntrepreneur Lounge** to exchange ideas with other founders and learn from experienced entrepreneurs.


The intense training format of the **BioEntrepreneur Bootcamp** enables teams of founders to design and validate their business concept in Munich as well as at our partner location in Oxford.

Every other year, Bio^M coordinates the **m⁴ Award**, a Bavarian pre-seed funding program that focuses on medical biotechnology and supports innovative academic projects with clear spin-off potential.

Founding teams can polish their presentation skills and receive honest and constructive feedback in **Pitch Doctor** sessions.


The **BioAngels** pitch event introduces investment-ready teams to investors who can potentially offer the financing that fits with the individual business model. Additionally, Bio^M fosters a lively, well-connected environment for start-ups with numerous and inspiring networking events such as the **BioEntrepreneurship Summit**.

Bio^M offers bioentrepreneurs a unique virtual incubator for life sciences start-ups.



INTERNATIONAL AFFAIRS

Bavaria going global



Prof. Horst Domdey, Managing Director Bio^M with Dr. Kazuhide Nomura, Associate Director Northern Osaka Biomedical Cluster, at the signing of the extension to the collaborative agreement.

As a central point of contact, Bio^M connects Bavarian life science companies with national and international companies, investors and relevant stakeholders, facilitating collaboration and joint ventures. Bio^M not only supports global life science players in their search for Bavarian business partners and contacts, but also offers numerous services to small and medium-sized companies in Bavaria looking to internationalize their business.

The right strategy for international success

For small companies it is often a big challenge to set up their business independently in unknown, complex markets outside Europe and to identify suitable business partners and contacts, a process that can be very time-consuming. Bio^M supports them in establishing networks worldwide, thus accelerating the process of collaboration and market entry, and providing intercultural training to prepare them for international business.

Global connections with a focus on Asia

Reflecting the interests of companies from the biotechnology cluster of Bavaria, Bio^M identifies particularly relevant global target regions and tailors its

internationalization services accordingly. In addition to agreements with collaborative partners in China, USA, Canada, Australia, South Korea and Brazil, Bio^M maintains a close and long-standing partnership with Japan. In October 2018, the collaborative agreement between Bio^M and Osaka Bio Headquarters was officially extended until 2022. Together, the partners aim to further promote and strengthen the regions of Bavaria and Kansai (Osaka, Kobe, Kyoto) in the field of biotechnology and life sciences.

Optimal market entry in Japan with Bio^M and EIT Health

Japan is the world's second largest healthcare market and ranks amongst Europe's top five pharmaceutical trading partners. Given Europe's leading position in life sciences and Japan's interest in novel technologies, services and products, this sector promises significant opportunities for innovative European SMEs. However, for European health service and product companies the introduction of new and complex cutting-edge technologies and the establishment of large companies in the conservative Japanese healthcare market can prove laborious and necessitate intensive consultation. Funded by EIT Health within the framework of its "GoGlobal" accelerator programme, Bio^M developed the "Start.Smart.Japan" training concept specially for start-ups and SMEs, whose

goal is to enter the Japanese life-science market. It is a contemporary, high-quality modular training course aimed at accelerating market entry in the challenging Japanese life science market. The training helps each SME to devise their specific market entry strategy for Japan.

In 2018, executives from nine SMEs received 12 months of training to help optimize their individual strategies for entering the Japanese life science market. Three of the participating companies are based in Germany. By the end of the project, the nine SMEs had established a total of 42 valuable, long-term business contacts and reported on the successes achieved with the Start.Smart.Japan project.



Networking during Start.Smart.Japan 2018 workshop.

For European SMEs, it usually takes a comparatively long time to achieve success in the challenging life science market of Japan, while establishing rewarding business connections can also be a lengthy process. With Start.Smart.Japan training and support, the participating SMEs

were able to accelerate their market entry. For example, eight CDAs and two collaborative agreements have been signed, and six parties have entered into more detailed negotiations with potential clients. Dr. Ignasi Sahun from the Spanish company ZeClinics views the experience he gained from the programme as very positive: “Start.Smart.Japan enabled me to understand the internal work flow of decision-making in negotiations with Japanese people, and also to better understand how they think and what doors I need to knock to succeed.”

Dr. Stephanie Wehnelt, project leader and Head of International Affairs at Bio^M, commented on completing the project: “In addition to the business contacts acquired through Bio^M and its Japanese partners, the participants also greatly benefited from each other by learning from the others’ experiences and by sharing their networks. Ultimately, several contracts were signed between the participants and even one joint EU proposal!”

Start.Smart.Global – in addition to Japan, Bio^M brings you to South Korea

Successful completion of the Start.Smart.Japan 2018 programme has paved the way for Start.Smart.Global 2019, an EIT Health funded extension of the training concept. It takes into account the lessons learned and transfers the concept to South Korea, as an additional target market. The training concept will continue to be optimized, and brings in the new project partner Medicen Paris Region, tapping into their global expertise and networks.

About EIT Health

The European Institute of Innovation and Technology Health (EIT Health) is a consortium of more than 50 core partners and 90 associate partners from leading businesses, research centres and universities from across 14 EU countries. The aim of EIT Health is to promote entrepreneurship and innovation in the areas of healthy living and active aging in order to increase the competitiveness of European industry, improve the quality of life of Europe’s citizens and the sustainability of healthcare systems. The European headquarter of EIT Health is located in Munich.



INNOVATION CENTERS IN BAVARIA

Regional Networks in Life Sciences

In Bavaria, a lively and successful biotech scene has established at five locations. Munich, Regensburg, Würzburg, Straubing and the Nuremberg metropolitan region are among the leading locations in the biotech sector in Germany. The neighbourhood of scientific institutions, providers, technology parks and support by cluster organisations creates perfect environments for attracting and founding biotech companies.

The cluster organisations are building a network of companies, universities, research facilities, university hospitals, chambers and associations, investors, funding authorities, advisers, and other players in the clusters.

Erlangen and Nuremberg

The European Metropolitan Area Erlangen-Nuremberg is an internationally leading location for medical technology.

Cluster organization:

Medical Valley Incubator

Medical Valley Centers

in Erlangen (>5,000 sqm) and

Forchheim (>2,300 sqm)

www.medical-valley-emn.de



Munich

Bio^M is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. The cluster organization Bio^M is the central point of contact for the biotechnology sector in Munich and Bavaria. Bio^M offers a wide range of services and events and has developed a comprehensive incubation program for company founders in the field of biotechnology.

www.bio-m.org



IZB Martinsried and Freising

The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on bio, agricultural and nutritional sciences) has developed into one of the top biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of optimal building infrastructure for biotechnology.

www.izb-online.de





Würzburg

The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive program for promoting start-up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg
Incubator: IGZ Würzburg (> 5000 sqm)
www.igz.wuerzburg.de



Regensburg

The Innovation center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg / Healthcare Regensburg
Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de



Straubing

The BioCampus in the port of Straubing focuses on creating value from biobased resources, biomass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and industrial biotechnology, it offers lab space, offices, start-up and business support. Cluster Organization: BioCampus Straubing GmbH
Incubator: BioCubator (1,200 sqm)
www.hafen-straubing.de



Industrial Biotechnology in Bavaria

Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects in Industrial Biotechnology and sustainable economy.
www.ibbnetzwerk-gmbh.com



THE SUCCESSFUL INNOVATION CENTRE MADE IN REGENSBURG



Health Industry of Regensburg

- 1.8 billion Euro turnover
- 20.000 employees

Cluster BioRegio Regensburg

- 55 companies (Life Sciences)
- 3.980 employees

BioPark Regensburg

- 18.000 sqm area
- 38 companies, 608 employees.
- 64 start-ups since 1999
- flexible leasehold concept & single offices
- direct motorway connection
- located on the University Campus
- own day-care facility
- conference rooms and theatre

A company of the City of Regensburg

Member of



20 YEARS OF BIOPARK REGENSBURG



Successfully looking back and looking forward for the Cluster in East Bavaria

In 1999 BioPark Regensburg kicked into action with its first building and today with 18,000 m² is the second biggest center of its type in Bavaria. Together with its subsidiary enterprise TechBase, currently over 30,000 m² of floor space is available in the technology and startup centers on the university campus in the city on the Danube with 166,000 inhabitants. For years prognostic studies have counted Regensburg as being amongst the most dynamic and fastest growing municipalities in Germany. A reason for this was and is the consistent economic promotion of the city, which with its active business and cluster policy has had a significant influence on the innovative location on-site.

“Small but fine” has been the motto time and again succeeding in bringing the decision makers spanning different parties in the cathedral city to the table and bringing them together on the way towards innovative projects. All of the building projects were able to be realized by funding from the EU, Federal Government, State of Bavaria, City of Regensburg and private equity. As an enterprise of the City of Regensburg BioPark Regensburg GmbH has been able to constantly further develop its cluster policy in the Regensburg BioRegion beyond its sole leasing business. It is a region certified in East Bavaria with a Silver Label in accordance with the European Cluster Excellence Initiative. In particular the interdisciplinary linking of biotechnology with other industries such as sensory technology has led to new industry branches at the location.

Today 55 companies with 3.980 employees are active in the Regensburg BioRegion, a good ten times more than 20 years ago. In this period of time we have successfully been able to bring 64 startup companies to the Business Plan Competition for North Bavaria. To date the companies have acquired 661 million, half as private equity and a quarter of this as venture capital or funding.

The success has many parents. The location is directly on the university campus surrounded by two universities and four clinics. The consistent support by the City of Regensburg and the State of Bavaria. A self-supporting BioPark Regensburg GmbH. The stakeholders on-site from university and businesses and of course the successful startups with their innovative applications.

With our youngest project “Healthcare Regensburg – managed by BioPark” we are just now expanding the next interdisciplinary cluster in healthcare in the region with the support of the State of Bavaria. For this we have produced a Healthcare Masterplan which denotes the potentials and recommendations for action for Regensburg and the Region in this field. A recent survey of the BioPark demonstrates since the last count in 2011 the number of employees with social security in the healthcare industry has risen by 26 % in the region and documents the growing importance of this industry. In 2018 this showed a total of 19,683 employees, with 10,955 employees work in the five hospitals in the City and the Region.

For the “Digital Health Initiative Regensburg” we are organizing innovation days e.g. in caregiving or supporting the networking of regional stakeholders for the exchange of data for multiprofessional and interdisciplinary care in the whole of East Bavaria. With an incubator in the field of medical engineering and accelerator in the field of healthcare we are promoting innovation and startups in regional healthcare.




DR. THOMAS DIEFENTHAL
CEO of BioPark Regensburg GmbH

Contact details

BioPark Regensburg GmbH
Am BioPark 13 / BioPark III
D 93053 Regensburg
Phone: + 49 (0)941 920 460
Fax: + 49 (0)941 920 4624
www.biopark-regensburg.de

Bio^M - YOUR GATEWAY TO THE BAVARIAN BIOTECH COMMUNITY



Bio^M is the central network organization for the biotechnology sector in Munich and Bavaria, supporting the community in a variety of ways with its extensive network. The cluster management offers centralized access and, as a central point of contact, Bio^M connects Bavarian life science companies with relevant national and international partners. Furthermore, Bio^M organizes a broad range of training courses, events and network meetings – also for start-ups.

For start-ups, in particular, the network organization provides comprehensive consulting services and specialized coaching, training and mentoring programs. In total, Bio^M has supported more than 200 start-up companies in 20 years. In addition to the above, the information portal at www.bio-m.org offers an extensive company database, news and events updates, and a popular job forum.

Company Profiles



Contact:

Am BioPark 11, BioPark III
D-93053 Regensburg
Phone: +49 (0) 941 20000890
E-Mail: info@2bind.de
Internet: www.2bind.de

2bind GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service

2bind is a CRO (certified by NanoTemper) in the area of biophysical analytics to study molecular interactions. With focus on early drug development (hit identification, hit validation and hit characterization). Four core technologies (MST, nanoDSF, BLI and ITC) allow our experts for studying molecular interactions in terms of classical binding parameters such as affinity, kinetics, thermodynamics and stoichiometry. We offer a broad portfolio of biophysical assays starting at High Throughput Screening, Binding analyses in bioliquids (such as sera) up to competition assays. Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods, from customized milestone-based projects with clear timelines and reliable cost structures. Be smart work with the experts!



Contact:

Fraunhoferstraße 22
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
E-Mail: public@4sc.com
Internet: www.4sc.com

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rare Disease, Orphan Drug, Drug Development, Small Molecules, Oncology

4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need. 4SCs pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of development: resminostat, domatinostat (4SC 202) and 4SC 208. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC had 47 employees as of 31 December 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

ABF GmbH

CRO

Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Clients are from the occupational, environmental, food, tobacco and pharma fields. Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions. We can offer skills of a staff (10 employees), almost all of them with an academic background, with a wide range of know-how, allowing flexible working approaches. Our aim is to provide excellent, high quality services; meeting or exceeding our customers' expectations. Our service goes beyond sample analysis, we help customers to evaluate and interpret data. Additional keywords: Instrumental Analytics, LC-MS/MS, GC-MS(/MS), Method Development, Validation and Application.

abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and de-centralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces.

Actarmo Medical GmbH

CRO

Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory

Actarmo is a Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experienced team we offer GMP laboratories as well as consultancy activities.



Contact:
Dr. Max Scherer

Semmelweisstraße 5
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 535395
E-Mail: max.scherer@abf-lab.com
Internet: www.abf-lab.com



Contact:

Raiffeisenstraße 34
D-85402 Kranzberg
Phone: +49 (0) 8166 9986 130
Fax: +49 (0) 8166 9986 140
E-Mail: info@abfdiagnostics.com
Internet: www.abfdiagnostics.com



Contact:

Robert-Koch-Allee 29
D-82131 Gauting
Internet: www.actarmo.com



Contact:

Wohraer Str. 37
D-35285 Gemünden
Phone: +49 (0) 6691 97990 0
Fax: +49 (0) 6691 97990 25
E-Mail: info@activoris.com
Internet: www.activoris.com

Activoris Medizintechnik GmbH

MEDTECH

Keywords: Regulatory Affairs, Logistics, Pneumology, Devices, In-Vitro-Diagnostics

Activoris is a German outsourcing specialist for pharma, medtech and diagnostics companies. Activoris supports its clients with contract manufacturing, device developments, regulatory and business consulting as well as administration support. Activoris' clients are among both well-established corporations and life science startups. With Activoris, they achieve more flexible, cost-efficiency and a faster time-to-market.



Contact:

Dr. Markus Waldhuber

Am Klopferspitz 19 c/o IZB
D-82152 Planegg-Martinsried
E-Mail: info@adivo.vet
Internet: www.adivo.vet

adivo GmbH

PHARMA ANIMAL HEALTH

adivo is a German biotech company based in Martinsried near Munich specializing in generating species-specific therapeutic antibodies for companion animals. The adivo team aims to initially address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future. Using its fully canine-based antibody library, adivo, either alone or with partners, intends to generate therapeutics for dogs that are well tolerated and efficacious as well as to continuously improve its technology.



Contact:

Prof. Dr. Götz Münch

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 2000 204-10
Fax: +49 (0) 89 2000 204-20
E-Mail: info@advancecor.com
Internet: www.advancecor.com

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. The company concentrates on innovative biological drugs in indications with unmet medical needs. One biological drug, Revacept has recently completed a phase II trial in patients with stroke and cerebral vascular syndromes. Another phase II clinical trial for the treatment of coronary artery disease is ongoing. Revacept is a lesion-specific inhibitor of atherothrombosis. Further preclinical candidates are under development, i.e. CD39-GPVI, a fusion protein which provides further effector functions compared to Revacept alone. Cyclic peptides are being investigated for their potential to treat Graves' disease. Further, anti-GPVI antibodies are also being developed in platelet activation syndromes. advanceCOR is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF, Occident and Bio^M AG. The founders and management of advanceCOR bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Advanced Identification Methods - AIM GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Laboratory, Molecular Diagnostics, NGS, PCR

We identify biological samples from animal sources quickly and reliably for you. We specialize in: Yard or forest pests, including larvae and eggs; Identification of insects from deadwood or ground samples by NGS; Insects from ecological assessment traps (e.g. Malaise traps); Samples from meat, fur, or skin; And much more for the identification, we use genetic DNA barcoding, a method in which we are leaders in Germany. We collaborate on the construction of an Internet-based genetic database of the German fauna. The skilled staff at AIM - Advanced Identification Methods GmbH - is hence performing species identification via routined DNA Barcoding protocols, fast, reliable & cost-efficient!



Contact:

Müllerstraße 17
D-80469 München
Phone: +49 (0) 8951 3089 89
E-Mail: info@aimethods-lab.com
Internet: www.aimethods-lab.com

Aenova Holding GmbH

BIOTECH & PHARMA PRODUCTION

With a planned turnover of around EUR 750 million in the current financial year, the Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group's portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. The Aenova Group high standards of quality, innovative technologies and clear vision for the future have enabled it to become European market leader in the business-to-business field. The company, which has its headquarters near Munich, operates 22 sites in ten countries throughout the world. More than 4300 employees contribute to the group's success.



Contact:

Dr. Dr. Mohammad Naraghi

Berger Straße 8 - 10
D-82319 Starnberg
Phone: +49 (0) 8151 9987-001
Fax: +49 (0) 8151 9987-499
E-Mail: info@aenova.de
Internet: www.aenova-group.com

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Bioanalytics, Laboratory

Agrobiogen focuses on and is experienced in the application of molecular genetic techniques in livestock animals (especially molecular genetic diagnostics and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for high-throughput analysis.



Contact:

Herr Dr. Lutz Plobner

Larezhäusen 3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: info@agrobiogen.de
Internet: www.agrobiogen.de



Contact:
Dr. Stefan Schwab

Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 85-29452
Fax: +49 (0) 9131 85-29449
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com



Contact:

Landsberger Straße 300
D-80687 München
Phone: +49 (0) 89 45 70 91 300
Fax: +49 (0) 89 51 51 87 21
Internet: www.alexion.de



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.

Alexion Pharma Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world. Alexion operates a branch office in Germany to support patients locally. Further information about Alexion can be found at www.alexion.com or at www.alexion.de.

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Infectious Diseases, Oncology

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since then we gained additional expertise in rheumatology and transplantation and entered the field of nutritional studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.

Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: Laboratory, Fine Chemicals/Reagents, Devices, Analytical Chemistry

Consumables for Chromatography (HPLC & GC), Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps) as well as chemicals and products for dairy and food industry. For more than 30 years Altmann Analytik from Munich, Germany, has been your competent and independent partner for instrumental analytics. Our main areas are Chromatography, Spectroscopy, and Sample Prep. We provide more than 140,000 different lab supply products from more than 30 different high-quality manufacturers, such as Agilent Technologies, Chiral Technologies, Grace, Hamilton, Macherey Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC. Our products can be found and purchased online.



Contact:
Tobias Thelen

Rupert-Mayer-Str. 46
D-81379 München
Phone: +49 (0) 89 724805-90
Fax: +49 (0) 89 724805-91
E-Mail: info@altmann-analytik.de
Internet: www.analytics-shop.com

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Amgen GmbH is an affiliate of Amgen Inc. (Applied Molecular Genetics). The US based company discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, osteoporosis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.



Contact:
Dr. Corinna Jacob

Riesstraße 24
D-80992 München
Phone: +49 (0) 89 149096-0
Fax: +49 (0) 89 149096-2000
E-Mail: corinna.jacob@amgen.com
Internet: www.amgen.de

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH, former Micromet, puts novel concepts in immunotherapy to work. Using proprietary technologies, the company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. It has established a powerful drug development platform: BiTE™ (Bispecific T cell engagers), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. Amgen Research (Munich) is an affiliate of Amgen Inc. (Applied Molecular Genetics Inc.). The US based company discovers, develops, manufactures and delivers innovative human therapeutics.



Contact:
Susanne Sporer

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-205
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-50
Fax: +49 (0) 8073 91693-55
E-Mail: info@amplexdiagnostics.de
Internet: www.eazyplex.com

AmplexDiagnostics GmbH Gesellschaft für molekularebiologische Diagnostik

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR

Since 2002 AmplexDiagnostics is establishing a network and cooperation to international scientists, which is still growing and energizing our R&D. Easy handling, competent training and an excellent support are given. AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on an isothermal amplification and real-time detection in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazyplex® system you confirm pathogenic bacteria within 15 min, screen for multi-resistant bacteria within 20 min or realise Meningitis diagnostics in 30 min. The new eazyplex® system, flexible and fast as never before!

AMS Advanced Medical Services

CRO

Keywords: Pharmacology, Medical Writing



Contact:
Dr. Gerlinde Jänel

Rosa-Bavarese-Str. 5
D-80639 München
Phone: +49 (0) 89 2000074-100
Fax: +49 (0) 89 2000074-400
E-Mail: Medical.Science@ams-europe.com
Internet: www.ams-europe.com

AMS is a privately owned, independent mid-size CRO and a competent partner to the pharmaceutical and healthcare industry since 1997. Today over 250 employees work in the business areas Medical Science, Clinical Research and Marketing & Sales. As an experienced CRO, AMS offers 360° customer support in Clinical Trials phase II - IV and non-interventional studies, Data Entry, Data Management, Biostatistics, Pharmacovigilance/Clinical Safety and Medical Writing. In addition we offer Quality Management including the conduction of Audits and provide support in Regulatory Affairs and Market Authorization. AMS invented the first Internet-Pharmaschool with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full-service CRO with significant experience in multiple therapeutic areas and strong medical expertise. The Medical Science Team of AMS combines years of experience in the global clinical development and benefit assessment of pharmaceuticals with the extensive knowledge in the field of pharmaceuticals and medical devices. We are an interdisciplinary team of more than 40 experts with profound experience in Biostatistics, Medical Writing, Health Economics, Public Health and Project Management. Our Team is supported by experts with over 15 years of experience in global clinical drug development. We are pioneers for the benefit assessment of pharmaceuticals since the German Act on the Reform of the Market for Medicinal Products came into effect in 2011. Due to our wide experience in methodological requirements we are also a strong European partner in the field of Health Technology Assessments (HTAs), Relative Effectiveness Assessments (rapid REAs) for pharmaceuticals and medical devices as well as method assessments for medical devices in Germany. Benefit from our extensive experience by choosing AMS as a competent and reliable partner for projects in the life cycle of your pharmaceutical or medical product.

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world's first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers have the unique functional properties of the natural product they are based on. The organic high-performance material can be used in multiple ways, including in medical or technical products as well as cosmetic ingredients. AMSilk high-performance biopolymers give everyday products unique properties. Among other things, the polymers are biocompatible, breathable and especially robust. AMSilk high-performance biopolymers are distributed in the form of Silkbeads (microparticles), Silkgel (hydrogel) or Biosteel® (fibers). They are currently used in coatings for medical-technology products, in the textile industry and as an ingredient in personal care products.

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians. We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

anteris medical GmbH

CONSULTANTS

Keywords: Regulatory Affairs, R&D Service, In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Devices, Drug Delivery

anteris medical supports the Pharma and Biotech companies with the development, quality control and approval of their products. As consultants we assist the experts. As service providers we integrate the required resources in the teams. Our expertise in the fields of requirements management, quality control and risks management (e.g. ISO 14971), usability engineering (e.g. IEC 62366, FDA Human Factors Guidance), Alliance Management as well as approval (e.g. ISO 13485 and 21 CFR 820) accompanies the products through the entire product life cycle. anteris medical brings together the manifold and longstanding experience of its founders and employees with medical products, combination products and in vitro diagnostics under one roof.



Contact:
Jens Klein

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 579 5393-0
Fax: +49 (0) 89 579 5393-30
E-Mail: info@amsilk.com
Internet: www.amsilk.com



Contact:
Prof. Dr. med. Reinhold P. Linke

Vinzenz-Schlüpfer-Straße 20a
D-81475 München
Phone: +49 (0) 89 745 022 73
Fax: +49 (0) 89 75 999 347
E-Mail: linke@amymed.de
Internet: www.amymed.de



Contact:

Münchner Straße 47e
D-83607 Holzkirchen
Phone: +49 (0) 8024 4686 652
E-Mail: info@anteris-medical.com
Internet: www.anteris-medical.com



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-130
E-Mail: contact@apceth.com
Internet: www.apceth.com

apceth Biopharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Cell Therapy, R&D Service, Gene Transfer

apceth Biopharma is a pioneering company in regenerative medicines and a leading and certified Contract Development and Manufacturing Organization for cell and gene therapeutics. The company has a comprehensive expertise in GMP manufacturing of autologous and allogeneic cell types that are either native or genetically modified. It has long-standing experience with various cell products, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSC), lymphocytes, monocytes, dendritic cells, cord blood derived stem cells, and has the potential to expand to CAR-T and induced pluripotent stem cell (iPSC) technologies. apceth has successfully obtained manufacturing licenses for multiple cell therapy products for clinical as well as commercial use.

APEX GmbH

CRO

Keywords: Pharmacology, Drug Development, Pharmacokinetics, Diabetes, Hepatology, Nephrology



Contact:
Dr. med. Gertraud Haug-Pihale

Landsberger Str. 476
D-81241 München
Phone: +49 (0) 89 896016-0
Fax: +49 (0) 89 896016-33
E-Mail: apexpkpd@aol.com
Internet: www.apex-research.com

Our Concept...

APEX is a highly efficient combination of investigator and CRO. Our aim is to provide our clients with a service which combines the access to patients of an investigator with the expertise to perform a complex, high quality research project of a CRO. We combine high level phase 1 data quality with the typical phase 2/3 study population.

Our Service...

Is the clinical performance of pharmacokinetic and proof-of-concept / PKPD studies.

Our Study Population...

are patients with impaired renal or hepatic function and patients with other chronic stable diseases (diabetes, hypertension, asthma etc.). Since the patients come into our clinic, rather than us having to go to them via their GP's, the data we generate are more complete and accurate, fewer patients are required and the project can be completed faster.

Our Clients...

are international pharmaceutical companies from medium sized to members of the world's top ten.

AptaIT GmbH

BIOTECH BIOINFORMATICS

Keywords: Informatics, Genomics, Personalized Medicine

AptaIT is a bioinformatics company dedicated to develop advanced and user-friendly software solutions for sequence driven biomedical research. Next-generation sequencing (NGS) currently transforms the procedures of modern drug discovery. AptaIT has developed intelligent software algorithms with an emphasis to discovery platforms of novel biologics by in vitro selection strategies or analysing the adaptive immune repertoire and response. THE SOFTWARE ENABLES - intelligent and efficient analysis of next-generation sequencing data. - profound quality control of synthetic nucleic acid libraries. - accelerated identification of ligands in combinatorial approaches. - comprehensive profiling of the adaptive immune repertoire. - improved patenting strategies by profound sequence information.

Assay.Works GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering/Cell Culture, Automation, Small Molecules, Laboratory, Pharmacology, R&D Service, Drug Development

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma ist Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North and South America, South Africa and Japan. Astellas is focused on the following key therapeutic areas: Transplantation, urology, dermatology, anti-infectives, pain and oncology. Astellas employs approx. 3,300 people in Europe across Sales & Marketing, Research & Development and Manufacturing. Astellas has 21 Sales & Marketing affiliates, 3 manufacturing plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Chertsey. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, oncology, dermatology, asthma/COPD, cardiology, infectious diseases, gastroenterology and pain. Astellas Pharma GmbH employs approx. 380 people including 230 sales representatives.



Contact:
Dr. Raymund Buhmann

Am Klopferspitz 19A
D-82152 Martinsried
Phone: +49 (0) 89 21541721
Fax: +49 (0) 89 59918 125
E-Mail: info@aptait.de
Internet: www.ngsdataanalysis.com



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 2000 1240
Fax: +49 (0) 941 2000 1241
E-Mail: contact@assay.works
Internet: www.assay.works



Contact:
Karina Oppitz

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1057
Fax: +49 (0) 89 4544-1329
E-Mail: info@de.astellas.com
Internet: www.astellas.de



Contact:
Dipl.-Ing. Gunther Pesta

Hansjakobstr. 127a
D-81825 München
Phone: +49 (0) 89 45 21 60 8-0
Fax: +49 (0) 89 45 21 60 8-22
E-Mail: lab@atres-group.com
Internet: www.atres-group.com



Contact:
Sigrid Messemer

Planegger Str. 9a
D-81241 München
Phone: +49 (0) 89 780 720 010
Fax: +49 (0) 89 921 851 85
E-Mail: info@aurigon.de
Internet: www.aurigon.de



Contact:

Am Klopferspitz 19
D-82152 Martinsried
E-Mail: marius.yildiz@avergen.com
Internet: www.avergen.com

ATRES engineering biogas

BIOGAS

Keywords: Bioprocessing, Agrobiotechnology

Our top products for the top performance of you biogas plant! Stable biogas production, high effectiveness, high availability of the plant.

Aurigon GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service

AURIGON is an independent, privately-owned contract research institute dedicated to preclinical services. AURIGON provides a full range of advisory and experimental services in pharmacology, bio-/analytics and toxicology. Ranging from early-phase product efficacy and safety evaluation to regulatory toxicology and late-stage pre-marketing testing, we cover all areas of non-clinical drug development. We are a trusted outsourcing partner for multinational pharmaceutical and chemical groups, food producers and dynamic biotechnology companies. AURIGON operates offices in Munich and state-of-the-art GLP- and/or GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest. Our study directors with decades of experience ensure optimum guidance to your project!

Avergen Pharmaceutical GmbH (APG)

BIOTECH THERAPEUTICS & DIAGNOSTICS

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. APG is focused on drug development until phase II clinical studies. The location of the company in Munich enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

AMW GmbH, Arzneimittelwerk Warngau

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery

Intelligent Pharmaceuticals AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capital of the Free State of Bavaria in Germany. Although still a small to medium-sized enterprise, we already act globally by providing licenses to partners throughout the world. Our partnering resp. licensing focus is the development, manufacture and distribution of medicinal products for indications such as oncology, neurology and pain treatment. What drives us at AMW is the fact, that despite significant progress in the treatment of severe diseases with highly active drugs, there are still several unmet needs in various therapeutic areas. Thus we strive for the development of a leading technology platform to achieve the maximum benefit for the patient by significantly improving the patient's adherence to the prescribed course of treatment. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Aptamer Technology, Pharmacokinetics, Pharmacology

Axolabs is a preclinical research organization for oligonucleotide therapeutics. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 14+ years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs. Oligonucleotide Manufacturing: High-throughput up to large scale, sequence/ structure optimization, drug substance production for GLP-Tox, process development, regulatory documentation; Analytics and Bioanalytics: HPLC, UPLC, MS, CAD, CE, DSC, thermophoresis etc., pharmacokinetics and biodistribution, ADME and DMPK; Pharmacology: Lead identification and optimization, in vivo efficacy and early safety, delivery.



Contact:

Birkerfeld 11
D-83627 Warngau
Phone: +49 (0) 8024 470999 0
Fax: +49 (0) 8024 470999 29
Internet: www.a-m-w.eu



Contact:

Dr. Roland Kreutzer

Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 82762-0
Fax: +49 (0) 9221 82762-99
E-Mail: info@axolabs.com
Internet: www.axolabs.com



Contact:
Dr. Thomas Frischmuth

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 9699 3401
Fax: +49 (0) 89 9699 4696
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu



Contact:

Elsenheimerstraße 7
D-80687 München
Phone: +49 (0) 89 7857674-0
Fax: +49 (0) 89 7857674-100
E-Mail: basilea.info@basilea.com
Internet: www.basilea.com

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology, New Materials, Fine Chemicals/Reagents, Clinical Diagnostics

baseclick GmbH is an ISO9001:2015-certified company located in Neuried, Germany, and was founded in 2008 with the shareholders of BASF SE, Ludwigshafen and the LMU Munich. The core of the baseclick technology is the „click reaction,“ a Cu-catalyzed cycloaddition allowing virtually unlimited and highly efficient functionalization of nucleotides, small synthetic oligonucleotides and large gene fragments. The Scripps Research Institute patented the click chemistry of the inventor B. Sharpless, Nobel laureate 2001. Beside our own patents, baseclick holds an exclusive worldwide license for the use of this technology in the field of nucleic acids and offers this technology just as products like cell proliferation kits, modified oligonucleotides, FISH products, click reagents and many more.

Basilea Pharmaceutica Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich. Skin diseases are an area of high medical need. Patients are suffering from disfiguring conditions such as hand eczema. Alitretinoin (Toctino®), a vitamin A derivative offers a significant quality of life improvement in the treatment of adults with severe chronic hand eczema unresponsive to topical corticosteroid.

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology


Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies. BN was founded in 1994 and is headquartered in Kvistgård, Denmark with subsidiary operations in Martinsried, Germany and Morrisville, NC, USA. The company has more than 400 employees and is listed on the Copenhagen Stock Exchange.

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



BAVARIAN NORDIC

Contact:
Francisco Lopez

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 255446-030
Fax: +49 (0) 89 255446-333
Internet: www.bavarian-nordic.com

Contact:
Lutz Knabe

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-177
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Contact:

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@beckmancoulter.de
Internet: www.beckmancoulter.de

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world. Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.

Bencard Allergie GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Leopoldstraße 175
D-80804 München
E-Mail: info@bencard.com
Internet: www.bencard.de

Bencard Allergie GmbH is a subsidiary of the parent company Allergy Therapeutics, an international firm specialized on delivering diagnostic and therapeutic solutions for allergic diseases. With its 19 branches and selling offices, Allergy Therapeutics is represented on the entire globe. In Worthing, a town located in the south of England, the allergen extracts and the formulations for diagnostics and therapeutics are produced according to the highest GMP-Standards. The company portfolio includes a broad spectrum of therapeutic and Prick-test solutions (a diagnostic test for allergic susceptibility) as well as over-the-counter formulations of symbiotic organisms which support the immune system through the intestinal flora. The recent research initiatives from Bencard Allergie include the development of other innovative adjuvants, as for example the Virus-like-Particles (VLPs). VLPs are developed through the Bencard-Adjuvant-Systems, a allergonomic program dedicated to the molecular characterization of the allergens. With its wide-ranging portfolio, its future oriented research activities and the increasing customers' trust; resulting also from a focused know-how built on 80 years of history. The strong company's growth occurred in the last 5 years confirms and mirrors the company's mindset.

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for human health!



Contact:

Herterichstraße 1
D-81479 München
Phone: +49 (0) 89 74987-0
Fax: +49 (0) 89 74987-200
E-Mail: contact@bene-arzneimittel.de
Internet: www.bene-arzneimittel.de

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Bernina Plus

Contact:

Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388-740
Fax: +49 (0) 89 52388-333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.



Contact:

Michael Ewers

Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74881-0
Fax: +49 (0) 821 74881-420
E-Mail: info@betapharm.de
Internet: www.betapharm.de



Contact:
Dr. Kai Lamottke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 820106-30
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Oncology, Infectious Diseases, Natural Compounds, Small Molecules, Nutraceuticals

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated plant extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus it's ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.

BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology



Contact:
Dr. Silke Martin

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-0
Fax: +49 (0) 89 5399-4505
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research: the world's first blood donor based biobank. A large pool of more than 400,000 active blood donors enables the identification of several thousands of diseased BIOBANK participants per year. Their serial, pre-diagnostic blood samples are a unique resource for investigating markers associated with the onset and progression of diseases. With a collection of more than 4 m plasma samples processed and stored using highly standardized, qualified processes (ISO9001:2008 certification) the »Blood Donor BIOBANK« is one of the largest biobank projects worldwide.

BioClinica GmbH

CRO

Former „CoreLab Partners“ is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies. In 2013 BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica. This merger brings together two of the most experienced and trusted authorities in medical imaging management for clinical trials and creates a new standard in imaging core lab services, cardiovascular safety monitoring, and eClinical trial management solutions.

Biogen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Biogen's mission is clear: we are pioneers in neuroscience. Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS). Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. The German affiliate is located in Ismaning.



Contact:
Dr. Michael Kersten

Landsberger Str. 290
D-80687 München
Phone: +49 (0) 89 202 444 97-0
Fax: +49 (0) 89 2024 4497-9
Internet: www.bioclinica.com



Contact:
Stefan Schneider

Carl-Zeiss-Ring 6
D-85737 Ismaning
Phone: +49 (0) 89 99617-0
Fax: +49 (0) 89 99617-199
E-Mail: stefan.schneider@biogen.com
Internet: www.biogen.de



Contact:
Markus Siegers

Weißenburgstr. 22
D-93055 Regensburg
Phone: +49 (0) 941 5699 6947
Fax: +49 (0) 941 5699 2168
E-Mail: biogents@biogents.com
Internet: www.biogents.com

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organisations (e.g. CDC, USA), several armed forces (e.g. „Bundeswehr“, Germany), other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Several consumer versions are marketed since 2009. The technology is protected by two granted patents and was awarded in 2007 by the world bank with money from the Bill & Melinda Gates Foundation. Biogents also offers a fee-for-service business for insect repellents and attractants. The company was started in 2003 as a spin-off from the University of Regensburg.



Contact:
Dr. Philipp Krubasik

Robert-Koch-Str. 2
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Informatics, Data Management and Biostatistics, Data Management, Bioinformatics

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. They focus on integrating information to enable a knowledge-based approach to develop innovative life science products. Their BioXM™ Knowledge Management Environment combines software products and knowledge resources to help customers eliminate the coding process, slash the implementation time of complex projects, harness the information overload and distill critical insights from data. The Viscovery® data mining software complements the BioXM system with tools to identify and validate diagnostic biomarkers. Biomax's worldwide customers include companies and research organizations in healthcare, drug discovery, diagnostics, fine chemicals, food and plant production.



Contact:
Claudia Caspers

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, ELISA/EIA, PCR, Clinical Diagnostics

Our core competence is the manufacture and distribution of CE marked products for clinical chemistry and quality control according to IVD Guidelines. Our area of activities covers also Infectious Disease Diagnostics. We are currently extending our focus to the Molecular Diagnostics field, for which we aim to develop and to market new products leveraging on our years of experience at home and abroad. Our success is tied to a continuous increase of know-how, an extensive expertise in the healthcare marketplace and specialized system solutions in the field of Laboratory Diagnostics.

Biomer

BIOTECH NEW MATERIALS AND COMPOUNDS

Biomer develops and produces raw materials such as PHB (polyhydroxybutyrate) which can be processed and used in the same way as classic thermoplasts, but are fully biodegradable. Articles made of Biomer formulations can be disposed of by composting. Being made from renewable feed stocks they do not add to the carbon dioxide concentration of the atmosphere even when they are burned. The core competence covers the production of biopolymers in microorganisms and formulation of the extracted polymers into resins for use by plastics processors.

Biometric GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Analytical Chemistry

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Analytical Chemistry, Oncology, Respiratory Diseases, Pain, Neurology

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders and on medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficant and safe preparations. The expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects. Bionorica has established an impressive network of scientists working in about 490 renowned universities, institutions and organisations worldwide.

BIOMER
biodegradable polymers



Contact:
Dr. Urs Hänggi

Forst-Kasten-Str. 15
D-82152 Krailling
Phone: +49 (0) 89 12765-136
Fax: +49 (0) 89 12765-137
E-Mail: mail@Biomer.de
Internet: www.biomer.de



Contact:
Sabine Zirngibl-Brandl

Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
Fax: +49 (0) 941 461 68 31
E-Mail: info@biometric-gmbh.de
Internet: www.biometric-gmbh.de



Bionorica[®]

Contact:
Thomas Jaik

Kerschensteinerstr. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 231-90
Fax: +49 (0) 9181 231-265
E-Mail: info@bionorica.de
Internet: www.bionorica.de



Contact:
Dr. Stefan Strobl

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 8188802-0
Fax: +49 (0) 89 8188802-20
Internet: www.biontech.de



Contact:
Dr. Roland Klösel

Landsberger Str. 234
D-80687 München
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontex.com
Internet: www.biontex.com

BioNTech Small Molecules GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Oncology, Medicinal Chemistry, Analytical Chemistry, Small Molecules, 3D-Structural Analysis, Molecular Modelling

BioNTech Small Molecules is a 100% subsidiary of BioNTech AG (Mainz, Germany) focusing on the discovery and preclinical development of small molecule drugs in the field of cancer immunotherapy. The most advanced project is currently undergoing regulatory preclinical evaluation, while the pipeline of earlier research projects ranges from hit finding, to hit-to-lead and lead optimization phases. BioNTech Small Molecules is offering services in virtual High Throughput Screening (vHTS) based on its proprietary modeling tools, and in Analytical Chemistry. Further keywords: Immunotherapy, Oncology, Small Molecules, Medicinal Chemistry, Analytical Chemistry, Molecular Modeling.

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontex Laboratories GmbH was launched in 1995 as an innovative biotech company in the field of genetic engineering with a focus on transfection, covering the introduction of genetic material (transfection) and proteins (proteofection) into eukaryotic cells. Biontex aims to continuously improve the success of this technology by advancing their synthetically produced carrier systems for nucleic acids and proteins and developing a variety of high-quality genetic engineering products. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952 by the late David Schwartz and his wife Alice. In the 1950s, Bio-Rad introduced the first analytical grade ion exchange resins for laboratory research applications, launching the company's Life Science Group. In 1957, Bio-Rad incorporated and in 1958 relocated its headquarters to Richmond, California. By 1966 the company sold its stock to the public and expanded internationally with its first overseas office in Germany, namely in MUNICH. Over the years, Bio-Rad has evolved into a global enterprise that manufactures and distributes a broad range of products around the world. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms, and classrooms around the world. Bio-Rad's key competencies include separation, purification, and analysis, and the company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing, and BSE and chronic wasting disease testing.

Biosepar Ges. für Medizin- und Labortechnik mbH

PHARMA ANIMAL HEALTH

The company Biosepar GmbH was founded in 1987. It produces and markets its own developed and internationally patented products sold in the meantime globally in many countries around the world. Special emphasis is the development of new, environmentally friendly products that need to be not only hygienic but also non toxic during the diagnostic work process. The ParasiTrap® system has revolutionized the parasitological stool diagnostics. The FixSepar® ECO - system gained importance by the replacement of formalin fixative throughout the human and veterinary medicine and in the biotechnological synthesis and analysis. The company is expanding and in 2016 opened in Simbach am Inn a new head office.



Contact:
Sonja Fischer

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-0
Fax: +49 (0) 89 31884-100
E-Mail: info@bio-rad.de
Internet: www.bio-rad.com



Contact:

Am Industriepark 2A
D-84453 Mühldorf
E-mail: mail@biosepar.de
Internet: www.biosepar.de



Contact:
Dr. Josef Scheiber

Konnorsreuther Straße 6g
D-95652 Waldsassen
Phone: +49 (0) 9632 9248325
Fax: +49 (0) 9632 6839984
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de



Contact:

Landsberger Straße 302
D-80687 München
Internet: www.breath-therapeutics.com

bioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Bioinformatics, Personalized Medicine, Biomarker Discovery & Development, Informatics, Pharmacogenomics, NGS

BioVariance GmbH offers biomedical data analyses and related software development in the area of precision medicine for the healthcare, pharma and biotech sector. To accelerate the data analytics, we use special algorithms and machine learning to automate complex analytical processes in a customized software pipeline and to develop prediction models. We develop user-friendly interfaces including mobile apps to simplify data collection, processing, visualization and research. One of our projects is about combining medication recommendations based on genetic analysis of patients with severe diseases together with therapy monitoring by a mobile app. This supports physicians to select the most suitable medication for an individual patient and to identify negative trends of treatment earlier.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Breath Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Breath Therapeutics is a biotechnology company focused on the development of aerosolized drugs to improve the treatment of rare and life-threatening pulmonary diseases. Our founding and management team includes highly experienced executives and internationally renowned experts in drug aerosol and immunosuppression therapy. With our lead program, BOSTON, we are developing the first therapy for treatment of Bronchiolitis Obliterans, which is a life-threatening lung disease without approved drug therapy.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthritis.



Bristol-Myers Squibb

Contact:
Eszter Viragh

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info-bms-germany@bms.com
Internet: www.bms.com/de

BSL BIOSERVICE Scientific Laboratories Munich GmbH

CRO

Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering a broad range of biological safety and activity testing services for (Bio-)Pharmaceuticals, Chemicals, Medical Devices, Agrochemicals and Food. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A highly experienced team of scientists and regulatory experts guarantees acceptance by national and international authorities and supports customers from early research until finalization of preclinical studies. BSL BIOSERVICE has been accredited with DIN EN ISO 17025 as well as with AAALAC and is certified in accordance with GLP and GMP. We are listed by the World Health Organization (WHO) and have successfully been audited by the FDA.



Contact:

Behringstr. 6 / 8
D-82152 Planegg-Martinsried
E-Mail: info@bioservice.com
Internet: www.bioservice.com

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture,

Carl Zeiss Microscopy GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss Microimaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss Microscopy GmbH is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.



We make it visible.

Contact:
Dr. Renate Burgemeister

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: microscopy@zeiss.com
Internet: www.zeiss.com/microscopy



Contact:

Europaring 4
D-94315 Straubing
Internet: www.cascad.de

CASCAT GmbH

INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY

CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 2000 664-40
E-Mail: info@catalym.com
Internet: www.catalym.com

catalYm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

CatalYm GmbH is an innovative Biotech Company developing innovative immune-therapy approaches against various types of cancer. CatalYm conducts preclinical to clinical development of therapeutic antibodies and works on new mechanisms of action to achieve more effective tumor treatment.

CatalYm's focus is on approaches that rely on combinations of approved checkpoint blockers or drugs under development with its own antibodies to increase the number of patients responding to immune-therapy. The objective is to significantly better control the cancer or even eradicate the cancer to substantially elongate patient survival.

CatalYm is a spin-out from the Women's Clinic at the University of Würzburg.



Contact:

Gerwin Winter

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: R&D Service, Bioanalytics, Laboratory, In-Vitro-Diagnostics, Biochips, Devices, Toxicology

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore we offer consulting services in the area of application development, data analysis and data interpretation. Our microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO₂) and morphology (impedance).

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices

CellTool is a company that develops, manufactures and distributes innovative systems for non-contact and marker-free recognition, quantitative characterization and gentle sorting of living cells based on Raman spectroscopy. CellTool systems are especially designed to meet the requirements of biologists and physicians. They are extremely user friendly. Cell handling and cell measurements are highly automated. In combination with innovative microfluidics cells can be characterized in a physiological environment keeping them viable for downstream applications. Capabilities are quality control of advanced therapeutic medicinal products, fast diagnosis of disease, patient-specific drug screening or monitoring of cell reaction upon drugs and toxins

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Medicinal Chemistry, Analytical Chemistry, Clinical Diagnostics

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2008 and ISO 13485:2003/AC: 2009, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by a wide range of immunoturbidimetric reagents and corresponding controls, Latex reagents, controls-calibrators, food chemistry reagents, cleaning solutions for several analysers and our registered additive for waterbaths Prothermal. The products are distributed worldwide. Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

cellasys

Contact:
Dr. Joachim Wiest

Illerstrasse 14
D-87758 Kronburg
Phone: +49 (0) 8394 257929
E-Mail: info@cellasys.com
Internet: www.cellasys.com



Contact:
Dr. Karin Schütze

Bahnhofstraße 17
D-82327 Tutzing
Phone: +49 (0) 8158 9064010
Fax: +49 (0) 8158 9042318
E-Mail: info-celltool@celltool.de
Internet: www.celltool.de



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 7243-00
Fax: +49 (0) 8762 7243-12
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Dr. Fabian Bös

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: fabian.boes@certara.com
Internet: www.certara.com

Certara Spain SL Zweigniederlassung Deutschland

BIOTECH BIOINFORMATICS

Keywords: Pharmacokinetics, Drug Development, Medicinal Chemistry, Molecular Modelling, Data Management and Biostatistics, Informatics, Data Management

Certara is dedicated to improving human health through a broad spectrum of software products and scientific consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibiotics, Agrobiotechnology, Drug Delivery, Pharmacology, Drug Development, Natural Compounds



Oskar Tropitzsch

Contact:
Michael Schäffler

Waldershofer Str. 51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
Fax: +49 (0) 9231 9619-60
E-Mail: info@cfmot.de
Internet: www.cfmot.de

Cfm Oskar Tropitzsch is your reliable and GDP-Certified partner for:

- Small scale (API) manufacturing (nonGMP/cGMP)
- Contract synthesis (nonGMP/GMP)
- Small molecules (> 700 substances)
- Phytochemicals (> 1000 substances)
- Phyto-Reference Substances
- Pharmaceutical raw materials
- Excipients
- Contract manufacturing of Excipients
- Chemical specialities (Curare, Picric acid incl. DMF)
- Natural toxins - synthetically produced
- Toxins
- HPAPIs - Cytotoxins - Payloads for ADCs.
- Sourcing for all kind of chemicals in small scale
- Sourcing for APIs

In very short: Tell us what you need - we try to provide it! Finding the best solution for you! We are in business since 1788!

Charles River Laboratories, Research Models and Services, Deutschland GmbH

CRO

Keywords: Drug Delivery

At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future.

ChromoTek GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Proteomics, Imaging, Laboratory

ChromoTek is pioneer and leading supplier of innovative tools, reagents and assays based on alpaka single domain antibodies (also known as nanobodies). Our products simplify, accelerate and improve research applications in biochemistry, proteomics, microscopy and live cell imaging. Nanobodies provide unique properties such as small size, conformational epitope coverage, nano- to picomolar binding affinity and exceptional chemical protein stability. The latest premium tool is the Spot-Tag and Spot-Tag nanobody system - the first peptide-tag/nanobody system for demanding capture and detection applications including high resolution imaging.

Cipla Europe NV

PHARMA & CHEMICAL INDUSTRY

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

Cipla offers a range of products in Europe —Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.



Contact:

Sandhofer Weg 7
D-97633 Sulzfeld
Phone: +49 (0) 9761 406 0
Fax: +49 (0) 9761 406 60
E-mail: dbestell@de.crl.com
Internet: www.criver.com



Contact:

Dr. Marion Jung

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 124 148 8 - 0
Fax: +49 (0) 89 124 148 8 - 11
E-Mail: info@chromotek.com
Internet: www.chromotek.com



Contact:

Inselkammerstraße 4
D-82008 Unterhaching
Phone: +49 (0) 89 6242208 10
Fax: +49 (0) 89 6242208 29
E-Mail: europe@cipla.com
Internet: www.cipla.com

CLARIANT

Contact:
Martin Vollmer

Semmelweisstraße 3
D-82152 Planegg b. München
Phone: +49 (0) 89 710 661-0
Fax: +49 (0) 89 710 661-122
E-Mail: biotech@clariant.com
Internet: www.clariant.com

Climedo

Contact:

Schellingstr. 109a
D-80798 München
Phone: + 49 (0) 89 122 290 82
E-Mail: info@climedo.de
Internet: www.climedo.de

Clinipace CLINICAL RESEARCH

Contact:

Helfmann-Park 10
D-65760 Eschborn
Phone: +49 (0) 6196 7009 - 0
Fax: +49 (0) 6196 7009 - 120
E-Mail: contact@clinipace.com
Internet: www.clinipace.com

Clariant Produkte (Deutschland) GmbH, Group Biotechnology

PHARMA & CHEMICAL INDUSTRY

Keywords: New Materials, Agrobiotechnology

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth, which is based on five strategic pillars: Increase profitability, reposition of portfolio, add value with sustainability, foster innovation and research & development, and intensify growth in emerging markets. The main focus of Clariant's Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.

Climedo Health GmbH

BIOINFORMATICS & DIGITAL HEALTH

Keywords: Data Management, Automation, Informatics, Cell Therapy, Gene Therapy, Personalized Medicine, Oncology

Climedo supports the research activities of the university clinics by providing an intelligent software capable to harvest, archive and analyze clinical data. Beside the internal optimization process of the software and the structured data collection, the collaboration with external research partners and production laboratories stands in the forefront.

Reference algorithms paired with functional Dashboard bring a completely new usage experience and provide the doctor with a detailed real-time inside in the ongoing clinical studies.

An IT-infrastructure which complies the data protection measures and requirements will be soon implemented and examined by the public authorities.

Through our technology/software new individualized therapies, such as cell and gene therapy, can be carried out during the clinical studies in a faster and safer way.

Clinipace GmbH

CRO

Keywords: R&D Service, Allergy, Clinical Trial Management and Monitoring, Oncology, Nutraceuticals, Nephrology

At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver collaboration and flexibility not possible in a traditional CRO environment. Our personalized solutions, local regulatory expertise and therapeutic leadership are designed to face industry challenges across all major therapeutic areas. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the areas GCP, Quality Management and Project Coordination for clinical trials. The set-up and handling of DSMBs / DMCs is also one of Clinrex' core competencies.

GCP/Quality Management Consulting:

- Assessment of systems or studies regarding GCP compliance
- Inspection preparedness
- SOP development/SOP streamlining
- GCP gap analyses
- Interface sponsor/CRO
- Investigator Initiated Trials

Training:

- All areas of GCP and project management of clinical trials
- Smart Training® or customised in-house training
- Training for sponsors, CROs, investigators and study nurses



Clinrex GmbH
your clinical research experts

Contact:
Dr. Dagmar Chase

Rosenkavalierplatz 12
D-81925 München
Phone: +49 (0) 89 9292 87-0
Fax: +49 (0) 89 9292 87-50
E-Mail: info@clinrex.com
Internet: www.clinrex.com

ClinTec GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Oncology, Drug Development, Regulatory Affairs, Functional Solutions, Rare Disease

Clintec International is a medium sized, global CRO which provides full and functional resourcing solutions across every trial service and stage to the pharmaceutical, biotechnology and medical device industry. Covering over 80 countries, we have a strong presence in Europe, USA and Asia-PAC as well as unique markets in Middle East & Africa, providing the global footprint to performing global trials. Clintec has a wealth of experience in conducting clinical trials in oncology and rare disease as well as other therapeutic areas. We use industry leading e-clinical technologies to support our focused, flexible and forward-thinking approach, ensuring excellence at every stage of the trial, everywhere in the world.



Contact:
Dr. Hans Wolf

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 8355
Fax: +49 (0) 89 5574 43
E-Mail: germany@clintec.com
Internet: www.clintec.com

COLORIMETRIX GmbH

BIOTECH ANALYTICS / INFORMATICS

At COLORIMETRIX we digitise analogue colorimetric tests. How do we do this? We can turn any smartphone into a portable spectrophotometer by using its camera and a mathematical algorithm. This way we read and interpret concentration values of the substances we measure on any colorimetric test (strips, dipsticks, lateral-flow tests, microplates, solution based assays). Our technology's advantage: # No hardware needed # Works on any high-end smartphone # Easy to use # Test results available in real time # Comparable accuracy to commercial readers # Very competitive pricing # Immediate access to the cloud # Analytics, trends, insights on the measurements.

COLORIMETRIX

Contact:

Michael-Huber-Weg 18
D-81667 München
E-Mail: contact@colorimetrix.com
Internet: www.colorimetrix.com



Contact:

Kolpingring 8
D-82041 Oberhaching
Phone: +49 (0) 89 673 4688 10
Fax: +49 (0) 89 673 4688 19
E-Mail: info@comphass.de
Internet: www.comphass.de



Contact:

Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: info@conreso.com
Internet: www.conreso.com



Contact:

Dr. Jörg Müller

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 41 77 60-0
Fax: +49 (0) 89 41 77 60-222
E-Mail: info@coriolis-pharma.com
Internet: www.coriolis-pharma.com

Compass GmbH

PHARMA SUPPLIER AND TRADE

Keywords: Logistics

Compass is a young and dynamic company in the south of Munich. As an independent service provider in the pharmaceutical setting our core business is to deal with all kinds of pharmaceutical registrations. Based on our 20 years of experience in the pharmaceutical industry we want to guarantee that the bought products are available in highest quality and as fast as possible for your sales staff and for your customers. We support you therefore in the selection of the best possible contract manufacturer and accompany you and the product up to the successful conclusion of first production

Conreso GmbH

CRO

Keywords: Vaccines, Oncology, Infectious Diseases, Clinical Trial Management and Monitoring, R&D Service, Data Management and Biostatistics, veterinary clinical trials

Conreso, established in 1990, BVMA member, offers a wide range of medical and clinical research services, from phase II to late phase and epidemiological studies in humans. Since 2008 the Conreso department of veterinary medicine provides also veterinary studies. Areas of particular expertise are paediatric, oncological and vaccine studies. Quality and service of Conreso are awarded by a constant repeat business rate of 90%. Your need for temporary insourcing can be met by Conreso with the permanent permission to temporarily lend staff.

Coriolis Pharma Research GmbH

CRO

Keywords: R&D Service, Peptide/Protein, Vaccines, Antisense/Nucleotides, Analytical Chemistry

Coriolis Pharma is an independent CRO specialised in formulation development for liquid and lyophilized biopharmaceutical products including vaccines and highly concentrated formulations. In this respect, Coriolis is also able to handle biosafety level S1 and S2 material. Coriolis is also a leading expert in biopharmaceutical characterization using state of the art and innovative analytical technologies to support e.g., manufacturability, trouble-shooting, comparability and higher order structure characterization studies, and forced-degradation studies. For characterization of gene therapy and viral based vaccine products Coriolis supports in particle morphology, aggregation size distribution, and purity analysis. Coriolis offers GMP-compliant testing of subvisible particles and aggregates, in the context of e.g., in-use studies, method development and validation and release testing.

Covance Clinical Development GmbH

CRO

Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development

Covance Inc., a global contract research organization (CRO), is the world's most comprehensive drug development company. We are dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical & commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing. We also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services and a top global provider of clinical trial services.



Contact:
Dr. Wolfgang Schläger

Carl-Wery-Str. 42
D-81739 München
Phone: +49 (0) 89 9210930
Fax: +49 (0) 89 913466
E-Mail: wolfgang.schlaeger@covance.com
Internet: www.covance.com

Creative Instruments GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Automation, Devices

Creative Instruments develops and manufactures customized solutions for laboratory automation, automation analysis for diagnostics and biotechnology as well as for measurement technology. The focus is on precision engineering, chemical and liquid handling, particularly in the optical detection and related evaluation. With a team of highly qualified and motivated specialists from the fields of physics, biology, chemistry, electronics, mechanics, optics and software, we are your partner for projects right from the design through to small series production, commissioning and maintenance. The certified and innovative company develops in close cooperation with customers tailored solutions to implement processes faster, more economically and precisely.



Contact:

Holzhofstr. 19
D-82362 Weilheim
Phone: +49 (0) 881 92 77 89 0
Fax: +49 (0) 881 92 77 89 69
E-Mail: info@creative-instruments.de
Internet: www.creative-instruments.de

CRELUX GmbH - a WuXi AppTec company

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis

CRELUX is a leading expert in premium drug discovery solutions for pharma, biotech and research organizations. Our services are highly individualized for our customers. We have been delivering customized solutions in drug discovery, hit finding, validation and optimization, X-ray crystallography, biophysical screening, fragment based screening and protein supply to global pharma and biotech for more than a decade. CRELUX is part of the WuXiAppTec family and as such integrated in global R&D services.



Contact:
Dr. Michael Schäffer

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-0
Fax: +49 (0) 89 700760-222
E-Mail: crelux_office@wuxiapptec.com
Internet: www.crelux.com



Contact:
Brigitte Skudelny

Arnulfstraße 19
D-80335 München
Phone: +49 (0) 89 9901649-0
Fax: +49 (0) 89 9901649-800
E-Mail: info@cri-muc.eu
Internet: www.cri-muc.eu



Contact:
Christine Wurm

Rüdesheimer Straße 15/1
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: jorge.garcia@cromsource.com
Internet: www.cromsource.com



Contact:
Vesna Stamenkovic

Konrad-Adenauer-Allee 1
D-86150 Augsburg
Phone: +49 (0) 821 450807-4
Fax: +49 (0) 821 450807-6
E-Mail: info@crosnt.com
Internet: www.crosnt.com

CRI – The Clinical Research Institute GmbH

CRO

Keywords: Devices, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Pharmacovigilance, Regulatory Affairs

CRI-The Clinical Research Institute GmbH is a full-service Contract Research Organization for phase III and IV clinical trials as well as for observational clinical projects (clinical registries). We perform clinical projects within Europe but we also have reliable partners in USA, Australia and Japan to offer services in those regions in addition. We offer special experience in large-scaled non-commercial trials (IITs) and in studies with medical device companies. In addition, we support medtech companies in scientific marketing challenges or technical solutions for all aspects of clinical research.

CROMSOURCE GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.

CROS DE GmbH

CRO

Keywords: Pharmacovigilance, Medical Writing, Data Management and Biostatistics

CROS NT is an international Contract Research Organisation (CRO) specialized in clinical data services. Founded in 1992, CROS NT has completed over 800 studies and remains focused on biometrics services including clinical data management, biostatistics (analysis and programming), pharmacovigilance, medical writing and life science technology. CROS NT can also offer expert consultancy services on trial design, CDISC standards, DSMB review and regulatory submissions. With offices in Italy, Germany and the UK, CROS NT has retained 100% of its customers due to advanced internal governance and client relationships built on trust.

CryoShop

OTHER SERVICES

Keywords: Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. We are supporting, serving and supplying customers in the healthcare and medical research sector. Over the years we developed an expertise in projects for ultra-cold and cryogenic preservation and storage of biological specimen. Furthermore our ‚cryo‘ experienced technical crew offers services, support and maintenance, when and wherever needed. We are a reliable and skilled partner for liquid nitrogen and cold storage equipment for biotech, pharmaceutical and research companies. CryoShop is offering value added cryogenic solutions; according to our customers individual requirements it is our aim to recommend the most suitable products/ solution. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we care about your staff’s safety while working in deep cold environments, offering special cryogenic personal protective equipment as well as training courses.



Contact:

WerkStadt Sendling / Haus 2
Flößergasse 4
D-81369 München
Phone: +49 (0) 89 63 899 012
Fax: +49 (0) 89 892 94 31
E-Mail: einfachcool@cryoshop.de
Internet: www.cryoshop.de



Your reliable supplier for liquid nitrogen equipment



- Cryopreservation storage, transport and supply equipment
- Cryogenic protective equipment and training courses
- Cryogenic labelling solutions
- Cryovials and Cryoboxes



Sample preparation

ice-free bench top cooling devices



Freezing

controlled rate freezing systems



Transport

cold-temperature stability devices for short and long distances



Deep cold storage

cryogenic and ultra-low storage freezers -190°C, -80°C



Thawing

automated, consistent and reproducible thawing devices



Contact:
Dr. Silke Ostermann

Trimburgstr. 2
D-81249 München
Phone: +49 (0) 89 20335359
Fax: +49 (0) 89 80919380
E-Mail: info@cso-pharma.eu
Internet: www.cso-pharma.eu



Contact:
Dr. Huber Heinrichs

Merianstraße 26
D-90409 Nürnberg
Phone: +49 (0) 700 - 1447 1447
E-Mail: info@curadis.eu
Internet: www.curadis.eu



Contact:

Schröfelhofstr. 66
D-81375 München
Phone: +49 (0) 89 30725921
Fax: +49 (0) 89 30725921
E-Mail: info@cytophorics.com
Internet: www.cytophorics.de

CSO Pharma Consulting GmbH

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs & medical science support and successful QM/GxP consulting. Our organization is build around our customers requirements and objectives. We do not only support you as experienced service provider but always serve you as your personal business partner. Successful delivery of your projects is a personal matter for us at CSO Pharma. We run our own quality management system and offer our customers reliable services and processes based on international standards. As a professional partner CSO Pharma supports the implementation of your own Quality Management/ GxP system and you can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.

Cytophorics GbR

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro-Diagnostics

The Cytophorics technology enables a variety of applications in the pharmaceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms.

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.



Contact:
Dr. Dietmar Scheddin

Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
Fax: +49 (0) 921 1511-255
E-Mail: info@cytox.de
Internet: www.cyttox.de

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Drug Development, Oncology

Daiichi Sankyo is a global pharmaceutical company that focuses on researching and marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than EUR 9.3 billion in fiscal year 2013, Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. Daiichi Sankyo has established affiliates in 12 European countries since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer.



Contact:

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu

Data Analysis Solutions DA-SOL GmbH

BIOTECH BIOINFORMATICS

Keywords: Informatics, Biomarker Discovery & Development, Personalized Medicine, Molecular Diagnostics, Drug Development, Data Management and Biostatistics, Data Management

DA-SOL is a services and consulting company providing advanced multivariate bioinformatics, biostatistics, chemometrics and data mining. Based on extensive experience in large scale industry projects and fostered by proprietary algorithms, DA-SOL develops innovative, tailored data analysis solutions for its clients and provides project support as well as training on all levels. Gene expression, proteomics, metabolomics, spectroscopy, imaging and other data – DA-SOL helps its clients to conduct their studies most efficiently and to harvest the full potential of their data. Focus areas are the analysis of process data, the development of medical diagnostics and the integration of diverse biomedical or pharmaceutical data.



Contact:
Dr. Jürgen von Frese

Moosstr. 36
D-82266 Inning am Ammersee
Phone: +49 (0) 8143 9977293
Fax: +49 (0) 8143 9977294
E-Mail: info@da-sol.de
Internet: www.da-sol.de



Contact:

Neuhauserstraße 25
D-80331 München
Phone: + 49 (0) 89 122 290 82
Internet: www.dm-matrix.com



Contact:

Dr. Michael Davids

Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948 228
Fax: +49 (0) 941 946 8119
E-Mail: info@dabio.de
Internet: www.davids-bio.de

DEFINIENS[®]
the tissue phenomics company

Contact:

Dr. Florian Leiss

Bernhard-Wicki-Straße 5
D-80636 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: fleiss@definiens.com
Internet: www.definiens.com

Data Matrix GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing

Data MATRIX's history goes back to 2014, when it was established as a spin-off from the data management department of OCT. As part of OCT, the team had been growing and developing constantly since 2009. With its high quality software products and professional team Data MATRIX has already successfully completed 74 projects with more than 58 current studies at different progress stages. We are trusted by such companies as Abbott, Novartis, R-Pharm and many others. - Full range of clinical data management services from study design development to preparation of clinical study report - Individual approach to every project - Team of dedicated professionals - ACDM & SCDM memberships. We are familiar with EDC, IWRS, PV, CTMS, eclinical solutions.

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

Davids Biotechnologie is a German custom manufacturer for antibodies since 1996.

- Polyclonal antibodies and monoclonal antibodies.
- Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells.
- Chromatographic and affinity purification services for purification of protein without a tag and with a tag.
- Cell-based natural killer cell assays for detection of active molecules and for control of human therapies.

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Drug Development, Microscopy, Personalized Medicine, Oncology, Toxicology, Biomarker Discovery & Development, Clinical Diagnostics

Definiens is the leading provider of image analysis and data mining solutions for Quantitative Digital Pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to advance personalized medicine and to significantly improve the quality of patients' lives.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest GmbH focusses on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We develop new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Huntington, Alzheimer's Disease or Canavan Syndrome and a genetic blood group test. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Contact:
Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de

Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany.

Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948.



Contact:
Dr. Mathias Seidel

Prinzregentenstraße 79
D-81675 München
Phone: +49 (0) 89 2300 29-0
Fax: +49 (0) 89 2300 29-480
E-Mail: pharma@denkpharma.de
Internet: www.denkpharma.de

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 8036-05
Fax: +49 (0) 8856 8036-07
E-Mail: contact@diaserve.de
Internet: www.diaserve.de



Contact:
Takatoshi Ezoe

Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 3540-4805
Fax: +49 (0) 89 3540-4806
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com

Dojindo EU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Dojindo produces over 500 well-known products used by research organizations over the world. Many of these products were developed jointly between Dojindo staff and outside researchers. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for this shortened product cycle because our creative researchers are working continuously to meet tomorrow's research needs.



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises. We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection

Dr. Pflieger Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. Pflieger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 350 employees and a sales turnover of € 92 million in 2018. Dr. Pflieger markets over 60 non-prescription and prescription medicines for indications in urology, gynecology, dermatology and areas of self-medication in Germany and selected territories world-wide. The financial surpluses generated by the company are passed onto the Doktor Robert Pflieger-Stiftung. The foundation is supporter of medical research and sponsor of the Robert Pflieger-Forschungspreis (research prize). Furthermore the Doktor Robert Pflieger-Stiftung fulfills social charitable purposes, in particular in the field of youth and elderly care.

Dust BioSolutions GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology

Dust BioSolutions is an industrial biotechnology company that improves sustainability and profitability of its clients through the application of a natural process that solidifies permeable materials. Its international and multi-disciplinary team has developed a technology platform around microbiologically induced calcite precipitation, a bio-geochemical process where bacteria precipitate calcium carbonate within the soil matrix. A first product offers various industries a customised solution to control dust more cost-efficiently and environmentally friendly than existing alternatives. Dust BioSolutions is continuously working on other applications of the technology and an expansion of its product portfolio.

DX-Labtrack GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Bioinformatics

DX-Labtrack closes the data gap between blood collection and lab analysis and enables a new quality standard for diagnostic decision making. We change medical diagnostics from a trust-based system into an evidence-based system. Our digital human sample fingerprint is a quantum leap forward for patient safety, the quality of medical decisions and sample turnaround time in the lab. We create a trustworthy and verifiably basis for the personalized medicine of the future.



Contact:
Mirjam Kraus

Dr.-Robert-Pflieger-Str. 12
D-96045 Bamberg
Phone: +49 (0) 951 6043-0
Fax: +49 (0) 951 6043-29
E-Mail: info@dr-pfleger.de
Internet: www.dr-pfleger.de



Contact:
Martin Spitznagel

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 339 800-510
Fax: +49 (0) 89 339 800-519
E-Mail: info@dustbiosolutions.com
Internet: www.dustbiosolutions.com



Contact:

Oberländerstraße 6
D-83677 Reichersbeuern
Internet: www.dx-labtrack.com

dynamic BIOSENSORS

Contact:
Dr. Ulrich Rant

Lochhamerstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 897 4544-0
Fax: +49 (0) 89 897 4544-11
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com

Electrochaea

Contact:
Rebekka Fründt

Semmelweisstraße 3
D-82152 Planegg
Phone: +49 (0) 89 3249 3670
E-Mail: info@electrochaea.com
Internet: www.electrochaea.com



Contact:
Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7093 9316
Fax: +49 (0) 89 7093 9440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

Dynamic Biosensors GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors offers solutions for label-free molecular interaction analysis and beyond. The proprietary switchSENSE® technology combines unrivaled analytical content with superior sensitivity. Apart from standard binding parameters (affinity and kinetics; even in the sub-picomolar range), switchSENSE® allows much deeper insights into the analyte. This includes determination of the absolute size of the molecule, analysis of conformational changes, characterization of complex binders, including affinity vs. avidity, as well as thermodynamic characterization. Overall, by combining the advantages of a dynamic molecular measurement with the benefits of a chip-based biosensor system, switchSENSE® offers a new level of information and flexibility in biosensing.

Electrochaea GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Electrochaea offers a nationally and internationally patented power-to-methane key technology based on biocatalysis, which cost-effectively recycles CO₂ and at the same time produces biological methane that can be stored and used at will from excess electrical energy. The first pilot plant on an industrial scale is operating successfully in Denmark. Another plant was opened in Solothurn, Switzerland in 2019. A plant in Colorado, USA is about to be commissioned. By 2025, plants with an output of more than one gigawatt are achievable. Electrochaea has 20 employees at the headquarters in Munich-Planegg, and in Denmark. CEO is Mich Hein.

ELLA Biotech GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics

Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technology and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

EMFRET Analytics GmbH & Co. KG

BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.



Contact:
Susanne Nieswandt

Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984 964
Fax: +49 (0) 700 3637 3800
E-Mail: service@emfret.com
Internet: www.emfret.com

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Peptide/Protein, Biomarker Discovery & Development, Antibody Production Service, Personalized Medicine, Clinical Diagnostics, Drug Development

EMP Genetech Recombinant Proteins from Human Cells Improving your Research Activities. EMP Genetech provides non-GMP services in recombinant protein production and the development of stable high producer cell lines. Protein purification to customer given purity is also conducted, as well as cell banking. We work with industrial and academical clients. Since 2000, the company has developed several dozen recombinant biomolecules.

EMP Genetech's Services:

- Gene Cloning
- Development of Stable High Producer Cell Lines
- Recombinant Protein Production
- Process Development
- Generation of Cell Banks
- Protein Purification
- Experience since 2000



Contact:
Dr. Franz X. Welser

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EPIGENE

Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigenet.de



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de



Contact:

Großhaderner Str. 9
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 2180 71862
E-Mail: info@epiqmax.de
Internet: www.epiqmax.com



Contact:
PD Dr. Carsten Rudolph

Semmelweisstrasse 3
D-82152 Planegg
Phone: +49 (0) 89 8955 788-0
Fax: +49 (0) 89 8955 788-18
E-Mail: recruiting@ethris.com
Internet: www.ethris.com

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

EpiQMax GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Clinical Diagnostics, Molecular Diagnostics, Proteomics, Personalized Medicine

EpiQMax measures epigenetic modifications on the DNA and quantifies them as diagnostic markers for their usage in the pharmaceutical industry or in clinics. Therefore, we have developed a KIT that offers robust and cost-efficient preparation of samples. By means of mass spectrometry we provide a unique quantitative analysis of modifications. Finally, our service includes innovative software programs with a real-time processing status as well as an intuitive and visual reporting of the results. Since 2018, we are a partner for the development of epidrugs and biomarker research in the epigenetic field. Headquartered nearby Munich, we operate a state-of-the-art mass spectrometer to facilitate epigenetic screenings into clinical applications.

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute). eticur cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen.



Contact:
Felix Raslag

Landsberger Str. 406
D-81241 München
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de

Eurofins BioPharma Product Testing Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology

Eurofins BioPharma Product Testing Munich is part of the world's largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich.



Contact:
Bettina von Klitzing-Stückle

Behringstr. 6/8
D-82152 Martinsried
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info-munich@eurofins.com
Internet: www.eurofins.de

Eurofins Genomics

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.



Contact:

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsgenomics.com



Contact:
Dr. Dirk Ullmann

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
Fax: +49 (0) 89 4524465-20
E-Mail: info@evotec.com
Internet: www.evotec.com

Evotec (München) GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Genomics, Proteomics, Small Molecules, Inflammation, Metabolic Diseases

PARTNERED DRUG DISCOVERY AND DEVELOPMENT Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. The Company's headquarters are located in Hamburg, Germany with 13 further operational sites in Europe and the USA and more than 2,500 employees worldwide. Evotec (München) GmbH based in Martinsried is the Company's centre of excellence for proteomics, biomarker and metabolomics services.



Contact:
Dr. Johann Peter Mörsdorf

Nürnberg Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 404-0
Fax: +49 (0) 9128 4045-81
E-Mail: info@excella-pharma-source.de
Internet: www.excella-pharma-source.de

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Recent investments have directed our focus towards high containment products (including OEB5) and a one-stop-shopping approach. Excella supplies products to the generic industry but although manufactures for big pharma life cycle end products and develops processes for innovative API's and novel solid dosage forms. Services offered range from early product development through registration support to state-of-the-art manufacturing. Excella's Feucht site has an excellent track record with the FDA and other regulatory agencies since 1983 and is Safebridge certified.

Exosome Diagnostics GmbH, a Bio-Techne company

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics, CNS, PCR, Genomics, Clinical Diagnostics

Exosome Diagnostics is developing biofluid based molecular diagnostic tests for use in personalized medicine applications. Exosomes and other microvesicles are shed into all biofluids, including blood, urine, and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. The Company which is located in New York, USA and Munich, Germany, has been acquired by Biotechne (USA) in 2018.

F-Select GmbH

PHARMA & CHEMICAL INDUSTRY

The element fluorine plays an increasingly important role in the field of high-performance materials and pharmaceuticals. The production of the necessary chemical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks.

FEI Munich GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, 3D-Structural Analysis, Microscopy, Devices

Industry-leading FEI life sciences workflows offer a proven path to results for structural and cell biology researchers. Our commitment to innovation has resulted in many industry firsts, placing customers at the forefront of advanced research capabilities. With our comprehensive range of flexible workflows including hardware, software, and consumables researchers at any level can move from questions to answers quickly and easily. Our teams of scientists understand customers disciplines, challenges, and goals, enabling us to build long-term partnerships that advance biological research. More customers achieve results and recognition working with FEI than with any other solution provider.



Contact:
Dr. Mikkel Noerholm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
Fax: +49 (0) 89 416172-69
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com



Contact:

Semmelweisstrasse 5
D-82152 Planegg
Phone: +49 (0) 89 74032330
Fax: +49 (0) 89 74033443
E-Mail: info@f-select.de
Internet: www.f-select.de



Contact:
Erika Weber

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 8956 62-0
Fax: +49 (0) 89 8956 62-101
E-Mail: LM.info@fei.com
Internet: www.fei.com



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-cro.com
Internet: www.fgk-cro.com

FGK Clinical Research GmbH

CRO

Keywords: CRO/CMO, Drug Development, Cell Therapy, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring

FGK Clinical Research GmbH is a Europe-based Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic, Hungary and UK, offering full service for all phases of clinical trials. Our international client base includes biotechnology, medical device, and pharmaceutical companies. With extensive experience in all major therapeutic areas and about 120 highly qualified medical, scientific and regulatory experts we can guide you through the clinical development process, from planning and approval up until the final report. FGK has the right size to handle multi-country, multi-center studies with hundreds of patients or single country studies with a few patients, but is still small enough to guarantee a personal service to the sponsor.

FGK Pharmacovigilance GmbH

CRO

Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics

FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies' obligations in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a stand-alone center of product vigilance on national, international or global level. - Continuity of support throughout the product life-cycle - Setup of product vigilance system, daily operation of vigilance system - Services of a responsible person for a product - Quality system setup and inspection preparedness.



Contact:
Dr. Edgar J. Fenzl

Heimeranstraße 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-pv.com
Internet: www.fgk-pv.com

FoodChain ID Testing GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Transgenic Plants, Laboratory, PCR, Genomics, ELISA/EIA

FoodChain ID Testing GmbH (former Genetic ID (Europe) GmbH) provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed.



Contact:
Christoph Wiemer

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 74776-30
Fax: +49 (0) 821 74776-38
E-Mail: info@foodchainid.de
Internet: www.foodchainid.com/de

Formycon AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development

Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines.



Contact:

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 864667-100
Fax: +49 (0) 89 864667-110
E-Mail: info@formycon.com
Internet: www.formycon.com

NOT JUST ANOTHER CRO – WE FEEL RESPONSIBLE.

- ▶ Customized conduct of clinical trials for biotech and medical device companies
- ▶ Highest quality standards, accompanied by frequent and clear communication
- ▶ Combined know-how in all major indications through our 120+ in-house experts in Europe

fgk-cro.com

UNIBRAND

Owned and managed by:

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Heimeranstrasse 35 · 80339 Munich · Germany

Delivering Reliability


FGK
CLINICAL RESEARCH

FREELINE

Contact:
Dr. Markus Hörer

Semmelweisstraße 3
D-82152 Planegg
E-Mail: infode@freelinetx.com
Internet: www.freelinetx.com



Contact:

Kirchplatz 1
D-82049 Pullach
Phone: +49 (0) 89 324 939 210
E-Mail: info@freshdetect.com
Internet: www.freshdetect.com



Contact:
Dr. Gerhard Hartwich

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 7244 09-25
Fax: +49 (0) 89 7244 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de

Freeline Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Freeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of gene therapies for bleeding and other debilitating disorders based on a next-generation AAV gene therapy platform developed by Amit Nathwani, Professor of Hematology at UCL and CSO of Freeline Therapeutics. The German branch located in Munich was established around the Adeno-Associated Virus (AAV) manufacturing platform developed by Rentschler Biotechnologie GmbH (Rentschler) and acquired by Freeline. The focus of the Munich site is to further advance the AAV platform technologies and large-scale manufacturing processes as well as to develop a broad analytical toolbox for gene transfer vector characterization.

FreshDetect GmbH

PHARMA & CHEMICAL INDUSTRY

FreshDetect GmbH, headquartered in Pullach, Germany, near Munich, develops and markets innovative measurement instruments and solutions for fast and reliable quality control for the food industry. Our employees are experts in the fields of spectroscopy measurement technology and microbiology. They have extensive experience in food processing technologies and the processing of microbiology data.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: [Chip/Array Technology](#), [Infectious Diseases](#), [Devices](#), [Clinical Diagnostics](#)

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies. The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.

GATTAquant GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy

The worldwide first commercial DNA origami application: The key innovation behind our nanorulers is the application of an elaborate nanotechnology method, which serves as a breadboard to position dye-molecules on the nanometer scale. The used technique, where DNA is folded into predefined shapes, is called DNA origami and allows to attach dye-molecules at will.



DNA NANOTECHNOLOGIES

Contact:

Am Schlosshof 8
D-91355 Hiltpoltstein
Phone: +49 (0) 9192 243 99 44
E-Mail: info@gattaquant.com
Internet: www.gattaquant.com

GBA PHARMA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Laboratory, Analytical Chemistry, Pharmacology, R&D Service

GBA Pharma GmbH with sites in Martinsried, Gräfelfing and Ulm is an analytical full-service provider operating under cGMP. The three pharmaceutical laboratory sites offer scientific and technical solutions for international customers from both, the private industry and research institutions. Operating under cGMP with more than 150 employees and over 5,000 m² of laboratory space GBA Pharma GmbH provides scientific and technical solutions for the development, validation, approval process, and quality control throughout every step of the product lifecycle. Gas and liquid chromatography, mass spectrometry, capillary electrophoresis as well as microbiological testing and development of tests for in-vivo-in-vitro correlation belong to the core competencies of GBA Pharma GmbH.



Contact:

Dr. Bernd Larisch

Fraunhoferstraße 11a
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 899229-0
Fax: +49 (0) 89 8577899
E-Mail: info@gba-pharma.com
Internet: www.gba-pharma.com

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS

For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. From the very start our experienced team of electro technology engineers and precision mechanics develops and manufactures a wide product range. From customized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics.



Performing Mechatronics
Made in Bavaria

Contact: Harry Flint

Fellnerstrasse 2
D-85656 Buch am Buchrain
Phone: +49 (0) 8124 5310-0
Fax: +49 (0) 8124 5310-20
E-Mail: info@gbn-systems.com
Internet: www.gbn-systems.com



Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals/Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales.

Chief products include:

- ÄKTAdesign™ chromatography systems and BioProcess™ media
- Filtration systems and devices
- Wave Bioreactor™ and mixers
- Cell separation for isolating and purifying cells, viruses, and sub-cellular particles
- Fast Trak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.



Contact:
Dr. Peter Haberl

Fürstenrieder Straße 281
D-81377 München
Phone: +49 (0) 89 4581901-0
Fax: +49 (0) 89 4581901-5
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).



Contact:
Dr. Hildegard Haas

Candidplatz 13
D-81543 München
Phone: +49 (0) 89 543448-0
Fax: +49 (0) 89 543448-20
E-Mail: info@genedia.de
Internet: www.genedia.de

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.

Genetic ID (Europe) GmbH

Labor für gentechnische Analysen

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID (Europe) GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, custom contract assay development) and immunological detection of allergens in food and feed.



Contact:
Christoph Wiemer

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info@genetic-id.de
Internet: www.genetic-id.de

Genomatix AG

BIOTECH BIOINFORMATICS

Keywords: Genomics, Devices, NGS, Informatics, Data Management and Biostatistics

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware, software & service solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis. Instead of looking at single strands of information separately, we access an exceptionally large pool of data from different sources. This wealth of data is continually expanding, so it is continually up to date. This meta-analysis leads to more relevant results, more precise scientific knowledge and a better chance of understanding the molecular contexts of gene regulation and expression. In 2018 Genomatix was acquired by Intrexon Bioinformatics.



Contact:

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599 766-0
Fax: +49 (0) 89 599 766-55
E-Mail: info@genomatix.de
Internet: www.genomatix.de



Contact:

Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 780 179 40
Fax: +49 (0) 89 780 179 44
E-Mail: info@gen-plus.de
Internet: www.gen-plus.de

Gen-Plus GmbH & Co. KG

CRDO

Keywords: Drug Development

Gen-Plus was founded in 1999 and is since then engaged in research and development of innovative formulation concepts for challenging drug substances. Today Gen-Plus is a state-of-the-art contract research and development organization (CRDO) fully equipped and capable of meeting our customers' ambitious goals in formulation development. Experienced and skilled experts are our key factor of success.

Gen-Plus offers following contract services:

- Wide experience in special formulation concepts and technologies for solid and semi-solid dosage forms to increase bioavailability, stability and consumer convenience
- Sophisticated formulation technologies for oral films (ODF) and transdermal patches (TTS)
- GMP facility enabling manufacturing of investigational medicinal products for proof of concept studies in humans
- Competence Center for in vitro liberation & dissolution (USP I,II,IV,V) and performance of customized permeation tests
- Drug Development of high potent drug substances in tailor-made containment systems
- Development of formulations containing controlled substances (narcotics)
- All necessary conditions as well as all legal requirements for handling narcotics are fulfilled

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening diseases in HIV as well as in Hepatitis B and C - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Research and development in Gilead focusses also on hematology and oncology, liver diseases and inflammation. Gilead's headquarter is based in Foster City, California with affiliates all over the world.

GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a research-oriented, highly specialized contract service partner in the field of pharmaceutical freeze-drying. Services include, but are not limited to, formulation development for pharmaceuticals (protein, peptide), freeze-drying cycle development, optimization of processes including Quality-by-Design and scale-up from laboratory to production. GILYOS offers a variety of analytical methods to fully characterize drug formulations (liquid and solid state), with special focus on the examination of the physicochemical properties of materials. Moreover, the company offers a full range of consulting services, including technical support for freeze-dryers and sales of equipment.

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Development and application of innovative online measurement systems for biotechnical process state variables. Gimbio sees itself as a company offering innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for post-marketing-surveillances. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. An expert group for benefit assessment of newly approved drugs in Germany (AMNOG process) is established. GKM provides flexible services with expert knowledge and dedication to your projects in accordance with ICH-GCP and other applicable national and international guidelines. More than 35 years experience: cost-effective quality combined with the latest standards and technologies.

GILYOS

Contact:
Dr. Margit Gieseler

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
Fax: +49 (0) 931 907056-79
E-Mail: info@gilyos.com
Internet: www.gilyos.com

GIMBIO

Contact:
Markus Fellner

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
Fax: +49 (0) 8161 986 5661
E-Mail: info@gimbio.de
Internet: www.gimbio.de

GKM
Gesellschaft für
Therapieforschung mbH

Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail: mail@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Contact:
Claudia Kubacki

Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.glaxosmithkline.de

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a research-based, globally operating healthcare company committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines and additionally in respiratory, urological and dermatological therapies. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV. Beyond that, we are a leading manufacturer of consumer healthcare products. From clinical development to manufacturing and commercialization of our products, GSK is closely associated with Germany as a business and science location: GSK has facilities in Munich, Heidelberg, Dresden and Marburg, to name a few. We owe our success to the incredible dedication and commitment of our global workforce. We have more than 100,000 employees in 115 countries worldwide, including 3,600 employees in Germany. Social responsibility and sustainability are at the heart of our corporate philosophy. This is the reason why we place such great emphasis on promoting projects at a local level. Our global headquarter is based in London, UK.



Contact:
Dr. Lars Ullerich

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207-180
Fax: +49 (0) 89 998 207-188
E-Mail: info@gna-bio.com
Internet: www.gna-bio.com

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Clinical Diagnostics, Devices, Analytical Chemistry

GNA Biosolutions has developed a laser-based, optothermal system to provide the world's fastest DNA diagnostics. The technology is based on nanoparticles within the sample solution. These nanoparticles can be heated up with a laser, and they cool down immediately after irradiation. As a result, the heating and cooling ramps are a million times shorter than in conventional thermocyclers, leading to ultra-fast DNA amplification (Laser PCR®).

The optical characteristics of the nanoparticles can also be utilized for a fluorescence-free detection (Nanostove®) that minimizes any upstream sample preparation. GNA's Pharos400 instrument will perform integrated Laser PCR® and Nanostove® read-out. The assay pipeline comprises tests for infectious diseases, with a focus on screening incoming patients for resistant micro-organisms directly during the admission. GNA was incorporated in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich and its chair for Photonics and Optoelectronics

Innovation and Entrepreneur Center Würzburg

Where IDEAS become successful STARTUPS



- renting of lab and office space
- coaching of start-ups
- consulting on financing
- support of the management
- networking / business contacts



Friedrich-Bergius-Ring 15
97076 Würzburg, Germany
phone +49 931 780857-0
www.igz.wuerzburg.de



Contact:

430 East 29th Street
 Alexandria Center for Life Science,
 Suite 1435E
 USA-NY 10016 New York
 E-Mail: bzech@gothamtx.com
 Internet: www.gothamtx.com

Gotham Therapeutics

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords:

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, Gotham aims to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The team is applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field. For more information, please visit: www.gothamtx.com



Contact:

Christian Heese

Gollierstr. 70
 D-80339 München
 Phone: +49 (0) 89 7264960-0
 Fax: +49 (0) 89 7264960-29
 E-Mail: info@gwk-munich.com
 Internet: www.gwk-munich.de

GWK Präzisionstechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Automation, Analytical Chemistry, Devices

GWK Precision Technology offers laboratory equipment and medical devices. Based in Munich we are a team of 20 specialists and serve industries since 1991. We provide special know-how in technical fields (precision mechanics, optics, image processing, sensors, microfluidics, cutting techniques, lateral flow, 3D-prototyping) and system techniques (automation, handling, electronics and machine control) as well as the certification of equipment and production systems.



Contact:

Passauerstraße 35
 D-81369 München
 Phone: +49 (0) 152 05390057
 E-Mail: info@hellsicht.ai
 Internet: www.hellsicht.ai

Hellsicht GmbH

BIOTECH BIOINFORMATICS / DIGITAL HEALTH

Keywords: Bioinformatics, Imaging, Data Management, Informatics

We build deep learning software to improve medical diagnosis by combining human expertise with machine intelligence in a unique hybrid approach.

Hematrix Wound Care GmbH

MEDTECH

Keywords: Devices

Hematrix Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.



Contact:
Dr. Dr. Stefan Bertsch

Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematrix.de
Internet: www.hematrix.de



*Creating new ideas
is your business.*

*Protecting these ideas
is ours.*

HUBER & SCHÜSSLER
Patentanwälte und Rechtsanwälte



hepacult


Contact:
Kurt Martin

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Liming.Ge@hepacult.de
Internet: www.hepacult.de



Contact:
PD Dr. Bernhard Kreymann

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: info@hepawash.com
Internet: www.hepawash.com



Contact:

Wilhelm-Wagenfeld-Str. 20
D-80807 München
Phone: +49 (0) 89 36090200
Fax: +49 (0) 89 360902020
E-Mail: info@hmnc.de
Internet: www.hmnc.de

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Tissue Engineering/Cell Culture, Drug Development, Analytical Chemistry

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

Hepa Wash GmbH

MEDTECH

Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices

Hepa Wash has established the ADVOS system, the first method in the world for extended and individualized support of the human body's main detoxification organs: the liver, the lungs and the kidneys. The company was founded in Garching near Munich in mid-2005 by renowned nephrology and multi-organ support expert Dr. Bernhard Kreymann who had been instrumental in establishing the previous gold standard of organ support using single-pass albumin dialysis. Building on this expertise, Hepa Wash is developing reliable treatment methods to close the therapeutic gap in multi-organ failure.

HMNC Brain Health GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a biotech company specialised in research and development of new drugs, gene tests and biomarkers against depression and anxiety disorders, that was founded in December 2010. The objective of HMNC is to enable a more precise characterization of patients suffering from depression or anxiety disorders by means of gene tests and biomarkers, leading to an improved identification of those patients who will benefit from specific personalized treatments. Such compounds already exist but have not been marketed due to a lack of suitable gene tests and biomarkers. HMNC is in possession of such laboratory markers and is conducting clinical studies to prove that personalized treatment of depression based on laboratory markers is a progressive innovation with high market potential.

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is an engineering supplier for products and technical service. We are developing customized solutions of instruments and automations. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expandable with many modules e.g. for labelling, barcode reading, filling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements.



Contact:
Ditte Heimberg

Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com

HumediQ

BIOTECH BIOINFORMATICS

Keywords: Informatics, Personalized Medicine, Devices

humediQ was founded in 2010 and has currently 10 employees. We see our mission in the development, production and sales of medical-technical systems – both software and hardware. The focus is on quality assurance systems in radiotherapy. Our vision is to develop high-quality medical devices. To achieve our product goals (transfer of scientific research results into clinical routine integration of innovation into clinical practice), we work closely together with hospitals and research institutions and form a highly qualified and motivated team.



Contact:
Dr. Margarete Martinez

Herrenwiesstr. 12
D-82031 Grünwald
Phone: +49 (0) 89 649 56 28 4
Fax: +49 (0) 89 649 5628 5
E-Mail: info@humediq.com
Internet: www.humediq.com

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Peptide/Protein, Infectious Diseases, Proteomics

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, antimicrobial and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes the endotoxin detection assays EndoLISA® & EndoZyme®, EndoTrap®, EndoGrade®, reagents for food diagnostics, Bacteria Capture Kits. Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin removal Service, From Gene to Protein Service. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.



creative bioscience solutions

Contact:
Dr. Wolfgang Mutter

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
Fax: +49 (0) 8158 9060-210
E-Mail: info@hyglos.de
Internet: www.hyglos.de



Contact:
Dr. Stefan Miller

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 173 8908929
Internet: www.hyperthermics.com



Contact:
Dr. Susanne Seifert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 520 46 17-0
Fax: +49 (0) 89 520 46 17-59
E-Mail: info@ibidi.de
Internet: www.ibidi.de



Contact:
Prof. Dr. Markus Veit

Fraunhoferstraße 9
D-82152 Martinsried
Phone: +49 (0) 89 200 0203-50
Fax: +49 (0) 89 200 0203-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic microorganisms are the "software". In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards "software development and update".

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

ibidi - cells in focus ibidi develops, produces, and distributes innovative labware products, instruments, and reagents for live cell analysis and cell-based assays specifically for high-end microscopy. An extensive line of cell-culture biochips - μ -Slides, μ -Dishes, and μ -Plates- offers solutions for immunofluorescence and basic cell culture, plus complex assays, such as angiogenesis, chemotaxis, wound healing, shear stress, and flow. The instrument line includes stage top incubators and a unique perfusion system that provides continuous flow for the simulation of blood vessels. The Fuse-It reagents allow for fast and efficient transport of mRNA, siRNA, and other particles into cells.

i.DRAS GmbH

CRO

Keywords: Devices, Regulatory Affairs, Toxicology, Pharmacology, Medical Writing, Analytical Chemistry, Drug Development

i.DRAS is a service provider for international drug regulatory affairs. i.DRAS offers support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover CTAs and MAAs and all respective documentations to be filed (IB, IMPD, CTD, NtA) for new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. The same applies to borderline medicinal devices and such incorporating an ancillary drug substance.

ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

ImevaX develops highly specific vaccines against pathogens which cause chronic infectious diseases. Our lead candidate is a vaccine against *Helicobacter pylori*, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Using an immunological screening approach, our research team was able to identify the factor responsible for the down-regulation of the immune system. Presentation of an inactivated form of this factor to the immune system led to the production of inactivating antibodies, which interfere with the mechanisms hampering the immune system, resulting in a full recovery of the immune response. It was shown that such an immune-modulatory principle is not only used by *Helicobacter pylori* but is often employed by other pathogens.

In 2011, ImevaX was awarded by the prestigious GO-Bio program, which provides essential funding for the preclinical development. As part of the GO-Bio start up program of the German Ministry of Research and Education (BMBF) further bacterial pathogens are analyzed to identify immune modulatory factors that are useful as vaccines against chronic infections. During the present funding period, our most advanced project, the *Helicobacter pylori* vaccine is envisioned to become phase I ready (IND/IMP stage). Following the establishment of the company, we plan to transfer the vaccine candidate into phase I/II clinical development.

IMGM Laboratories GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, , Pharmacogenomics

IMGM Laboratories, founded in 2001, are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and bio-distribution studies of nucleic acid compounds. We provide vast experience in Expression Profiling, Mutation Analysis and SNP detection based on Next Generation Sequencing, Microarray and qPCR. IMGM offer a fast and reliable service complemented by consultancy and comprehensive bioinformatics analysis. In close collaboration with the Center of Human Genetics and Laboratory Medicine, Martinsried, our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification; comprehensive analysis of the human microbiome from different sources (eg. stool, skin, saliva) and high resolution HLA-typing by NGS as part of clinical studies under GCP. Our customer base is formed by biotech companies and start-ups, academic groups as well as bio-pharmaceutical companies across the globe.



Contact:

Grillparzerstr. 18
D-81675 München
Phone: +49 (0) 89 4140 2477
Fax: +49 (0) 89 4140 4139
E-Mail: info@imevax.com
Internet: www.imevax.com



Contact:

Dr. Eva Laußermair

Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 452 4667-0
Fax: +49 (0) 89 452 4667-410
E-Mail: info@imgm.com
Internet: www.imgm.com



i m m a t i c s

Contact:
Dr. Nikola Wiegeler

Machtlfinger Straße 11
D-81379 München
Phone: +49 (0) 89 540415-0
Fax: +49 (0) 89 540415-905
E-Mail: info@immatics.com
Internet: www.immatics.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Genomics, Proteomics

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules, directed against targets which will transform the current landscape of tumor therapy. Two discovery platforms allow a full range of cancer therapies to be developed: (1) Immatics' proprietary and world-leading XPRESIDENT® technology is the most sensitive, unbiased and high-throughput technology capable of identifying and validating targets in virtually any type of cancer. (2) Immatics' powerful TCR discovery technology enables the generation of safer and effective T-cell-redirecting products.

Quick Facts:

- 150 Team members
- >100 Targets covering 20 major solid and liquid tumors
- About 80% of discovered targets are novel
- 2 proprietary technology platforms
- 8 proprietary development programs, thereof 2 in the clinic in 2017
- Best in class - Adoptive Cell Therapies and Bispecific TCR molecules
- Multiple partnered programs
- Raised more than \$230m in cash in five financings

Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology – Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization
- Cell-separation
- Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.



Contact:
Wolfgang Mayer

Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Autoimmune Diseases, Inflammation, Drug Development, Immune Therapy

Immunic AG is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases. The company's three development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program), an inverse agonist of ROR-gamma-t (IMU-935 program), and IMU-856 (targeting intestinal barrier function). The company was founded in 2016 and is based in Planegg-Martinsried, Germany. Immunic is supported by several renowned healthcare investors.



Contact:

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 250079460
Fax: +49 (0) 89 250079466
E-mail: info@immunic.de
Internet: www.immunic-therapeutics.de

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, established in 1997. Core competences are

- Manufacturing of novel research antibodies,
- Full service custom antibody production and purification,
- Marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specializations:

Through sophisticated schemes of immunization, affinity purification & depletion on multiple proteins or peptides immunoGlobe® has specialized in the generation of highly specific antibodies against:

- any combination of (de)phosphorylation states of neighboring double-phosphorylation sites
- neo-epitopes (e.g. cleavage sites)
- isoforms, variants, and point mutations
- Epitope mapping services with single amino acid precision complete the service catalog.



Contact:

Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.



Contact:

Martin Sahiri

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 7263718-54
E-Mail: info@implen.de
Internet: www.implen.de



Contact:
Patrick McManus

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 8935 69-0
Fax: +49 (0) 89 8935 69-22
E-Mail: request@inamed-cro.com
Internet: www.inamed-cro.com

Inamed GmbH

CRO

Keywords: Drug Delivery, Medical Writing, Respiratory Diseases

Inamed GmbH - „THE Respiratory CRO“ INAMED was founded in 1998 and is an experienced, independent, privately owned and managed CRO with its headquarters located at the periphery of Munich, and with its roots in basic research and clinical medicine. We are an international contract research organization with true respiratory expertise. Complementing our solid experience in conducting clinical trials, INAMED's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services. Besides our clinical trial operations at all phases of development and our fully staffed, in-house Phase I-IIa unit with twenty beds, INAMED performs in-vitro studies in our own labs and is the only CRO in continental Europe able and approved to perform radio-labeling studies. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. INAMED offers an opportunity for sponsors to get their products to market more successfully.

INC Research GmbH - a Syneos Health Company

CRO

Keywords: CRO/CMO, Clinical Trial Management and Monitoring, Medical Writing

The coming together of INC Research and inVentiv Health as one global company, called Syneos Health™, has created the industry's only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capabilities with today's most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.



Contact:

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993913-0
Fax: +49 (0) 89 993913-160
E-Mail: reza.khosravani@syneoshealth.com
Internet: www.syneoshealth.com

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software. You benefit from sophisticated systems, in which your cell lines or microorganisms develop their full potential in a reproducible way, thus contributing to your success.

For your applications, we offer the right solutions:

- Fermentation of microorganisms (bacteria, fungi and yeasts)
- Cell culture (mammalian cells, insect cells, plant cells and algae)
- Biofuel (biodiesel and bioethanol)
- Parallel bioprocesses
- Custom-made bioreactors and incubation shakers
- Bioprocess control software
- Qualification of bioreactors and incubation shakers

Closeness to the customer, high quality, innovation and flexibility are our greatest strengths.

InGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases, Automation

Institut Virion\Serion GmbH is a German in-vitro diagnostic company with more than 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests recommended for quantified antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against various viral, bacterial, fungal and parasitic infections. SERION ELISA antigen tests enable a direct antigen detection of pathogens. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens using flow cytometry. Parallel to immunoassays we have introduced the Immunomat™ for automated processing and analysis of SERION ELISA classic and SERION ELISA antigen tests.

INFORS HT

Contact:
Dr. Burkhard J. Feigel

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



Contact:

Sonnenstraße 24-26
D-80331 München
E-Mail: contact@ingeneron.com
Internet: www.ingeneron.com



virion\serion

Contact:
Andrea Aelker

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
Fax: +49 (0) 931 3045-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:
Dr. Frank Becker

Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895 572-80
Fax: +49 (0) 89 895 572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, R&D Service

Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Intana employs single molecule sensitive fluorescence correlation spectroscopy (FCCS) to measure affinities and rate constants of drug target interactions. The method does not require protein purification and assays are carried out under physiologic conditions. In particular for challenging targets FCCS has shown to be the method of choice. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements.



Contact:

Rosenheimer Str. 52
DE-81669 München
Phone: +49 (0)89 4111 124 11
E-Mail: info-DE@interceptpharma.com
Internet:
www.interceptpharma.com/about/germany

Intercept Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, New York, Intercept now has operations in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the 'liver community'.



Contact:
Angelika Geier

Fraunhoferstraße 13
D-82152 Planegg-Martinsried
Internet: www.iomx.de

iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

iOmx Therapeutics is a novel immuno-oncology target discovery and drug development company. Its founders have developed a high-throughput siRNA-based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. To date, this screening technology has been applied to multiple tumor entities. More than twenty novel targets have been identified which form the basis of the company's pre-clinical product portfolio. For more details, please refer to: <http://www.iomx.de/> or Follow us on: <https://www.linkedin.com/company/iomx-therapeutics>

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties.
2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, PASylation, PGA Poly(glutamic acid) and multi-functional dendrimers).
3. Reagents for Life Sciences and Diagnostics: substrates, inhibitors, cross-linker, immunologic tools, carbohydrates, dyes and fluorescent labels.
4. We carry out custom synthesis in all areas above. Our strengths are compounds with one or several chiral centers.

IRUBIS GmbH

BIOTECH DEVICES & REAGENTS

We are innovating ATR infrared spectroscopy by making it easier, cheaper and better. Boost the performance of your ATR device with the IRUBIS crystals and accessories. The New State of the Art: We developed a procedure to manufacture cost-effective and high-quality ATR crystals. Our products are made of silicon, can be functionalized and achieve spectrums comparable to results with diamonds.

ISAR Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Industrial Biotechnology, Drug Development, Tissue Engineering/Cell Culture, Biomarker Discovery & Development

ISAR Bioscience GmbH (Institute for Stem Cell & Applied Regenerative Medicine Research) is a translational research company founded 2018 in Planegg, Germany. Our goal is to overcome current limitations of stem cell research in order to advance discovery of novel therapeutics and industrial biotechnology products. We use iPSC (induced pluripotent stem cell) and genome engineering technologies to build the next generation of disease models as well as cell-based models for industrial biotechnology applications. ISAR will forge strategic partnerships with industry partners and translate academic achievements and ideas into industrial solutions and products. ISAR attracted an initial 20 Mio € funding from the Free State of Bavaria.



Contact:
Dr. Thomas Bruckdorfer

Adalbert-Zoellner-Straße 1
D-95615 Marktrechwitz
Phone: +49 (0) 9231 97121-15
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de

IRUBIS

Contact:

Friedrichshafener Straße 1
D-82205 Gilching
E-Mail: info@irubis.com
Internet: www.irubis.com



Contact:

Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (89) 3564 754-00
Fax: +49 (89) 3564 754-10
E-Mail: info@isarbioscience.de
Internet: www.isarbioscience.de



Contact:
Dr. Andrea Kottke

Leopoldstraße 254-256
D-80807 München
Phone: +49 (0) 89 890 831-0
Fax: +49 (0) 89 890 831-491
E-Mail: info@isarna-therapeutics.com
Internet: www.isarna-therapeutics.com



Contact:
Christian Wiest

Zielstattstr. 13
D-81379 München
Phone: +49 (0) 89 700 7449-0
Fax: +49 (0) 89 700 7449-90
E-Mail: info@ithera-medical.com
Internet: www.ithera-medical.com



Contact:
Nicola Scharrer

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 329 8986 600
Fax: +49 (0) 89 329 8986 66
E-Mail: info@itm.ag
Internet: www.itm.ag

ISARNA Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: RNAi & Antisense, Biomarker Discovery & Development, Drug Development

Isarna Therapeutics has an unmatched commitment to developing selective TGF- β inhibitors to fight cancer and to effectively treat ophthalmic and fibrotic diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotope Technologies Munich AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, the ITM Group has established the GMP manufacturing and a robust global supply network. ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM's main objectives are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of targeted radionuclide therapies in precision oncology.

PRECISELY FOR ME.

Dedicated to giving cancer patients better answers than “maybe”.

**TARGETED RADIONUCLIDE THERAPY
IN PRECISION ONCOLOGY.**



Contact:

Elisabeth-Selbert-Weg 4
93055 Regensburg
Phone: +49 (0) 941 30798265
E-Mail: kalbitzer-innovations@t-online.de
Internet: www.kalbitzer-innovations.de

KANTAR HEALTH

Contact:
Mercedes Apecechea

Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600 1005
Fax: +49 (0) 89 5600 1400
E-Mail: info@kantarhealth.com
Internet: www.kantarhealth.com

Kalbitzer Innovations UG

BIOTECH DNA/PROTEIN ANALYTICS

Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Biochemistry (University of Regensburg) that provides novel experimental as well computational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR-based analytics. AUREMOL is a software package for automated NMR spectrum evaluation and protein structure determination, compatible with AURELIA and developed in cooperation with the University of Regensburg and Bruker BioSpin GmbH. High Pressure NMR Spectroscopy: The application of high pressure (up to 200 MPa) provides very important additional information about the conformational balance of proteins, especially in the characterization of folding, dynamics and structure of folding intermediates.

Kantar Health GmbH Clinical Research

CRO

Keywords: Logistics, Pharmacovigilance, Oncology, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

Kantar Health GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmacoeconomic studies. Our operations span local agencies in over 45 countries worldwide. Kantar Health combines more than 30 years of CRO expertise in drug research including development of innovative web-based applications (InTrial© and InDrums©). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.

KLIFO GmbH

CRO

Keywords: Medical Writing, Data Management and Biostatistics, Pharmacovigilance, Clinical Trial Management and Monitoring, Regulatory Affairs, Drug Development

KLIFO, an integrated drug development consultancy. KLIFO is a leading drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. At KLIFO, we offer cross-functional consulting and operational solutions spanning all areas of clinical research, clinical trial supply, CMC development, regulatory affairs, pharmacovigilance and the development of pharmaceutical and biotech products and medical devices. KLIFO is headquartered in Copenhagen, Denmark, and recently expanded into Germany with the acquisition of medicomp GmbH, a CRO based in Munich having more than 30 years experience in providing a wide range of services across all steps of clinical trial handling.

KLIFOVET AG

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Data Management and Biostatistics, Clinical Trial Management and Monitoring

KLIFOVET AG provides high quality services for the Animal Health and Animal Nutrition Industry acting as a CRO, CMO and regulatory consultancy for the registration and marketing of all kind of veterinary medicinal products and feed additives. We offer: Project management and regulatory consultancy from the idea to the marketed veterinary pharmaceutical or immunological product or feed additive/ feed. Regulatory strategic consultancy, dossier writing, negotiations with the authorities. CRO: Planning and conduct of veterinary clinical safety and efficacy studies in all target animal species. Full life cycle management incl. pharmacovigilance and QPPV services. CMO support for EU QP release. We handle EU, US or other projects with our partners and provide over 20 years of experience.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is your service partner for organismic studies e. g. in Conservation Biology, Zoology, Phylogeny, Taxonomy, and Molecular Biology to clear up specimens' identities by means of molecular/genetic analyses (Sample preparation, PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population structure and integrity, a.s.o. In addition, we are experienced in making microscopic preparations, carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand, and acting as project manager and consultants.



Contact:
Doris Wiegel

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-mail: info@medicomp-cro.de
Internet: www.medicomp-cro.de



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580 082-0
Fax: +49 (0) 89 580 082-7777
E-Mail: info@klifovet.com
Internet: www.klifovet.com



Contact:
Dr. Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 8161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

LABOKLIN

LABOR FÜR KLINISCHE DIAGNOSTIK GMBH & CO. KG

Contact:

Dr. Elisabeth Müller

Steubenstr. 4

D-97688 Bad Kissingen

Phone: +49 (0) 971 7202-0

Fax: +49 (0) 971 68546

E-Mail: mueller@laboklin.de

Internet: www.laboklin.com



LABOR
FRIEDLE
GMBH

Contact:

Albrecht Friedle

Von-Heyden-Str. 11

D-93105 Tegernheim

Phone: +49 (0) 9403 967 98-0

Fax: +49 (0) 9403 967 98-20

E-Mail: info@labor-friedle.de

Internet: www.labor-friedle.de

LS|AG

Contact:

Denise Baumbach

Mangelsfeld 4, 5, 6

D-97708 Bad Bocklet

Phone: +49 (0) 9708 9100-0

Fax: +49 (0) 9708 9100-36

E-Mail: service@labor-ls.de

Internet: www.labor-ls.de

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Labor Friedle GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an accredited analytical laboratory for analytics of chemical residues like heavy metals, pesticides, mycotoxins and radioactivity testing. Our scope includes furthermore food ingredients, nutrient content analytic, examination of human biological matrices, microbiological and molecular biological examinations and examination of indoor air pollutions.

Labor L+S AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor L+S AG is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the company's experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered. In a state of the art plant with 10,000 sqm of laboratory space, 450 experts handle more than 250,000 samples/a. Establishment of new methods is a key strategic factor of the company's success, triggered by customers requests and changes in regulatory requirements from FDA or European agencies. Both agencies successfully inspect on a regular basis.

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM GmbH is an ISO 15189 accredited reference laboratory focused on Personalized Molecular Medicine and Personalized Molecular Diagnostics for customers throughout Europe and surrounding regions. We offer an ever-expanding menu of internationally harmonized tests to support patient diagnosis and monitoring, stratification and enrollment of patients in clinical trials and development of companion diagnostics. Our test menu includes FLT3 and NPM1 mutational assays, B- & T-cell clonality, MRD screening and NGS gene panels, all with design-controlled reagents, kits and bioinformatics software, developed and manufactured under ISO 13485 in our FDA-registered facility. Our successful partnerships have led to the approval of the first ever AML companion diagnostic.

Lead Discovery Center GmbH, LDC - Abteilung Antikörper

BIOTECH PRECLINICAL SERVICES

Keywords:

The lead discovery center GmbH was founded in 2008 by the Max Planck Society in order to exploit the potential of the excellent basic research for the development of new, urgently needed drugs. The Lead Discovery Center collects promising academic research projects and develops them further into pharmaceutical lead structures (Proof-of-concept in model systems). In close collaboration with leading academic and industrial partners the Lead Discovery Center develops an extensive project portfolio in the fields of small molecules (Dortmund) and therapeutic antibodies (Planegg) with high medical and commercial potential.

leon-nanodrugs GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Small Molecules

Leon-nanodrugs GmbH (Munich) is a speciality pharmaceutical drug development company for oral and parenteral products. Based on its proprietary MJR-nanotechnology platform Leon is focussed on the reformulation of poor / non- water soluble APIs (BCS II / IV) which reflect more than 60% of all medical drugs used worldwide. Leon's MJR-technology - a continuous solvent / antisolvent precipitation - can be applied to a wide spectrum of compounds such as small molecules and peptides; we can create API-specific crystalline and polymeric nanoparticles from 4 nm to 30µm without any limitation in capacity (>60 KG API/h). Leon can provide its industry partners a complete development range: from concept to CTM and commercial production.



Contact:
Dr. Stefanie Zorbas-Seifried

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 899 480 780
E-Mail: szorbas-seifried@labpmm.de
Internet: www.invivoscribe.com/clinical-services



Contact:

Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (0)231 97 42 70 00
Fax: +49 (0)231 97 42 70 39
E-Mail: info@lead-discovery.de
Internet: www.lead-discovery.de



Contact:
Clarita Krüger-Crusius

Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 4142 4889-0
Fax: +49 (0) 89 4142 4889-88
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com



Contact:
Michael Scholl

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.com
Internet: www.leukocare.com

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

- LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics
- LEUKOCARE technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products.
- LEUKOCARE provides development services based on fee for service during implementation of its technologies.
- LEUKOCARE's technologies provide manifold benefits:
 - Improved shelf-life / stability / quality
 - Terminal sterilization of biologics
 - Significant production cost savings

lifespın GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 942 898 0
Fax: +49 (0) 941 942 898 29
E-Mail: info@lifespın.de
Internet: www.lifespın.de

Keywords: Biomarker Discovery & Development, Analytical Chemistry, Agrobiotechnology, Laboratory, Bioanalytics, In-Vitro-Diagnostics, R&D Service

lifespın offers innovative NMR-based diagnostic / analytical methods, including software solutions and databases, for the support of research and development, routine industrial use, in vitro diagnostics and quality control. lifespın methods and products are used in medical research, diagnostics and the pharmaceutical industry, as well as in plant research and biotechnology. The portfolio ranges from standardized multiparameter quantification of target substances to the comparison of metabolite profiles with specific references/masters, to targeted metabolomics-based classification. For individual requirements tailor-made analytical methods including appropriate software solutions for data analysis and automation are developed.



Contact:

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700 766 24
E-Mail: horst.lindhofer@lindisbiotech.com
Internet: www.lindisbiotech.com

LINDIS Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

LINDIS Biotech was founded to develop ektomun®, an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options. The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.

Passion for Performance

A world-class biopharmaceutical CDMO

- Experts in cell culture bioprocess development and manufacturing
- Family-owned company, thinking globally and focused exclusively on our client projects
- Biopharma pioneer with commitment to advanced technology and innovation leadership
- Extensive track record and 40 years of experience

New
U.S. Manufacturing Site
Milford, MA

Our partners:
one contact – one contract – one quality

 **LEUKOCARE**
BIOTECHNOLOGY

Best-in-class formulations
provide significant
competitive advantages

 **Rentschler**
Fill Solutions

Best-in-class facilities
for aseptic filling
and lyophilization

Rentschler Biopharma SE

Erwin-Rentschler-Str. 21 · 88471 Laupheim · Germany

info@rentschler-biopharma.com · www.rentschler-biopharma.com



Contact:
Markus Matuschka von Greiffenclau

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 28096-208
E-Mail: info@lisando.com
Internet: www.lisando.com



Contact:
Prof. Dr. Matthias Schieker

Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
Fax: +49 (0) 8151 917922
E-Mail: info@livimplant.de
Internet: www.livimplant.de



Contact:
Dr. Caroline Freye-Minks

Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
Fax: +49 (0) 8104 616-48
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

LISANDO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Lysando is a manufacturer of medical devices. Lysando AG and the R&D centre Lisando GmbH are owned by the TGI Group, which is specialised in environmentally supportive technologies and manufacturing.

Achievements:

In 2010 our team received the Food Safety Innovation Award for a novel method to detect bacterial contamination in food. In October 2012 LYSANDO AG has been rated with the best rating possible by Dun&Bradstreet.

Cooperations:

Lysando cooperates with various Universities and Institutes in Europe, Thailand, Japan and United States of America.

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops and sells innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Experimental Surgery and regenerative Medicine department of the Ludwig-Maximilians-University of Munich (www.experimed.de) and a close collaboration with the Veterinary Clinic of the University of Giessen, LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases

Lophius' mission is to transform treatment paradigms and patient management with novel molecular diagnostic solutions for life threatening and highly-contagious infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB). Lophius has developed a proprietary blood-based multi-marker solution, run on widely available platforms, to deliver a significant improvement on TB infection detection over existing approaches. Lophius is advancing biomarker combinations which would disrupt the field by being able to differentiate between active TB disease and latent TB infection. In addition, the company is commercializing a clinically validated CE-marked diagnostic kit to individualize transplant patient management by personalized CMV disease risk stratification.

lophius
biosciences

Contact:
Bernd Merkl

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 6309 197-0
Fax: +49 (0) 941 6309 197-9
E-Mail: request@lophius.com
Internet: www.lophius.com

LRE Medical GmbH

MEDTECH

Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics

LRE Medical GmbH is a leading developer and manufacturer of medical, in vitro diagnostic (IVD) and life sciences instrumentation for OEM customers. LRE focuses on products for Handheld, Point-of-Use and Laboratory markets based on a variety of technologies including solutions for molecular diagnostics. For more than 40 years we look for ways to optimize product design and manufacturing processes that improve product quality, reliability and performance and reduce overall program and product costs. LRE provides full turnkey projects 'One Stop Shopping' solutions (Engineering, Manufacturing, After Sales Service and Lifetime Product Support) for the development and manufacturing of innovative devices in compliance with ISO 13485, ISO 14001 and FDA CFR Part 820 for Class I-III Medical Devices.

Esterline
LRE Medical

Contact:
Claudia Strehle

Georg-Brauchle-Ring 89
D-80992 München
Phone: +49 (0) 89 354803-47
Fax: +49 (0) 89 354803-67
E-Mail: info@lre.de
Internet: www.lre.de



Contact:

Am Windfeld 35
 D-83714 Miesbach
 Phone: +49 (0) 8025 2867-0
 Fax: +49 (0) 8025 2867-28
 E-Mail: info@luyepharma.eu
 Internet: www.luyepharma.eu

Luye Pharma AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma Group Ltd. announced the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino in November 2016. The acquired business is a global leader in niche transdermal markets and will greatly enhance Luye's developmental efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards, thereby helping to pave the way for Luye's expansion into the global markets. The acquired business is one of the largest independent TDS manufacturers in Europe, with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone spaces under several successfully commercialised and hard-to-make formulations such as Rivastigmine, Buprenorphine, Fentanyl and fertility control patch. Luye Pharma is a leading Chinese pharmaceutical enterprise driven by innovation and primarily focuses on therapeutic areas such as Central Nervous System, Oncology, Cardiovascular, and Metabolic diseases. Since inception, Luye Pharma has adopted innovation and globalization as its core growth drivers. As one of the pioneering Chinese pharmaceutical enterprises to have conducted clinical trials in international markets, Luye Pharma currently has 5 innovative products at various stages of clinical research with significant breakthroughs in the U.S.



Contact:
 Dr. Stephan Fischer

Forstenrieder Str. 8-14
 D-82061 Neuried
 Phone: +49 (0) 89 990 178-0
 Fax: +49 (0) 89 990 178-199
 E-Mail: info@mabdiscovery.com
 Internet: www.mabdiscovery.com

MAB Discovery GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

MAB Discovery, based in Munich, Germany, is a provider of high quality IND ready monoclonal antibodies obtained from a unique immunization approach exploiting the natural immune system in combination with a sophisticated B-cell cloning and cultivation technique. Early functional testing allows the identification of highly potent monoclonals which eliminates the need for further time consuming affinity maturation. The diversity of the immune responses not only guarantees unprecedented epitope coverage but also ensure success against targets heretofore considered intractable. We offer simple and straightforward business terms by eschewing the traditional IP license approach.

MagForce AG

MEDTECH

Keywords: Oncology, Nanobiotechnology

MagForce AG, listed in the Scale standard (MF6) of the Frankfurt Stock Exchange, together with its subsidiaries MT MedTech Engineering GmbH and MagForce USA, Inc., MagForce is a leading medical device company in the field of nanomedicine in oncology. The headquarters of MagForce AG are in Berlin. The Medical Clinical Development Team is located at the Munich office. The group's proprietary NanoTherm® therapy enables the focal treatment of solid tumors through the intratumoral generation of heat via activation of instilled superparamagnetic nanoparticles by an alternating magnetic field applicator. The nanoparticles are instilled into a tumor via a minimal invasive procedure and remain at the site of injection due to their patented aminosilane coating. Based on the amount and location of the instilled nanoparticle depots and the applied magnetic field strength the company's therapy planning software simulates the temperature distribution within the treatment area prior patient treatment. NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors.



Contact:

Bunsenstraße 7
D-82152 Martinsried
Phone: +49 (0) 89 954 7795 60
E-Mail: info@magforce.com
Internet: www.magforce.de

Weitnauer

Attorneys

Munich
Berlin
Hamburg
Mannheim

Finance
Technology
Transactions



Contact:
Dr. Matthias Borgmann

Lilienthalstrasse 4
D-82205 Gilching
Phone: +49 (0) 8105 7783 30
Fax: +49 (0) 8105 26152
E-Mail: pr@mdservices.de
Internet: www.mdservices.de

medigene

Contact:
Julia Hofmann

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 2000 33-0
Fax: +49 (0) 89 2000 33-2920
E-Mail: medigene@medigene.com
Internet: www.medigene.com



Contact:

Keltenring 15
D-82041 Oberhaching
Phone: +49 (0) 89 12 11 26 36
Fax: +49 (0) 89 12 11 26 37
E-Mail: info@medizone.com
Internet: www.medizone.com

Medical Device Services GmbH

PHARMA & CHEMICAL INDUSTRY

Biological Safety of Medical Devices: Our test laboratories at Medical Device Services have been synonymous with success for medical device manufacturers for 20 years.

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy

Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. Medigene's TCR technology aims at arming the patient's own T cells with tumor-specific T-cell receptors. The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body (ex vivo).

Medizone Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Clinical Trial Management and Monitoring, Logistics, R&D Service

Medizone Germany is your reliable partner for high-service sourcing solutions. Our main services are the supply of comparators /CTM and analytical samples for Biosimilar development. We are authorized to import comparators into the EU with proper certification through our Qualified Person. Our extensive network of manufacturers and wholesalers and our experience allow us to offer products with different origins at high quality standards!

Also various local sourcing projects, for example in Russia, Japan or PRC have been successfully carried out by our team!

The supply of standard of care medicines at attractive prices belongs to the range of our services as well!

Medpace Germany GmbH

CRO

Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases, Imaging, Pharmacovigilance, Drug Development, Regulatory Affairs

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.

MedPharmTec GmbH

CRO

Keywords: Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

MedPharmTec GmbH is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec activities include medical information, i.e. medical and scientific translations, Labeling Compliance Service, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

metabion

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.

Contact:
Dr. Alfred Fraunhofer

Theresienhöhe 30
D-80339 München
Phone: +49 (0) 89 895 5718-0
Fax: +49 (0) 89 895 5718-100
E-Mail: info.de@medpace.com
Internet: www.medpace.com

Contact:
Veronika Peschkes

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-199
E-Mail: office@medpharmtec.de
Internet: www.MedPharmTec.de

Contact:
Dr. Regina Bichlmaier

Semmelweisstr. 3
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: info@mymetabion.com
Internet: www.metabion.com



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 151 1799 7111
E-Mail: info@metaheps.com
Internet: www.metaheps.com



Contact:

Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.net



Contact:

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat.de

MetaHeps GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

MetaHeps®: Clearing Drugs from Liver Injury Issues (DILI) = Enabling Better Therapies for Patients. MetaHeps® is an innovative service provider using a technology that allows to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank. Customers are pharmaceutical companies and global acting CROs, using Metaheps' services in clinical phases of drug development as well as postmarketing/pharmacovigilance.

Metronomia Clinical Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

Metronomia is a specialized CRO for statistical consulting, biostatistical services and clinical data management, based in Munich (Germany). Our customers are pharmaceutical-, biotech-, and medical device companies, universities and clinical CROs. In more than 25 years, Metronomia has been successfully involved in more than 500 clinical projects. We have a proven track record in all major therapeutic areas and all clinical phases / NIS. Our customers particularly esteem the high-quality and reliability of our data, our commitment to flexibility and personal service through stable teams, and the competitive cost-benefit ratio. Our services: - Statistical consulting - Biostatistical services and statistical programming - Clinical data management - Medical Writing - IWRS.

Microcoat Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA

Custom Development: Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols Contract manufacturing Diagnostik kit and component manufacturing Service. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating, filling, freeze-drying, kit-assembly, ISO 9001 and 13485. Laboratory Services: Bioanalytics, companion diagnostics and platform development support. Biomarker Services: PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, method and System benchmarking, GLP, GC(L)P, cGMP.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: PCR, Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip/Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The companies scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are consistent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

mk2 Biotechnologies

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Bioanalytics, Industrial Biotechnology

mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. This includes arbitrary chain length, charge, polarity and hydrophobicity. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics

MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research, operating within a highly innovative environment. United within a single facility, the interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis thanks to a steady flow of information between the following departments: cytomorphology, chromosome analysis, immunophenotyping, cytogenetics, FISH, molecular genetic techniques such as PCR and next-generation sequencing. The combination of our routine diagnostics, science, automation and digitization guarantees high-quality diagnosis that gives medical professionals an essential foundation to ensure ideal patient care.

MIKROGEN
DIAGNOSTIK

Contact:
Dr. Erwin Soutschek

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: meyer@mikrogen.de
Internet: www.mikrogen.de



mk2 Biotechnologies

Contact:

Fallstrasse 9
D-81369 München
Phone: +49 (0) 160 777 0880
E-Mail: info@mk2.bio
Internet: www.mk2.bio



Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 990 17-0
Fax: +49 (0) 89 990 17-111
E-Mail: info@mll.com
Internet: www.mll.com



Molecular Machines & Industries

Contact:
Stefan Niehren

Breslauer Strasse 2
D-85386 Eching
Phone: +49 (0) 89 319 048 40
Fax: +49 (0) 89 319 048 59
E-Mail: info@molecular-machines.com
Internet: www.molecular-machines.com

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

Molecular Machines & Industries (MMI) is the leading provider of microscope based micromanipulation solutions for the life sciences, material sciences, and healthcare. We specialize in single cell handling, laser microdissection and optical tweezers for a wide range of clinical and research based applications. MMI is a high value partner for our customers providing worldwide unique competence in micromanipulation and single cell handling. Founded in 1998 by Prof. Dr. Stefan Seeger in Heidelberg, Germany, MMI moved in 2001 to Zurich, Switzerland. Since then, MMI emerged into the global market and today has established a broad instruments base all over the world.



Molecular Networks
Inspiring Chemical Discovery

Contact:
Dr. Oliver Sacher

Medical Valley Center, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, Small Molecules

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.



Contact:
Alena Haas

Landshuter Allee 12
D-80637 München
Phone: +49 (0) 89 360 900 900
Fax: +49 (0) 89 360 900 901
E-Mail: info@molekula.com
Internet: www.molekula.com

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents

Molekula is a leading chemical supplier offering research chemicals and biochemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this constantly evolving industry. Molekula is different - we specialise in hard-to-source chemicals using production laboratories across the world. Our catalogue now holds over 8000 ex-stock products and our ability to source high-quality compounds quickly and easily means our product list is growing all the time. Since 1999 both our business and the industry have changed significantly, with Molekula evolving from a small start-up to an industry leader.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Inflammation, Drug Development, Antibody, Infectious Diseases, Oncology, Autoimmune Diseases

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases, with focus on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya®, marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology. The Company's most advanced proprietary candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for r/r DLBCL.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines

MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD's core business is the discovery, development, production and distribution of prescription medicines, vaccines, biologic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dollars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich.

Twitter: @MSD_Deutschland

MUC Research GmbH

CRO

Keywords: Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Regulatory Affairs, Hepatology, Infectious Diseases

MUC Research is specialized in clinical research, i.e. the planning, conduct and analyses of clinical and diagnostic studies. MUC Research has extensive research experience in the field of infectious diseases such as HIV/AIDS or hepatitis B and C as well as in various other therapeutic areas. The services of MUC Research include the statistical planning of interventional and observational cohort studies, the establishment of electronic study platforms involving medical data bases and electronic case report forms (eCRFs), data management, clinical monitoring, statistical analyses and medical writing.



Contact:

Semmelweisstraße 7
D-82152 Planegg OT Steinkirchen
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com



Contact:

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 800 673 673 673
Fax: +49 (0) 800 673 673 329
E-Mail: infocenter@msd.de
Internet: www.msd.de



Contact:

Dr. Eva Wolf

Karlsplatz 8
D-80335 München
Phone: +49 (0) 89 5998 933
Fax: +49 (0) 89 5998 9353
E-Mail: info@mucresearch.de
Internet: www.drevawolf.de



multi-service-monitoring

Contact:
Anca Todea

Maxhüttenstraße 11
D-93055 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de

multi service monitoring

CRO

Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development,

multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".



Contact:
Prof. Dr. Gabriele Multhoff

Kirchenstrasse 82
D-81675 München
E-Mail: graham.pockley@multimmune.com
Internet: www.multimmune.com

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy, Antibody, Drug Development, Personalized Medicine, Oncology, Immune Therapy

multimmune GmbH is a biopharmaceutical company dedicated to the discovery and development of new drug candidates for treating heat shock protein 70 (Hsp70) positive tumors - surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, brain, breast, colon, pancreas. Four pipelines are currently being pursued: (1) extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (currently in Phase II for lung cancer), (2) using an antibody against membrane Hsp70 (preclinical), (3) inducing tumor-specific apoptosis using a recombinant human serine protease (preclinical), (4) direct infusion of an Hsp70 peptide (preclinical).



Contact:

Nymphenburger Strasse 3c
80335 München
Phone: +49 (0) 89 54 54 62-0
E-Mail: info@cinfabiotech.com
Internet: www.cinfabiotech.com

Mundipharma Biologics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Mundipharma Biologics, former Cinfa Biotech, is a member of the Mundipharma network of independent associated companies. Cinfa Biotech developed Pelmeg®, (pegfilgrastim) as a biosimilar of Neulasta® to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy which was approved by the European Commission in November 2018. The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars.

MVZ Martinsried GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Genomics, Bioinformatics, Oncology, Personalized Medicine, Laboratory

The Center for Human Genetics and Laboratory Diagnostics in Martinsried continues to broaden its expertise and competencies. Expanding from molecular genetics, the company has a focus on integrated diagnostics or "multiomics diagnostics". The interdisciplinary collaboration between five medical specialist areas (Human genetics, Laboratory Medicine, Microbiology/Virology, Transfusion Medicine, Molecular Oncology/ Pathology) enables diagnostic questions to be more efficiently, comprehensively and accurately resolved. The laboratory is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The center's clinical consultation focuses on pediatric genetics, infertility and inherited diseases. Among the applied technologies are: PID, NIPT, Microbiome Analysis, NGS, FACS, FISH, HPLC, Blotting.

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is a spin-off company of the LMU Munich and Minitube, specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a leading provider of automated patch clamp (APC) electrophysiology systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS) instruments recording from 384 cells simultaneously. Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanion has expanded its product range over the years to include in vitro systems for membrane pump and transporter recordings, bilayers, and contractility measurements (impedance) from beating monolayers of cells, e.g. induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs), and confluency measurements of, e.g. hepatocytes for hepatotox screening using impedance.

ZENTRUM FÜR HUMANGENETIK UND LABORATORIUMSDIAGNOSTIK (MVZ)
Dr. Klein, Dr. Reut und Kötter



Contact:
Dr. Hanns-Georg Klein

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-780
E-Mail: info@medizinische-genetik.de
Internet: www.medicinische-genetik.de



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-0
Fax: +49 (0) 8709 9229-39
E-Mail: csimmet@minitube.de
Internet: www.mwm-biomodels.com



Contact:
Dr. Niels Fertig

Ganghoferstraße 70a
D-80339 München
Phone: +49 (0) 89 2190 95-0
Fax: +49 (0) 89 2189 97-960
E-Mail: info@nanion.de
Internet: www.nanion.de



Contact:
Dr. Michael Steiner

Würmstraße 4
D-82319 Starnberg
Phone: +49 (0) 8151 959022-0
Fax: +49 (0) 8151 959022-9
E-Mail: info@nanosaar.com
Internet: www.nanosaar.com

nanoSaar AG

NANOTECHNOLOGY

Keywords: Nanobiotechnology

nanoSaar AG, based in Starnberg, is the exclusive license owner of the patented MJR nanotechnology. Our business approach is to commercialize our proprietary economic MJR production capabilities in the following industries: pharma OTC, food & beverage, cosmetics, consumer products, medical, fragrance, (petro)chemical additives, biocides, catalyzers, paints/coatings, construction, batteries and electronics. The MJR technology can produce nano/micro-particles, emulsions and encapsulations with a highly defined size. Our MJR technology creates superior results compared to spray drying, milling, high pressure homogenization and other technologies. The continuous low cost production setup allows for an unlimited industrial scale-up. We offer product development services and buildup of MJR production capacity at the customer site. We also offer in-house production services with our proprietary products and common new business development for nano applications in licensing and joint venture models. The nanoSaar team has a long term experience and a worldwide contact network. Additional keywords: MJR nanotechnology, nanoparticle, nanoemulsion, nanoencapsulation



Contact:
Dr. Philipp Baaske

Flößergasse 4
D-81369 München
Phone: +49 (0) 89 4522 895-0
Fax: +49 (0) 89 4522 895-60
E-Mail: info@nanotemper.de
Internet: www.nanotemper-technologies.com

NanoTemper Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Bioanalytics, Devices

NanoTemper Technologies is a high-tech company providing solutions for biomolecular analytics. The company develops, produces and markets innovative technologies and instrumentation used by thousands of scientists across four continents. NanoTemper Technologies stands for strong commitment to quality and high precision instrumentation made in Germany. The deeply experienced and globally operating team of experts strongly focuses on the user's benefits by ensuring maximum efficiency for research in Pharmaceutical or Biotech industries as well as in an academic basic research setting. With headquarters in Munich, Germany, and subsidiaries in the UK, Poland, US, Brazil and India, the company is rapidly expanding worldwide.

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA Group is one of the leading Regulatory Affairs consultancies in Europe. With ~100 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 15 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.



Contact:
Dr. Rainer Paffenholz

Neumarkter Straße 18
D-81673 München
Phone: +49 (0) 89 3585-4000
Fax: +49 (0) 89 3585-4010
E-Mail: munich@ndareg.com
Internet: www.ndareg.com

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics

Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy. neaSNOM thus allow to study chemical, structural and electronic properties of a sample at a spatial resolution up to 1000-times higher when compared to conventional technology like micro FT-IR. The non-destructive measurement method is equally suited for organic and inorganic samples and requires only standard AFM sample preparation.



Contact:
Dr. Stefan Schiefer

Bunsenstr. 5
D-82152 Martinsried
Phone: +49 (0) 89 787939-78
Fax: +49 (0) 89 787939-79
E-Mail: info@neaspec.com
Internet: www.neaspec.com

NEOVII Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH (formerly Fresenius Biotech GmbH) is a globally operating company dedicated to deliver targeted biopharmaceutical treatment options in transplantation medicine and hematological oncology. The focus of the activities is the development and commercialization of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. Clinical and development activities as well as manufacturing are located in Germany with an additional development unit in the USA. Neovii Biotech is manufacturing and commercializing the medicinal product 1. Grafalon® and holds the EU marketing authorization for the trifunctional antibody Removab® (INN: Catumaxomab). Neovii Biotech GmbH is a company of the Neopharm Group.



Contact:

Am Haag 6+7
D-82166 Gräfelfing
Phone: +49 (0) 89 898888-0
Fax: +49 (0) 89 898888-619
E-Mail: info.germany@neovii.com
Internet: www.neovii.com



Contact:
Dr. Thomas Rohrmeier

Keilsteiner Breiten 6
D-93055 Regensburg
Phone: +49 (0) 941 785 369-0
Fax: +49 (0) 941 785 369-9
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com



Contact:

Moosstr. 92 c
D-85356 Freising
Phone: +49 (0) 8161 8870979
Fax: +49 (0) 8161 8878332
E-Mail: mena.eidens@new-diagnostics.com
Internet: www.new-diagnostics.com

NIGU

AlzChem Group

Contact:
Verena Löber

c/o AlzChem Trostberg GmbH
Dr.-Albert-Frank-Str. 32
D-83308 Trostberg
Phone: +49 (0) 8621 86-2622
Fax: +49 (0) 8621 86-502622
E-Mail: info@alzchem.com
Internet: www.nigu.de

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in preclinical validation projects.

New Diagnostics GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Toxicology, Bioanalytics, R&D Service, Endocrinology, In-Vitro-Diagnostics

The new_diagnostics GmbH is a biotechnology company based in Freising with a subsidiary in Dresden. We are your partner for biosensor technology and effect-directed analysis in the areas of environment, food and beverages as well as medical diagnostics. With our validated yeast-based bioassays (A-YES®, A-YAS® and A-YPS), we focus on effect-related analyses of hormonally active substances in water samples and extracts. Our A-YES® is currently participating in the standardization process within the framework of the ISO working group ISO 19040-2 Water quality Determination of the estrogenic potential of water and waste water. Besides onsite trainings on how to use our assays, we also offer order analyses. With our bioanalytical expertise we offer customized solutions for your needs.

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.

Novartis Pharma GmbH

PHARMA

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.



Contact:
Angelika Gaufer

Roonstr. 25
D-90429 Nürnberg
Phone: +49 (0) 911 273-0
Fax: +49 (0) 911 273-12653
E-Mail: angelika.gaufer@novartis.com
Internet: www.novartis.de

numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares HEALTH develops and markets integrated test systems for human diagnostics. These create a detailed image of the human metabolism from bodily fluids on the basis of nuclear magnetic resonance (NMR). Diagnostic tests interpret the individual metabolic images of the patient with the help of innovative software solutions and provide valuable information about the formation, extent and severity of diseases. The ability to perform different tests on the same platform in fully automated and high throughput operations shows the efficiency and cost-effectiveness of numares systems.



Contact:

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 698 091-00
Fax: +49 (0) 941 698 091-01
E-Mail: info@numares.com
Internet: www.numares.com

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.



Contact:

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
Fax: +49 (0) 731 9840-280
E-Mail: bdinfo@nuvisan.com
Internet: www.nuvisan.com



Contact:

Friedemann-Bach-Str. 95
D-82166 Gräfelfing
Phone: +49 (0) 89 21538575
E-Mail: support@octamer.com
Internet: www.octamer.de



Omegamatrix GmbH

Contact:

Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5506 300-7
Fax: +49 (0) 89 5506 300-8
E-Mail: info@omegamatrix.eu
Internet: www.omegamatrix.eu



Contact:

Dr. Hannes Hahne

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161-976289-0
E-Mail: info@omicScouts.com
Internet: www.omicScouts.com

Octamer GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcriptional regulation. However, with now > 15 years of pharma experience in drugging epigenetic mechanisms, we understand some of the culprits in epigenetic drug discovery: Epigenetic targets generally are multi-domain or multiprotein complexes. Some epigenetic targets are activated by marks they don't place (e.g. Dot1L methyltransferase is activated by ubiquitin-H2B, UHRF1 E3 ligase is activated by hemimethylated nucleosomal DNA) Affinities for non-natural substrates are generally low (e.g. μM for peptides, nM for nucleosomes) This is why nucleosomes offer the unique opportunity to provide disease-relevant substrates to epigenetic targets - both for academic research and drug discovery.

Omegamatrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University - USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegamatrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.

OmicScouts GmbH

BIOTECH BIOINFORMATICS

Keywords: Proteomics, Bioinformatics, Drug Development, Biomarker Discovery

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. Founded by leading proteomics researchers, the company has a track record in delivering significant collaborations with top pharmaceutical and biotechnology companies. We provide and develop proteome-wide assays that work with native proteins in a physiological setting and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents. We provide complementary tests using a complete 80+ cell line panel: an in vitro combination of more than 500 combination pairs, development of drug tolerance or test of different drug schedules using a longer (3-4 weeks) drug treatment. All these data are requested in translational research and clinical development and help our customers to increase confidence in making drug development decisions.

Optores GmbH

MEDTECH

Optores GmbH is a pioneer in ultrafast swept lasers and optical coherence tomography. With sweep rates of several million OCT A-scans per second, Optores' founders coined the term "MHz-OCT". These ultrahigh speeds are ideal for novel OCT applications, such as real-time surgical guidance with 4D-OCT, large-area surveys, visualization of blood flow, and high-throughput industrial inspection.

Optores GmbH is a privately held company based in Munich, Germany. It was founded in 2013 based on Prof. Robert Huber's groundbreaking work on Fourier-domain mode-locked lasers and ultrafast OCT, for which he was awarded the European inventor award 2018, together with OCT inventor Prof. James Fujimoto from MIT and Eric Swanson. Optores' core technology is protected by several patents.

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany. Origenis runs its own patented drug discovery platform MOREsystem®. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space. Origenis runs research alliances as well as active in-house programs. Origenis is currently focusing on anti-inflammatory and CNS drugs. Origenis is offering a variety of out-licensing opportunities. Origenis offers access to its proprietary patent database Cippix® - www.cippix.com.



Contact:
Claudia Stibi

Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 151 2062 1612
Fax: +49 (0) 89 380122159
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com



Contact:
Dr. Thomas Klein

Gollierstr. 70
D-80339 München
Phone: +49 89 927 78775
E-Mail: thomas.klein@optores.com
Internet: www.optores.com



Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de



Contact:

Marktplatz 1
D-85598 Baldham
Phone: +49 (0) 8106 21 311-0
Fax: +49 (0) 8106 21 311-66
E-Mail: info@oryx-medicine.com
Internet: www.oryx-medicine.com



Otsuka Novel Products GmbH

Contact:

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 30
Fax: +49 (0) 89 2060 205-55
Internet: www.otsuka-onpg.com



Contact:

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 640 791 02
Fax: +49 (0) 941 505 90 01
E-Mail: kontakt@oxfordbiolabs.com
Internet: www.oxfordbiolabs.com

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials. Currently, the oncolytic virus ParvOryx is being further developed in a Phase I/IIa pilot study in patients with metastatic pancreatic cancer and VicOryx, one of the therapeutic vaccines, is being tested in an additional clinical Phase I trial in combination with standard cisplatin-based chemotherapy. ORYX holds exclusive, worldwide patents and utilization licenses for all its development projects.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as an subsidiary of Otsuka group company. With an international network of 145 subsidiaries and 39,000 employees in 23 countries, and regions across Europe, Asia-pacific, America and the Middle East, Otsuka researches, develops, manufactures and markets innovative and original products with a focus on pharmaceutical products for the treatment of diseases. ONPG will initially focus on infectious diseases, working in collaboration with other group companies to develop improved diagnostic tools and novel products for the treatment of tuberculosis.

Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS

Oxford BioLabs Ltd. is a science-based company tackling Androgenetic Alopecia (AGA). A small group is located in Regensburg, BioPark. Our goal is to create a new standard of care for the treatment of AGA. Oxford BioLabs is developing novel therapies for the treatment of androgenetic alopecia (AGA), which is commonly known as male and female pattern baldness. Available therapies include drugs or hair transplant surgery, which treat acute symptoms but lead to side effects, hospitalization and unsatisfactory patient outcome. Currently there is no cure against AGA and new treatment options are urgently needed.

PaediaCRO GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Medical Writing

PaediaCRO – your specialised CRO for your product development in paediatric use. Founded in 2007 by Prof. Dr. med., Dr. rer. nat., Dr. h. c. mult. Dieter Adam, Dr. rer. nat. Josef Hofer and Dipl.-Math. Jürgen Wyen, PaediaCRO will support you in the development of solutions for your products in paediatric use. A smile of a healthy child is our vision. To achieve this, PaediaCRO develops with its partners medicinal products to save children's life and improve their quality.



Contact:

Dachauer Str. 44a
D-80335 München
Phone: +49 (0) 89 551553-50
Fax: +49 (0) 89 551553-51
E-Mail: info@paediacro.de
Internet: www.paediacro.eu

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH, founded in 1988, is a modern and innovative company with its headquarters in Aidenbach/Germany. PAN-Biotech has been certified by the international quality management standards of DIN ISO 9001 and the strict EN ISO 13485. Today PAN-Biotech is a major producer of biotechnological products which are distributed worldwide. Specialized in cell culture products like sera, serum-free systems, media, reagents, biologicals and more we deliver our goods to customers from research, clinics and the biopharmaceutical industry. PAN-Biotech developed also a multi-patented, award winning automated cell culture system, the PANSys3000. Our highly skilled team guarantees product development based on the needs and requirements of our customers. Individual wishes are always welcome.



Contact:

Jens Hartmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 6016-30
Fax: +49 (0) 8543 6016-49
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.



Panacea Biotec
Innovation in support of life

Contact:

Gerd-Peter Heberling

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 83-50
Fax: +49 (0) 89 5455 83-33
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de



Contact:
Michael Hahn

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 742846-0
Fax: +49 (0) 89 743846-30
E-Mail: eFlow-partnering@pari.com
Internet: www.pari-pharma.com

PARI Pharma GmbH

MEDTECH

Keywords: Respiratory Diseases, Infectious Diseases, Antibiotics, Analytical Chemistry, Drug Delivery

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. eFlow® Technology devices are designed to significantly improve upper and lower respiratory tract deposition and reduce the burden of treatment for patients with severe respiratory conditions. Examples are: the Altera® nebuliser for Cayston® (Gilead), the Zirela® nebuliser for Quinsair (Horizon), the Magnair® nebuliser for Lonhala® (glycopyrrolate) Inhalation Solution (Sunovion) and the recently FDA approved Lamira® nebuliser for the administration of Arikayce® (amikacin liposome inhalation suspension, Insmed).

Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications.

- Tissue Dissociation Enzymes
- Defined & Xeno-free Media
- Human & Animal Primar & Stem Cells
- Diseased Human Primary & Stem Cells
- Cancer Stem Cells
- Tagged & KO Cells
- ES/iPS Cells, Media & Tools - Reprogramming Tools & Small Molecules
- Cryo-Preservation Media w/ & w/o DMSO
- Cytokines, Growth Factors & Chemokines
- 2D/3D Cell Culture Systems and 2D/3D Microfluidic Systems
- Cell based Assays
- TR-FRET Reagents
- Premium Grade & GMP Products
- High-Performance Microsphere Products for Sample Preparation



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 51728659-0
Fax: +49 (0) 89 51728659-88
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

Keywords: Ophtalmology, Respiratory Diseases

Experience in manufacturing eye drops in bottles and single-dose-units for more than 30 years. Pharma Stulln fulfills international standards in modern production of sterile preparations. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc. Pharma Stulln is specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions, Lens care products. In our production building in seven separate rooms high-performance bottelpack[®]-filling machines are placed for manufacturing individual products. A modern zone concept fulfills European and international standards for the production of sterile fluid pharmaceuticals. Advanced water treatment and ventilation technology combined with continuous monitoring ensure a continuous high level of quality production.

Pharmalog – Institut für klinische Forschung GmbH

CRO

Pharmalog Institut für klinische Forschung GmbH acts as an European full service CRO with an excellent reputation in clinical trials phase I - IV and in non-interventional studies since 1983. We operate in Germany and all EU/EEU-countries, using our large pool of motivated investigators in clinics/practices. Our local monitors are native speakers. We work

- transparent for our clients
- accurate in planning, realization and evaluation of clinical trials
- flexible focusing the needs of our customer
- friendly to assure a long lasting and strong collaboration with our clients .

We have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products according to legal and normative requirements for more than 80 nat./internat. companies. We offer full service or modular approach (e.g. monitoring, data management/ statistics), reasonable pricing due to short contact ways and low overhead costs. Pharmalog is TÜV - certified and member of the BVMA.

pharma **STULLN**

Contact:
Dr. Karl Luschmann

Werksstraße 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
Fax: +49 (0) 9435 3008-99
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de



PHARMALOG[®]
Institut für klinische Forschung GmbH

Contact:
Holger Stammer

Oskar-Messter-Str. 29
D-85737 Ismaning
Phone: +49 (0) 89 544637-0
Fax: +49 (0) 89 544637-50
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com



Contact:

Am Haag 14
D-82166 Gräfelfing
Phone: +49 (0) 89 7879790
Fax: +49 (0) 89 7879799
Internet: www.sgp-pharma.com/de/

PharmaSGP GmbH

PHARMA & CHEMICAL INDUSTRY

The PharmaSGP GmbH located in Gräfelfing near Munich belongs to the fastest-growing pharmaceutical companies in Europe. Our rich portfolio includes numerous drugs, medical products and dietary supplements in several indications. The over 10 million sales of high-quality medicines testify the trust in our products. The satisfaction towards our extensive offer is reflected in many customers' view and prompts us every day to elaborate new, innovative health solutions. Not for nothing in 2015 the company has been awarded by a top-class jury as the best german OTC-Pharma company.



Contact:

Rosenheimer Str. 43
D-83064 Raubling
Phone: +49 (0) 8035 88-0
Fax: +49 (0) 8035 88-143
E-Mail: info@pharmazell.com
Internet: www.pharmazell.com

PharmaZell GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

The in-house development and production of various multi-customer active pharmaceutical ingredients is one pillar of PharmaZell API business model. A product list of currently offered generic APIs is available and information about new products under development and/or evaluation can be provided upon request. The development and production of different single-customer (exclusive) active pharmaceutical ingredients is the other pillar of our API business model. PharmaZell draws upon a long history of successful custom synthesis projects, performed on a proprietary basis for innovation driven pharmaceutical companies worldwide. The company is also diversified into finished dosage form development. Formulation and analytical development labs as well as pilot/pivotal facilities are available at its Indian site in Vizag. The site develops entire dossiers and modular services to customers.



Contact:

Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: GermanOffice@pharm-olam.com
Internet: www.pharm-olam.com

Pharm-Olam

International Deutschland GmbH

CRO

Pharm-Olam International is a global, full service, Phase I-IV CRO with offices across Europe, North America, Latin America, South Africa, and India. In Germany, we have conducted trials since 1999 and have a local office in Munich along with regional staff. Our staff are highly experienced and can provide a range of services including Marketing Surveillance (AMG § 67.6) - from protocol writing to delivery of final report, auditing, monitoring and regulatory. Our Munich office also supports neighboring Austria and Switzerland. Let us evaluate your protocol at several of the largest centers in Germany and worldwide to determine projected enrollment by contacting german.office@pharm-olam.com

PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Antibody, Tissue Engineering/Cell Culture, Drug Delivery, Drug Development, Regulatory Affairs

You think about Quality-Management (QM) to improve efficiency, data reliability and comparability? However, you work at full capacity and additional resources are not available? We offer individually tailored QM-Concepts in Research and Development as well as preclinical Study-Management with regard to regulatory requirements in Pharmacology / Toxicology (in vitro / in vivo). Our support is customized based on international standards like GLP/GMP, ISO, We operate from a scientific point of view and with our "hands-on" mentality we have strong execution skills. With our network of competence and capabilities we guide your project to success. Benefit from our know-how and our network of experienced partners: selected experts, toxicologists and more than 40 accredited testing laboratories.



Contact:
Dr. Thomas W. Becker

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
Fax: +49 (0) 89 444 899-43
E-Mail: info@phatocon.com
Internet: www.phatocon.com

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 natural compounds). Phytochem synthesizes or isolates also degradation products and impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented method validation. Additional products and consulting services in the fields of functional foods, dietary supplements, food additional and cosmetics are new focuses from Phytochem.



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy

Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.



Contact:

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411 400
Fax: +49 (0) 8161 1411 444
E-Mail: info@pieris.com
Internet: www.pieris.com



Contact:
Dr. Gudrun Vogeser

Raiffeisenstr. 31a
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Dr. Werner Deininger

Industriestraße 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
Fax: +49 (0) 9405 96 999-28
E-Mail: info@polyquant.com
Internet: www.polyquant.com



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688-0
Fax: +49 (0) 8191 985 688-99
E-Mail: info@postnova.com
Internet: www.postnova.com

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, In-Vitro-Diagnostics, Laboratory, Biomarker Discovery & Development, Peptide/Protein, Clinical Diagnostics

PolyQuant offers customized solutions for quantitative proteomics, based on our proprietary QconCAT technology. Building on our expertise in design and synthesis of concatenated polypeptides, our products comprise: custom-made QconCATs as internal standards for absolute protein quantification, calibration kits for LC and MS instrument standardization, full fee-for-services: entire assay development and/or absolute protein quantification workflows and technical support for the implementation of targeted proteomics assays. Present as a polypeptide, QconCATs facilitate simultaneous multiplex absolute protein quantification by mass spectrometry. They are also well-suited to function as research tool for the identification and validation of biomarkers in disease diagnosis/prognosis.

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova Analytics is manufacturer of Field Flow Fractionation (FFF) for nanoparticle, protein and bio/polymer separation, fractionation and characterization. Postnova offers a complete FFF product range for applications in Biopharmaceutical, Nanotechnology, Environmental, Food, Cosmetics and Polymers. Field-Flow Fractionation coupled to Multi-Angle Light scattering (MALS), Dynamic Light Scattering (DLS) and ICP-MS detection offers access to high resolution size and molar mass separation, characterization and element speciation. Products are CentrifugalFFF for Nanoparticles, FlowFFF for Biopharmaceuticals and ThermalFFF for Polymers.

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.



Contact:
Dr. Peter Oberosler

Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
Fax: +49 (0) 89 57877-400
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com

PreciPoint GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.



Contact:

Alois-Steinecker-Str. 22
D-85354 Freising
Phone: +49 (0) 8161 976979-0
E-Mail: vertrieb@precipoint.de
Internet: www.precipoint.de

PreOmics GmbH

BIOTECH DEVICES & REAGENTS

PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 23 14 163-0
Fax: +49 (0) 89 23 14 163-99
E-Mail: info@preomics.com
Internet: www.preomics.com



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors. It develops, manufactures and distributes sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices. PreSens offers out-of-box products and engineering of customized sensors, focusing on parameters which are essential for life: oxygen, pH, carbon dioxide and biomass - and other parameters on request. Over the last 17 years, we have delivered our special microsensors and our non-invasive systems for various applications such as respirometry, biology, or medical research. We also offer imaging solutions: 2D-sensing of oxygen-, pH- and CO₂-distributions. PreSens is certified EN ISO 13485:2003 + AC:2007 and ISO 9001:2008. Together with its partners it offers service all over the world.



Contact:

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 58 00 82-0
Fax: +49 (0) 89 58 00 82-7777
Internet: www.prevtecmicrobia.com/en/

Prevtec microbia GmbH

PHARMA ANIMAL HEALTH

Prevtec microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Prevtec microbia's mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.



Contact:

Dr. Andreas Schütz

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
Fax: +49 (0) 89 452289-717
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com

ProJect Pharmaceuticals GmbH

CRO

Keywords: Drug Development, Drug Delivery, Liposomes, Antibody, Peptide/Protein, Small Molecules, Vaccines

ProJect Pharmaceuticals formulates delicate pharmaceutical molecules into pioneering drugs. We are experts in formulation and pharmaceutical process development for liquid or lyophilized rec. proteins, high-concentration products, ADCs / cytotoxics and live virus vaccines. We develop a quality product and its manufacturing process on a sound scientific rationale pursuant to international guidelines, that provide highest safety levels at maximum convenience. Dedicated GMO S2 / BSL-2 safety facilities and a profound understanding of the challenges when formulating and processing live virus vaccines enables us to provide specific solutions for this group of highly complex products. Teamed up with manufacturing experts, we smooth technology transfer from pre-clinical to large-scale supply.

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros is Europe's largest and most experienced biotechnology company in the field of X-ray protein structure analysis and a leading partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Proteros services delivers protein crystallography, profiling and screening and tailor-made proteins. Lead discovery combines these unique technologies and medicinal chemistry to generate novel lead compounds for a variety of therapeutically relevant target proteins. Flexible business models, makes Proteros an ideal partner to the Pharmaceutical and Biotech Industry.



Contact:
Dr. Torsten Neuefeind

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com

PSI CRO Deutschland GmbH

CRO

PSI is a privately-owned, full-service contract research organization (CRO) of 1,600 staff, operating globally. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. In bi-annual CenterWatch Investigator Surveys of 2015 and 2017 PSI was repeatedly voted Number One Global CRO. Global headquarters are located in Switzerland, the German branch office is in Planegg near Munich.



Contact:

Behringstrasse 7
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 89996080
Fax: +49 (0) 89 89996051
Internet: www.psi-cro.com

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the electronic lab notebook quattro/LJ or the compound management solution quattro/CM. quattro research offers software and consulting services to build and integrate heterogeneous data sources and applications, such as compound registration, HTS, LIMS or SAP, into efficient and user friendly data management platforms.



Contact:
Dr. Bernhard Schirm

Fraunhoferstraße 18a
D-82152 Martinsried
Phone: +49 (0) 89 990 1629-0
Fax: +49 (0) 89 990 1629-99
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com



Contact:
Dr. Florian Odoj

Kettelerstr. 3-11
D-97222 Rimpfing
Phone: +49 (0) 9365 8826-43
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. The company collaborates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies. Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.



Contact:
Dr. Albrecht Pfahler

Bruckmannring 6
D-85764 Oberschleißheim b. München
Phone: +49 (0) 89 5402889 - 50
Fax: +49 (0) 89 5402889 - 60
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

REMARK GmbH Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services: - Strategic Consulting - Project Management - Sponsor Representative - Clinical Trial Liaison / Medical Science Liaison - Medical Affairs Services / Medical Writing - Quality Assurance Services Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing.



Contact:
Michael Fuchs

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-48
E-Mail: medical@ritter-online.de
Internet: www.ritter-medical.de

Ritter GmbH, Medical

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, PCR, Pharmacogenetics, Proteomics, Devices, Automation, ELISA/EIA

Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 70 countries, millions of Ritter medical products are used in clinical and biotechnological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products.

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research focused healthcare with combined strength in pharmaceuticals and diagnostics. Roche is also the world's largest biotech company with medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience and is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe for research, development and production of biotechnology based diagnostics and active pharmaceutical ingredients. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring. Pharma specializes in therapeutic human proteins with focus on monoclonal antibodies and biomarkers for oncology.



Contact:
Dr. Gabriele Pestlin

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de

R-Pharm Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Automation, Logistics

Since many years, we manufacture and package medicinal products for patients in over 150 countries. Innovative technologies and a highly motivated and skilled team guarantee utmost reliability and quality standards as well as extraordinary value for money. Furthermore, we set ourselves the highest standards in regards to patient safety and customer satisfaction using face-to-face contact with our customers and business partners whenever possible. We are proud to be able to look back on over 150 years of company history - both as an independent company and within the global production network of Pfizer, Inc. in the past. [former Pfizer Manufacturing Site].



Contact:
Dr. Peter Remiger

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
Fax: +49 (0) 7303 12-387
E-Mail: r-pharm-germany@r-pharm.com
Internet: germany.r-pharm.com

SanoLiBio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

SanoLiBio focuses on automation in circulating tumor cells (CTC) enrichment and analysis for diagnostic standardization. Cost-efficiency, accessibility, scalability, and diagnostic precision drive our innovation. We are perfecting our magnetic bead technology that is based on the negative selection principle for highest and untouched cell recovery and unbiased cell selection. So far, we achieved significant advancement in the field as credited by a peer-reviewed process (Schreier et al. 2017) with ongoing improvements. SanoLiBio's market priority is CTC enrichment, expanding rapidly into cancer therapy support and thrive to pioneer cancer screening for cancer prevention by CTC based liquid biopsy.

SanoLiBio GmbH

Contact:

Walpurgisstraße 4
D-81677 München
Phone: +49 (0) 89 20 333 292
E-Mail: info@sanolibio.com
Internet: www.sanolibio.com



Eine gesunde Entscheidung

Contact:
Ameet Mallik

Industriestr. 25
D-83607 Holzkirchen
Phone: +49 (0) 8024 476-0
Fax: +49 (0) 8024 476-2599
E-Mail: service@hexal.com
Internet: www.sandoz-biosimilars.com

Sandoz International GmbH - Hexal AG

PHARMA & CHEMICAL INDUSTRY

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the 1st position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 21546375
E-Mail: info@secarna.com
Internet: www.secarna.com

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Secarna Pharmaceuticals GmbH & Co. KG ("Secarna") is a biopharmaceutical company based in Munich, Germany. The company has developed a state-of-the-art drug discovery platform, encompassing proprietary bioinformatic systems, screening platforms, as well as advanced in vitro compound characterization assays, focusing on next generation antisense molecules. Currently, Secarna has active pre-clinical programs in a range of indications including immuno-oncology, immunology and anti-virals. Our strategy is to leverage our drug discovery platform to develop disruptive and highly differentiated therapeutics, also with industry partners.

Securetec Detektions-Systeme AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules



Contact: Dr. Torsten Stadthagen

Lilienthalstr. 7
D-85579 Neubiberg
Phone: +49 (0) 89 2030 8016-51
Fax: +49 (0) 89 2030 8016-52
E-Mail: info@securetec.net
Internet: www.securetec.net

Established in 1995, Securetec Detektions-Systeme AG provides leading edge technologies to facilitate detection of drugs, explosives and other hazardous substances. By close cooperation with its customers Securetec understands the specific demands of traffic safety, customs and drug enforcement authorities across the globe. Securetec's competencies cover tailor-made development and production of immunological test solutions reflecting in highly reliable products for day-to-day use. The specific technologies are successfully employed across a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.



Biologische Detektions- und Schnelltestsysteme

Contact:
Dr. Marcus Meyr

Provinostr. 52, Gebäude B14
D-86153 Augsburg
Phone: +49 (0) 821 455799-0
Fax: +49 (0) 821 455799-22
E-Mail: info@sension.eu
Internet: www.sension.eu

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Sequiserve offers the following custom services in molecular biology: Sanger-DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking, direct sequencing of bacterial pellets). Purification of PCR products and Plamid-DNA preparation for subsequent sequencing. Sequiserve - your expert in DNA-sequencing since 1994!



Contact:
Eva Metzger

Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: CNS, Cardiovascular Diseases, Drug Development

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.



Contact:
Arnd Prilipp

Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: arnd.prilipp@servier.com
Internet: www.servier.de



Contact:

Solalindenstraße 84
D-81827 München
Phone: +49-89-90184124
Internet: www.shivom.io

SIGMA-ALDRICH®

Contact:

Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-0
Fax: +49 (0) 89 6513-1169
E-Mail: deorders@sial.com
Internet: www.sigma-aldrich.com



Spezielle Immunologie
Forschung + Entwicklung GmbH

Contact:

Kurpromenade 2
D-95448 Bayreuth
Phone: +49 (0) 921 730052-10
Fax: +49 (0) 921 730052-15
Internet: www.simfo.de

Shivom.io, c/o Axel Schumacher

BIOTECH BIOINFORMATICS

Keywords:

Shivom is spearheading the next era of Genomics & Precision Medicine and powering the transition to value-based healthcare. Our focus is on the transformational convergence of OMICS technologies with blockchain, artificial intelligence, cryptography and other real cool technologies to enable secure and personalized medicine with global scalability.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

SIMFO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords:

SIMFO GmbH is a research and development facility with advanced expertise in personalized medicine, based in Bayreuth, Germany. It focuses particularly on the development of innovative analysis methods in oncological diagnostics in order to optimize personalized therapy. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. This allows more rapid intervention options and therefore better treatment. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development. The maintrac® platform enables to effectively distinguish chemotherapeutical responders from non-responders. The maintrac® Liquid Biopsy method is increasingly being used to streamline clinical guidelines and is available in over 40 countries worldwide.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@sinatur.net
Internet: www.sinatur.net

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, R&D Service, Viruses, Cell Therapy, Gene Therapy, Drug Development

SIRION Biotech stands for sophisticated custom virus engineering that caters to academic groups as well as the industrial gene-therapy and immune-oncology markets. All major virus systems, AAV - Lentivirus - Adenovirus, can be fully customized to the specific goals of the customer to optimize their vector strategies and increase their success in pre-clinical and clinical applications. SIRION Biotech technology has been validated in more than 250 projects with academic and industrial organizations worldwide. Commercial arrangements range from fee-for-service over exclusive rights on specific developments, all the way to milestone & licensing arrangements. The latter are suited for longer term complex product developments in the areas of gene therapy,



Contact:
Dr. Christian Thirion

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
Fax: +49 (0) 89 700961-998
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

siTOOLS Biotech GmbH

BIOTECH DEVICES & REAGENTS

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich's biotech cluster in Planegg/Martinsried. "siPools" are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.



Contact:

Lochamer Straße 29a
D-82152 Planegg
Phone: +49 (0) 89 4431 2584
E-Mail: info@sitoolsbiotech.com
Internet: www.sitoolsbiotech.com



Contact:
Ulrich Schubert

Mühlthaler Str. 91c
D-81475 München
Phone: +49 (0) 89 854 665-13
Fax: +49 (0) 89 854 665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

Sourcia.

Contact:

Lochhamer Strasse 31
D-82152 Martinsried
Phone: +49 (0) 151 74403195
Internet: www.sourcia.eu



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 540 4134-0
Fax: +49 (0) 89 540 4134-20
E-Mail: info@spherotec.com
Internet: www.spherotec.com

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software from a single source. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems

Sourcia

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

Spherotec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.

SSS International Clinical Research GmbH

CRO

Keywords: Medical Writing, Respiratory Diseases, Oncology, Cardiovascular Diseases, Hematology

SSS International Clinical Research is a Functional Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania, Poland and UK. We provide cost-effective, high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for nearly 20 years and through many successful projects. The services include feasibility surveys in European countries, regulatory document preparation and submissions, site identification and initiation, investigator contract negotiations, clinical trials management, monitoring, and quality assurance. Our indication focus in the past years has lied on Oncology, Neurology, Nephrology, and Pulmonology. Due to our long standing partnerships we have deep insights into the potentials of many possible study sites in these areas.



INTERNATIONAL CLINICAL RESEARCH

Contact:
Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
Fax: +49 (0) 89 800 650-555
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu

Staburo GmbH – Statistical Consulting

CRO

Keywords: Biomarker Discovery & Development, Bioinformatics, Data Management, Cardiovascular Diseases, Oncology, Data Management and Biostatistics

Staburo is a Munich-based biostatistics company, specialized in statistical consulting and programming in the field of clinical trials. We develop tailor-made client solutions, based on our 6 pillars: Clinical Statistics, Translational Medicine & Biomarkers, PK/PD, HTA, Non-clinical Statistics and Statistical Programming. Our customers are pharmaceutical companies, CROs and biotech companies, with whom we work on a flexible basis.



Contact:
Hannes Buchner

Aschauer Str. 26b
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



Contact:
Fabian Schuler

Sternberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
Fax: +49 (0) 89 850 7646
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de



Contact:

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 550 66 760
E-Mail: mail.de@sobi.com
Internet: www.sobi.com

Swedish Orphan Biovitrum GmbH, SOBI

BIOTECH THERAPEUTICS & DIAGNOSTICS

Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases.



Contact:

Gubener Str. 39
D-86156 Augsburg
Phone: +49 (0) 821 521570
Internet: www.synlab.de

Synlab Holding GmbH, Synlab Umweltinstitut GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Laboratory, Bioanalytics, In-Vitro-Diagnostics

The combination of Labco and synlab has made the new SYNLAB Group the market leader in laboratory services in Europe. Combining the Europe-wide network and extensive range of diagnostic tests of both companies, SYNLAB now offers reliable and local laboratory services in more than 30 countries. SYNLAB particularly focuses on the implementation of innovative laboratory medicine methods and on networking specialist diagnostic competences (SYNLAB Centres of Excellence). SYNLAB maintains additional laboratories (strategic business units) in individual countries for veterinary medicine and environmental analysis. This services portfolio is rounded off by expert medical imaging centres in certain countries. The group works closely with research institutions and universities and also maintains an educational institution of its own, the SYNLAB Academy.



Contact:

Dr. Alexandra Dietrich

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 6860-0
Fax: +49 (0) 9441 6860-30
E-Mail: info@syntacoll.de
Internet: www.syntacoll.de

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

Synteract GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain

Synteract is an innovative CRO providing full-service, Phase I-IV services to biopharma companies in bringing new medicines to market. We align our operational excellence, therapeutic expertise, and the right technology to support each client's clinical development needs. Over its nearly 30-year history, Synteract's leadership has been proven in the core development areas of oncology, dermatology, neuro-degenerative disorders, rare/orphan disease, and pediatrics and has contributed to more than 240 product approvals in these and additional therapeutic areas. We work closely with customers in bringing clinical trials to life, because patients are waiting!



Contact:

Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Fax: +49 (0) 89 126680-2444
Internet: www.synteract.com

Systasy Bioscience GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

Systasy Bioscience GmbH, a growing start-up company founded 2012 in Munich, provides cost-effective and highly innovative solutions for the pharmaceutical industry to address critical and unmet medical needs. Systasy's products and services are ranging from the analysis of cellular target activities and specificities up to the simultaneous analysis of multiple signaling pathways in living cells. Products and services are based on Systasy's proprietary splitSENSOR and EXTassay technologies. Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneously occurring cellular events to customers. Thus, Systasy's services and products are designed to match customers' needs in the early phases of drug discovery and personalized medicine.



Contact:

Adams-Lehmann-Str. 56
D-80797 München
Phone: + 49 (0) 89 2155 3085
Fax: + 49 (0) 89 44005 5853
E-Mail: info@systasy.de
Internet: www.systasy.de

T-CURX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

T-CURX develops new generation UltraModularCARTM T cells for personalized cancer immunotherapy, built on cutting-edge technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR-T. T-CURX's UltraModularCARTM T cells are a transformative, one-shot, chemotherapy-free cancer treatment. Patient T cells are reprogrammed using revolutionary gene transfer technology to destroy tumor cells. UltraModularCARTM T cells are living drugs that persist life-long and provide protection from relapse. T-CURX's target pipeline addresses several unique cancer indications. The lead product is targeting breast and lung cancer (oncology), chronic leukemia and mantle cell lymphoma (hematology). T-CURX has a solid IP portfolio on its platform technologies, established manufacturing capability and positive reviews from regulators, enabling rapid progress towards initiation of clinical POC studies.



Contact:

Friedrich-Bergius-Ring 15
D-97076 Würzburg
E-Mail: info@t-curx.com
Internet: www.t-curx.com



Contact:

Propst-Hartl-Straße 8
D-82398 Polling
Phone: +49-881-12123876
E-Mail: info@ncd-company.com
Internet: www.ncd-company.com

Therawis *Pharma | Diagnostics*

Contact:

Grillparzerstrasse 14
D-81675 München
Phone: +49 (0) 89 41 42 45 57-0
Fax: +49 (0) 89 41 42 45 57-40
E-mail: info@therawis.com
Internet: www.therawis.com

The NCD Company UG

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology

The NCD Company is an independent project company and provides all services of a non-clinical development department for biotech and pharma companies with an experienced team at highest level. By outsourcing pre-clinical development, you will increase flexibility, save internal resources and ensure the access to a broad spectrum of knowledge and experience. We provide Early Drug Development Planning and Management, Safety Testing/Toxicology, ADME/DMPK, Outsourcing, Quality Assurance and Regulatory Submission. Our team of interdisciplinary non-clinical development experts with many years of experience in pharma, biotech, regulatory agencies and contract research offers customized services, ensuring that small and medium-sized pharmaceutical and biotech companies perform high-quality preclinical research through „insourcing“ of individual preclinical functions. Together with our partner Proceeder Ges. mbH we support Biotech Startups from creation of the business or financial plan up to the establishment of the business. Additional keywords: Early drug development, toxicology, pharmacology, ADME, preclinical study management and monitoring, startup support, Quality GLP/ISO, Medical Writing

Therawis Pharma / Diagnostics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Clinical Diagnostics, Drug Development, R&D Service

Therawis Pharma GmbH is a privately held, profitable oncology-specialized company with offices located in Munich, Germany, and was founded in April 2014. We provide European-wide support in clinical trial development in oncology. Therawis Pharma GmbH has founded together with clinicians and scientists of the Technical University of Munich Therawis Diagnostics GmbH in September 2015. Therawis Diagnostics is dedicated to the development and commercialization of novel predictive diagnostic biomarker assays. The overall strategic vision of Therawis Pharma/Diagnostics is to combine highly innovative and novel diagnostics with effective therapeutics in oncology: The theranostic mission.

Thermo Fisher Scientific GENEART GmbH

BIOTECH

Keywords: Genomics, Combinatorics

Since entering the Gene Synthesis market in 2000 GeneArt has established as the global market leader. GeneArt provides key technologies for Synthetic Biology projects for example for the construction of bacteria which produce complex biopolymers such as biofuels or organisms which degrade environmental toxins. Furthermore the company contributes key technologies necessary to develop and produce new therapeutics and vaccines. Customers also rely on GeneArt services to improve enzymes, such as the ones used as additives in detergents. GeneArt was awarded the worldwide largest gene synthesis contract for the completion of the „Mammalian Gene Collection (MGC) Program“ by the U.S. National Institutes of Health (NIH). In addition, GeneArt produced subgenomic elements for the construction of the first synthetic bacterial genome by the J. Craig Venter Institute. GENEART provides the key technologies for the development and production of new medicines, services for the improvement of proteins (e.g. industrial enzymes, antibodies) or to construct cells for complex biological processes (e.g. bio-factories for the production or degradation of (bio-)polymers). The Regensburg location is now part of Thermo Fisher Scientific Inc, the world leader in serving science, with revenues of \$17 billion and 50,000 employees in 50 countries.

ThermoFisher
SCIENTIFIC

Contact:
Dr. Marcus Graf

Im Gewerbepark B35
D-93059 Regensburg
Phone: +49 (0) 941 94276-0
Fax: +49 (0) 941 94276-711
E-Mail: geneart.info@lifetech.com
Internet: www.thermofisher.com



WANDER
IMMOBILIEN

Tel.: +49 (89) 85 89 63 - 0
kontakt@wander-immobilien.de



You are looking for suitable laboratories?

We are your specialist!


www.wander-immobilien.de

Office, laboratories and production space

from 250 sqm – 10.000 sqm

**We are looking forward to send you
an attractive offer.**





Contact:
Dr. Pascal Schweizer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7167 760-31
Fax: +49 (0) 89 7167 760-49
E-Mail: info@thermosome.com
Internet: www.thermosome.com



Contact:
Jean-Philippe Sobczak

Lichtenbergstraße 8
D-85748 Garching
E-Mail: info@tilbit.com
Internet: www.tilbit.com



Contact: Dr. Carolina Glas

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 2032 4142-20
Fax: +49 (0) 89 2032 4142-90
E-Mail: info@till-id.com
Internet: www.till-id.com

Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome® is leveraging its proprietary drug delivery technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Through its TSL technology, drug-loaded nanocarriers („Thermosomes“) are created which after i.v. infusion release their content locally upon the influence of mild heat of 40-42°C achieved by various clinically established targeted heating techniques such as microwave or ultrasound. Thus, up to 15 fold higher local drug concentrations can be reached while simultaneously markedly reducing systemic exposure and potentially associated side effects. Our lead candidate is a formulation of a potent, but highly toxic chemotherapeutic agent and is envisioned to enter a FiH study in locally-advanced solid tumors.

tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service

tilibit nanosystems specializes in the development and fabrication of nanostructures using the DNA origami method. This technology allows building discrete objects with user-defined shapes and mechanical properties on the scale of 10 to 1000 nanometers molecule by molecule from the bottom-up. User-defined chemical and mechanical features can be positioned with near-atomic control, and nanostructures can be assembled into macroscopic materials with novel mechanical or optical properties. Because of these capabilities, DNA origami is an enabling technology that creates novel and unparalleled opportunities toward the construction of „bionano“ products that promise tremendous technological progress. Tilbit nanosystems can design, assemble, purify, and characterize a fully customized nanostructure according to your specifications.

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. GmbH is a small company at the interface of research and industry. We develop innovative concepts for light microscopy. Our aim is to take the microscope from the 19th into the 21st century by applying a scalable embedded approach rather than a modular one. Our inspiration is the smartphone, which can be differentiated into a variety of application-specific tools (apps). Our microscopes are platforms with a common design but the flexibility to combine different imaging techniques and light sources. The idea to build an intelligent, user-friendly microscope persists not only in the microscopes hardware, but also in our newly developed software. The prototypes are validated through our partners in the field of life science and medicine and innovative solutions are licensed to our industrial partners.

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001 certified service provider with high end research facilities for proteomics, protein analytics, target and biomarker discovery and validation. The company has outstanding expertise in proteome analysis, protein identification and characterization with more than 15 years experience. A portfolio of proprietary technologies has been developed and/or licensed that is able to significantly enhance the rate of discovery of potential biomarkers and novel therapeutic targets. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 2441 45412-81
Fax: +49 (0) 89 2441 45412-86
E-Mail: info@toplab.de
Internet: www.toplab.de

TRIGA-S e.K. Scientific Support

CRO

Keywords: Other Diagnostics, Logistics, Molecular Diagnostics, Clinical Trial Management and Monitoring, In-Vitro-Diagnostics

TRIGA-S Scientific Support is a Clinical Research Organization for planning and conducting clinical and technical studies phase I-IV in the In-Vitro-Diagnostics (IVD) and medical device industry. During the past 20 years, TRIGA-S supported more than 50 clinical and technical studies worldwide, including >300 sites and >60,000 patients, in accordance to ICH-GCP, international and local guidelines. TRIGA-S provides service as contract laboratory and testing site for serum and body fluids based clinical chemistry, immunology or further IVD applications, including organization and preparation of samples for technical reviews. Our services: study management/ monitoring, data management, contract laboratory, testing site, sample management/ storage/ preparation, logistics.



Contact:
Dr. Yannick Böge

Mühlal 5
D-82392 Habach
Phone: +49 (0) 8847 695 78-0
Fax: +49 (0) 8847 695 78-29
E-Mail: info@triga-s.de
Internet: www.triga-s.de

TRION Research GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab[®] antibody candidates and the support of non-clinical and clinical development of Triomab[®] antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs. TRION Research is ISO 9001:2008 certified. The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays



Contact:
Dr. Horst Lindhofer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 766-0
Fax: +49 (0) 89 700 766-11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:

Industriestr. 1
DE-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
Fax: +49 (0) 9405 96 999-28
E-Mail: bcdiagnostics@uroquant.com
Internet: www.uroquant.com

UroQuant GmbH

BIOTECH

Transforming Cancer Diagnostics Using protein biomarkers, UROQUANT will revolutionise diagnostics. The first product, UROQUANT BC for diagnosing bladder cancer directly from urine will be established as novel gold standard for routine cancer patient care. UROQUANT BC is based on a defined protein expression pattern indicative for bladder cancer. Quantitative mass spectrometry analysis of a multimarker protein panel that is highly specific for BC diagnostics enables fast and robust diagnosis of BC. The multi-combinatorial power of the individual protein biomarkers significantly enhances sensitivity and specificity making UROQUANT BC a superior diagnostic standard in clinical routine.



Contact:

Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.



Contact:

Bernhard Müllinger

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
Fax: +49 (0) 89 897969-22
E-Mail: info@vectura.com
Internet: www.vectura.com

Vectura GmbH

MEDTECH


Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.



The Bavarian Biotech Cluster

Bavaria – top location for biomedical innovation



Cluster activities

- Bavarian biotech report: the annual survey of the biotechnology sector
- close collaboration of all Bavarian biotech locations
- representation at international trade fairs
- interlinking business and science
- innovation transfer



Contact:
Barbara Brandlhuber

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
Fax: +49 (0) 89 15882-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:

Sonnenstr. 19/Geb. 2, 2nd floor
D-80331 München
Phone: +49 (0) 89 20602-9900
Fax: +49 (0) 89 20602-9907
Internet: www.cftr-info.de/content/vertex



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 18516-11
Fax: +49 (0) 8161 18516-12
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon is an innovative and international solutions provider for microbiology. Having its roots in the original development of FISH, the company can now look back on two decades of expertise. The development of VIT® (vermicon identification technology) made FISH accessible not only for academic research but also for every industrial microbiologist or anyone relying on microbiology in their decisions. vermicon's highly qualified team of experts and its powerful technology portfolio enables the company to meet even complex microbiological challenges. Their philosophy states that only cultivation-independent methods allow real insights into microbiology. With satisfied customers worldwide, vermicon creates impressive solutions and is actively driving the evolution of modern microbiology.

Vertex Pharmaceuticals (Germany) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe (incl. Munich/Germany), Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers molecular biology services in the field of functional genomics with focus on Next Generation Sequencing (NGS) especially on transcriptome sequencing (RNA-seq). The company offers a complete product line, ranging from project consulting, nucleic acid isolation, sample preparation and DNA sequencing to bioinformatic sequence analysis and data mining. The strength of the VERTIS is customer-oriented flexibility, which is based on an innovative technology platform, the company has developed in its 13-year history. VERTIS is a pioneer in the analysis of small non coding RNAs (sncRNA) and of bacterial transcriptomes.

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

Verum has been the first Western-Standard CRO specializing in CEE countries, operations starting in 1992. Our core business and key competence is Full Clinical Service for Phase II-IV in CEE countries. Our team consists of about 100 experts that share our experience of more than 120 trials with some 35,000 patients in indications like cardiovascular, neurology, psychiatry, pain, CNS-diseases and oncology. With offices from Eastern Europe to the US we are pooled for the success of our trials.



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800777-60
Fax: +49 (0) 89 800777-88
E-Mail: verum@verum.de
Internet: www.verum.de

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.



Contact:
Dr. Martin Kintrup

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de

vivoPharm Europe Ltd, a CGI company

CRO

Keywords: Bioanalytics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology, Vaccines

vivoPharm, a CGI company (NASDAQ:CGIX) is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services from bench to bedside (and back) worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We're a unique IO precision service organization, active in preclinical and clinical services. All work is carried out under well-defined standard operating procedures (SOPs) by highly qualified technicians in state-of-the-art laboratories in seven locations with AAALAC accredited and GLP compliant audited facilities in Australia and the US, as well as CLIA certified and CAP accredited facilities in the US



Contact:
Dr. Melanie Keller

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 122 287 6-90
Fax: + 49 (0) 89 122 287 6-99
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.com



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. The division focuses on developing customized solutions for growth sectors such as food additives and pharmaceutical actives.



Contact:
Jens Winicker

Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
Fax: +49 (0) 911 92680-8839
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com

Winicker Norimed GmbH Medizinische Forschung

CRO

Winicker Norimed GmbH, located in Nuremberg, is an independent, owner-operated contract research organization. Our experienced, interdisciplinary team of approximately 132 employees manages your projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients standard operating procedures. In cooperation with hospitals and primary care physicians, we manage phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.



Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

XL-protein GmbH

BIOTECH

Keywords: Drug Development, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company utilizing its proprietary ‚PASylation‘ technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. PASylation - the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and/or Ser - provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.



Contact:
Dr. Per Sonne Holm

Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 9931 7446
Fax: +49 (0) 89 5155 6413
E-Mail: info@xvir.com
Internet: www.xvir.com

Zeta Biopharma GmbH

BIOTECH & PHARMA PRODUCTION

The Zeta group of companies specializes in the development and supply of tailored process and procedure solutions for sterile and aseptic applications. Zeta Biopharma: Early cooperation in all technical disciplines within the framework of projects enables us to provide customers with: reliable, high-quality and integrated process solutions and technologies a user-oriented, productivity- and maintenance-optimized layout optimum economic, functional and technical safety for the operator without interfaces, for the purpose of a simultaneous engineering concept based on our specific knowledge and our project experience from the pharmaceutical industry and biotechnology. We have made it one of our central objectives to offer our customers added value in the shortest possible time via activated technology investment in order to have a sustainable positive impact on their return (ROI). Short project accomplishment times in accordance with the schedule, predominantly through efficient project management and targeted project accomplishment at the highest technical level and the heavy involvement of our customers and partners in the project development and accomplishment process are our strategies for fulfilling this requirement.



Contact:

Moosburger Str. 7
D-84072 Au i.d. Hallertau
Phone: +49 (0) 8752 8656-71
Fax: +49 (0) 8752 8656-72
E-Mail: manfred.seifert@zeta.com
Internet: www.zeta.com

Zimmer BioTech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Founded in October 2016, Zimmer BioTech, a Neu-Ulm, Germany-based drug development startup is advancing Alevin deep, a drug based on the compound 5-Aminolevulinic acid (ALA), which is used in the treatment of actinic keratoses in combination with photodynamic therapy (PDT). The spin-off also fulfils the legal requirements in the field of pharmaceuticals, as a quality management system focusing on pharmaceutical products has been put in place. In 2017 Zimmer BioTech raised € 7m in funding. Investors included Zimmer MedizinSysteme GmbH, the medical device producer which spun off the company, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer.



Contact:

Junkersstraße 9
D-89231 Neu-Ulm
Phone: +49 (0) 7304 9283270
Internet: www.zimmer.de



FORUM

Science & Health

3.- 4. Juli 2019

Veranstaltungsforum Fürstenfeld
Fürstenfeldbruck bei München

- > Fokus Medizin der Zukunft
- > Fachdisziplinen überbrücken
- > Neue Technologien, therapeutische Ansätze, DataScience
- > Reflektieren, Diskutieren, Interagieren und Vernetzen

>> www.bio-m.org/forum <<

← 1
WORKSHOP
2,3 →



managed by



Bio^M for BioEntrepreneurs

we guide you from idea to success

- Mentor Circle
- Pitch Doctor
- Boot Camp
- BioAngels
- m⁴ Award
- BioEntrepreneur Lounge
- BioEntrepreneurship Summit



THINK BEYOND. CHOOSE PASSION!

full-service CRO: international, smart, accurate

TAILORED TO YOUR NEEDS

- clinical trials
- non-interventional studies
- value dossiers

- drugs
- medical devices

INNOVATIVE CONCEPTS

- medical advising
- study planning

RELIABLE SERVICE

- medical writing
- regulatory
- project management
- biostatistics
- vigilance
- quality assurance
- data management
- monitoring
- GCP training

www.gkm-therapieforschung.de



Imprint

Editorial staff:

Gabriele Klingner,
Dr. Georg Kääh
Dr. Alessandra Pasquarella,
Dr. Ruoyu Sun

Company Profiles:

Dr. Christina Grimm
Dr. Alessandra Pasquarella

Data analysis was compiled together with
BIO-Deutschland e.V.

We thank the Bavarian companies and the regional
organizations of the Bavarian Biotechnology Cluster for
supporting this survey.

April, 2019

Contact

Prof. Dr. Horst Domdey, CEO Bio^M

Spokesman of the Bavarian Biotechnology Cluster

**The Bavarian and the Munich Biotechnology Clusters
are managed by:**

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a

D-82152 Martinsried

Phone: +49 (0)89-899679-0

Fax: +49 (0)89-899679-79

E-Mail: info@bio-m.org

www.bio-m.org



Cover: iStock by Getty Images

The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Layout-Design: MxM, Munich, www.mxm.de

Pictures copyright as indicated

Supported by the Bavarian Ministry of Economic
Affairs, Regional Development and Energy


www.stmwi.bayern.de/en/



**Innovation and
Start-up Center
Biotechnology**

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Tel. + 49 (0)89.55 279 48-0
Fax + 49 (0)89.55 279 48-29
info@izb-online.de
www.izb-online.de



**YOU HAVE THE IDEA.
WE HAVE THE LOCATION.**

- S1 and S2 laboratories
- Real estate and facility management on site
- Faculty Club and conference rooms for up to 100 people
- Kindergarden (Bio Kids), Chemistry School Elhardt
- IZB Residence CAMPUS AT HOME
- Restaurant SEVEN AND MORE, Café Freshmaker
- On the Martinsried Campus: over 60 start-ups in the IZB, two Max Planck Institutes, ten faculties of the LMU, Clinic of the University Munich

WHERE THE FUTURE BECOMES REALITY



Messe München

Connecting Global Competence

F₃

U₂

TU

RE₄

NE₃

TW

O₄

RK

GL

O₃

B₂

AL₂

THE WORLD'S NO. 1

Auf der weltweit größten Labormesse finden Sie alle Produkte und Lösungen für Ihr Industrie- und Forschungslabor. Die wissenschaftlich hochkarätige *analytica conference*, Weltneuheiten, Produktpremieren, einzigartige Live Labs, Sonderschauen, Foren und Fokustage warten auf Sie.

Jetzt anmelden: Standvergabe seit 3. April



analytica

31.03. – 03.04.2020 | *analytica*

31.03. – 02.04.2020 | *analytica conference*

27. Internationale Leitmesse für Labortechnik, Analytik, Biotechnologie und *analytica conference*

analytica.de